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Background. Human African trypanosomiasis (HAT) is fatal unless treated. Pentamidine has 
been used to treat first-stage (hemolymphatic) HAT since the 1940s, but it is ineffective 
againstsecond-stage (meningoencephalitic, or central nervous system) infection. Research has 
suggested that hOCT1 and P-gp are involved in the transport of pentamidine across the blood-
brain barrier (BBB). The aim of this study was to investigate if through the formation of ion-pairs 
the passive diffusion and hOCT1 and P-gp mediated BBB transport of pentamidine could be 
improved.  
 
Methods. Structural properties (stoichiometry, binding sites and binding affinities) of ion-pairs 
formed between pentamidine and taurodeoxycholate, octanoate and xinafoate (selected to 
generate an ion-pair with a +1 charge) were examined by HPLC, NMR spectroscopy and 
fluorescence spectroscopy. The lipophilicity of pentamidine with an excess concentration of the 
counter-ions was measured by octanol-water shake-flask method at pH 7.4. Hyperquad 
Simulation and Speciation (HySS) studies predicted the percentage of pentamidine ion pairs that 
would be formed in plasma and CNS and determined the concentrations utilised in the biological 
studies. Molecular docking studies were performed using Dock Ligands from Discovery Studio 
version 4.0 to simulate and confirm the binding of pentamidine with hOCT1 and P-gp. The 
influence of counterions on the passive permeability properties of pentamidine was explored 
using a simple membrane xenopus oocytes which were injected with water. The influence of 
counterions on pentamidine transport by hOCT1 was studied using (i) human brain endothelial 
cells (hCMEC/D3) (ii) a xenopus oocytes system in which functional expression of hOCT1 was 
confirmed using the hOCT1 endogenous substrate acetylcholine (kinetic uptake, 1-120min). The 
influence of counterions on pentamidine transport by human P-gp (MDR1) was examined using 
(i) cultured Madin-Darby Canine Kidney (MDCK)-wild-type and MDCK-MDR1 cells and (ii) a 
xenopus oocytes system expressing P-gp and its functional expression of P-gp was confirmed by 
the efflux of two P-gp substrates [3H]dexamethasone and [3H]corticosterone. Data were analysed 




Results. The lipophilicity (log D, 7.4) of 33µM pentamidine with 20 times molar ratio of 
taurodeoxycholate, octanoate by 1.15 and 1.06 units, respectively. The lipophilicity (log D, 7.4) of 
8µM pentamidine with 20 times molar ratio of xinafoate increased by 0.82 units compared to 
pentamidine respectively. NMR revealed that ion-pairing occurred through the pentamidine 
amidine groups. The binding constants (pKa) of pentamidine with taurodeoxycholate, octanoate, 
or xinafoate were determined by HPLC and ranged from 3.1 - 4.1. The binding of pentamidine 
with counterions is relatively weak, compared to the reported highly stable metal complexes: 
pKCu2+-EDTA= 18.8, pKMg2+-EDTA= 8.8 (Wang and Tomasella, 2016). The percentage bound of 
pentamidine with 20 molar ratios of xinafoate is predicted to be 0.07% and 38.5% when 
pentamidine is 9nM and 8µM, respectively. The accumulation of [3H]pentamidine in hCMEC/D3 
cells was either unchanged or reduced with all the counterions. Initial molecular docking showed 
the energy of pentamidine-hOCT1 was -27.0 kcal/mol compared to -27.6 prazosin (substrate) and 
+26.6 kcal/mol for sucrose (non-substrate). Uptake of [3H]acetylcholine confirmed the functional 
expression of hOCT1 in oocytes (hOCT1: 2.23±0.73 pmol/oocyte/h vs sham: 1.19±0.28 
pmol/oocyte/h n=28-32). Pentamidine utilized hOCT1 to accumulate in the oocyte (hOCT1: 
86.35±18.99 vs sham: 40.00±12.06 fmol/oocyte/h, n=23-24 p<0.05) and its Km (half-saturation 
constant) was 279.9±112.4 µM (determined using 2-500 µM of pentamidine; n=6-8). Comparing 
the uptake of [3H]pentamidine ion-pairs in water-injected oocytes, when pentamidine was in the 
ion-pair complex, more pentamidine could be passively diffused across the membrane if the 
counterion had a small molecular weight. This is due to the improved lipophilicity of the 
pentamidine ion pair compared with pentamidine alone. However, less pentamidine interacted 
with hOCT1 as the ion-pairs could inhibit pentamidine to be influxed by hOCT1. Molecular docking 
showed the energy of pentamidine-P-gp was -31.0 kcal/mol compared to -31.8 kcal/mol for the 
substrate, dexamethasone and +2.9 kcal/mol for the non-substrate, sucrose. The efflux of 
[3H]pentamidine-xinafoate ion-pair in oocytes expressing P-gp indicated that the efflux of 
[3H]pentamidine by P-gp was not affected by forming ion-pairs with xinafoate.  
 
Conclusions. The counterions taurodeoxycholate, octanoate, and xinafoate in this study 
generated an ion-pair complex with pentamidine, which was more lipophilic than the parent drug, 
presumably due to the shielding of one of pentamadine’s two +ve charges. HySS studies 
predicted that the percentage of ion pairs present in solution would increase dramatically when 
increasing the concentration of pentamidine regardless of excess of counterions. This structural 
VI 
modification improved BBB uptake by enhancing the passive transport of pentamidine. The 
molecular docking studies and the hOCT1 and P-gp expressing oocytes confirmed the role of 
hOCT1 and P-gp in pentamidine transport. When pentamidine forms ion-pairs with xinafoate, its 
influx across the BBB by hOCT1 is prevented. Pentamidine is still effluxed by P-gp and its efflux 
by P-gp is not affected by forming ion-pairs with xinafoate. This may be because the size of 
pentamidine-xinafoate ion-pair is outside the normal MW range for OCT1, but is within the range 
for P-gp substrates. It may also because forming ion-pairs with xinafoate affect the binding pocket 
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Chapter 1 Drug delivery across the blood-brain barrier 
1.1 General introduction  
In the last decade, several major pharmaceutical companies had to shut down their centres for 
central nervous system (CNS) drug development. The main reason behind this phenomenon was 
the low success rate of CNS drug development. Also, the cost of developing a new drug is high 
at 10-15 billion US dollars (Wegener and Rujescu, 2013). CNS drugs in general have a higher 
failure rate than non-CNS drugs and the main obstacle is the blood-brain barrier (BBB) (Gribkoff 
and Kaczmarek, 2017). It is estimated that 98% of small drug molecules and almost all large drug 
molecules cannot cross the blood-brain barrier (BBB) (Pardridge, 2005). Therefore, it is of great 
importance to design CNS drugs that can cross the BBB. The current drug delivery methods, both 
invasive or non-invasive, suffer multiple issues such as high cost, toxicity, and low efficacy (Lu et 
al., 2014). Novel drug delivery methods are continually being sought which improve drug delivery 
across the BBB, are cost-effective and safe. 
 
In this chapter, I will introduce a fatal CNS disease called human African trypanosomiasis (HAT) 
and how it is treated. I will focus on the drug pentamidine and how its inability to cross the BBB 
prevents it from treating the CNS stage disease.  Then I will explain in detail the structure of the 
BBB and compare current drug delivery strategies across the BBB. Finally, I will propose a new 
drug delivery method using an ion-pairing strategy for pentamidine to improve the delivery of 
pentamidine across the BBB and reformulate pentamidine to treat CNS stage HAT.  
 
1.2 Human African Trypanosomiasis (HAT) 
Human African trypanosomiasis (HAT), also known as Sleeping Sickness, is a fatal infectious 
disease in sub-Saharan Africa. The causative parasite, Trypanosoma brucei, was first identified 
by David Bruce in 1899 and affects both cattle and humans in sub-Saharan areas (Kennedy, 
2013). It was originally called nagana. HAT is a neglected disease that affects 70 million 
population in sub-Saharan Africa. The treatment of HAT is mainly led by the World Health 
Organisation (WHO). Due to their efforts, the global incidence of T.b.gambiense HAT was 
reduced to below 3,000 cases in 2015 (Aksoy et al., 2017). According to (WHO, 2019), the 
number of HAT cases further dropped to less than 1,000 cases in 2018 and of which the majority 
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were T.b.gambiense type. The target for 2030 set by WHO is to completely eradicate the 
T.b.gambiense infection.  
 
Figure 1-1 Number of cases of HAT from 2000 to 2020. The figure was downloaded from (WHO, 2019).  
 
HAT is fatal unless treated. The life cycle of Trypanosoma brucei, as summarised by Kennedy 
(2004), is composed of 8 steps (Figure 1-2): (a) An infected tsetse fly bites humans and injects 
metacyclic trypomastigotes. (b) The metacyclic trypomastigotes are converted into bloodstream 
trypomastigotes. (c) The trypomastigotes multiply in the blood, lymph and spinal fluid. (d) The 
trypomastigotes in blood become infective. (e) The tsetse fly bites infected humans or animal 
hosts. (f) The trypomastigotes in blood become procyclic trypomastigotes and multiply. (g) The 
procyclic trypomastigotes become epimastigotes (h) Epimastigotes multiply in salivary gland and 
become metacyclic trypomastigotes (Aksoy, 2003; Kennedy, 2004).  
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Figure 1-2 The life cycle of Trypanosoma brucei. The image was taken from (Kennedy, 2004) and the image 
was drawn by Alexander J. da Silva and Melanie Moser, Centers for Disease Control Public Health Image 
Library. 
 
For humans, the infection of HAT starts with a bite from a tsetse fly. Then after a minimum of five 
days, the skin area becomes swollen and the disease starts to progress to the first stage, also 
known as the hemolymphatic stage, where parasites proliferate in the lymphatic system and the 
blood (Stich, Abel and Krishna, 2002). At this stage, patients usually experience fever for many 
weeks. Patients in West Africa also have unnoticeable symptoms like lymphadenopathy in the 
neck and a light rash, while patients in east Africa normally have more severe symptoms with 
10% of death rate at the first stage (Stich, Abel and Krishna, 2002). The second stage is the 
meningo-encephalitic stage where trypanosomes pass through the BBB and infect the brain and 
the cerebrospinal fluid. The second stage of HAT is difficult to treat, due to the low permeability 
of drugs across the BBB. If the patients are left untreated, patients will fall into a coma, suffer 
organ failure, and eventually death (Wenzler et al., 2009; Franco et al., 2014).  
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Figure 1-3 Trypanosoma brucei in blood (left) and the brain pathohistological changes of a patient infected 
with HAT. The image was taken from (Stich, Abel and Krishna, 2002).  
 
There are two types of HAT: T.b.rhodesience and T.b.gambiense. The two types of HAT differ in 
the region affected in Africa and have different severity. T.b.rhodesience is found in East Africa 
while T.b.gambiense is found in West and Central Africa. The majority (97%) of HAT cases were 
T.b.gambiense while only 3% of cases were T.b.rhodesience. T.b.rhodesience is more acute and 
more severe than T.b.gambiense. Therefore, T.b.rhodesience is a much more significant concern 
for European and American travellers who visit East Africa and then return to their countries 
(Kennedy, 2013). It can take six months from the initial infection for T.b.rhodesience to cause 
death with a more chronic progress of up to 3 years for people infected with T.b.gambiense 
(Franco et al., 2014). 
 
The majority of T.b.rhodesience reservoirs are animals, particularly in livestock. When cattle are 
infected with T.b.rhodesience, they become ill and lose milk, and eventually die (Stich, Abel and 
Krishna, 2002). The human serum resistance-associated (SRA) gene can be isolated from 
T.b.rhodesience infected individuals (Gibson, Backhouse and Griffiths, 2002). Therefore, the SRA 
gene is often used to diagnose T.b.rhodesience in humans since this type of HAT cannot be 
observed by microscopy (Radwanska et al., 2002). The TgsGP gene can be used as a molecular 
marker to identify T.b.gambiense. TgsGP is a T. b. gambiense specific receptor and it can only 




To understand how parasites cross the blood-brain barrier (BBB) and subsequently invade the 
central nervous system, Mulenga et al., (2001) injected rats with Trypanosoma brucei (Tb) brucei., 
a subspecies of T.brucei which causes disease in cattle, but is nonpathogenic in humans. At late 
stages post-infection when parasites were found in brain parenchyma, the tight junctional proteins, 
occludin and zonula occludens 1 (ZO1), were preserved in the cerebral vessels. This implied that 
parasites pass the BBB without compromising its paracellular integrity. Studies on a murine model 
of human African Trypanosomiasis also revealed that Trypanosoma brucei brucei could reach the 
blood-CNS interfaces at the early stage of infection when the tight junctions of the BBB were 
remained (Sanderson et al., 2008). During the course of infection, the concentrations of brain 
parasites increased. At day-28 post-infection, the blood-brain barrier was dysfunctional, as 
evidenced by the increased concentration of [3H]eflornithine and [14C]sucrose delivery in brain. 
The integrity of the blood-brain barrier did not reinstate, and animals died around 5-6 weeks post-
infection (Sanderson et al., 2008). Further studies have found that some bloodstream forms 
of parasites have the capacity to enter the human BMECs. Parasites may permeate into 
endothelial cells by triggering the G protein-coupled receptor. A study revealed that T.b. 
rhodesiense showed greater efficiency of crossing brain microvascular endothelial cells than T.b. 
brucei. When cathepsin L-like cysteine proteases were inhibited by N-methylpiperazine-urea-
Phe-homopheylalanine-vinylsulfone-benzene, T.b. rhodesiense was not able to cross the BBB 
and at the same time did not cause calcium fluxes. In addition, the transport of T. b. brucei was 
enhanced by incubating with supernatants with cathepsin L-like cysteine proteases. This studies 
indicated that calcium signalling triggered by parasite cysteine protease was involved in the ability 
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The options of drugs for HAT are limited and expensive. Currently, there are limited options of 
drugs for the treatment of human African Trypanosomiasis. All the options are expensive and 
















Figure 1-4 Structures of drugs for the treatment of HAT. Pentamidine and Suramin are used for the first 
stage of HAT. Melarsoprol, eflornithine, nifurtimox, and Fexinidazole can be used for the s (late) stage of 
HAT (Babokhov et al., 2013). 
 
Pentamidine  
Pentamidine (or pentamidine isethionate) is an aromatic diamidine with two positive charges at 
physiological pH. It is effective against the first stage of T.b.gambiense HAT. In clinic, pentamidine 
is administered through intramuscular injection at the concentration of 4 mg/kg per injection per 
day for 7-10 days. Pentamidine has a half-life in plasma of 22-47 hs (Babokhov et al., 2013). DAPI 
staining and TUNEL assay revealed that pentamidine could bind to DNA and disrupt trypanosome 
mitochondrial, causing the loss of kinetoplast DNA. Kinetoplast DNA is responsible for membrane 
potential since the A6-subunit of the ATP synthase is encoded by kinetoplast (Bornstein and 
Yarbro, 1970; Bacchi, 2009; Thomas et al., 2018). The advantage of pentamidine is that it does 
not cause trypanosomal drug resistance (Babokhov et al., 2013). Pentamidine has several 
limitations: Firstly, it is ineffective against the s stage of HAT. Sly, it is not convenient for patients 
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as it has to be administered by intramuscular injection. Thirdly, pentamidine causes side effects, 
including hepatic toxicity and hypoglycaemia. Despite these, pentamidine is still safer than drugs 
for stage 2 treatment. It is well tolerated, and most reactions are reversible (Sanderson et al., 
2008; Paine et al., 2010).  
 
Suramin 
Suramin (Bayer 205), a polysulphonated naphthylamine based compound, is the preferred drug 
for the treatment of T.b.rhodesience HAT (Wenzler et al., 2009). Suramin is administered through 
intravenous injections at the concentration of 20 mg/kg every 3-7 days for one month. It has a 
long half-life time of 44-54 days in plasma. The advantages of suramin include its high 
effectiveness against T.b.rhodesience, and not causing drug resistance, resulting from suramin’s 
inhibition of multiple metabolic pathways and enzymes. The disadvantage of suramin is that it can 
only be used for the early stage of T.b.rhodesience, due to its large size (MW)and its inability to 
cross the BBB (Sanderson, Khan and Thomas, 2007; Babokhov et al., 2013).  
 
Melarsoprol 
Melarsoprol is an arsenical and until 1990 it was the only drug available for treating the s stage 
of both T.b.gambiense and T.b.rhodesience HAT. It is highly lipophilic and has to be administered 
intravenously by dissolving in propylene glycol. The dose is 2.2 mg/kg melarsoprol per day for 10 
days which has a success rate of 93.9% after treatment and 86.2% after 2 years post-treatment. 
The arsenic group makes it very toxic with approximately 10% of patients experiencing post-
treatment reactive encephalopathy (PTRE) with symptoms of high fever, seizures and dizziness. 
Up to 50% of patients with PTRE die within 2 days after being administered with melarsoprol. In 
addition to its toxicity, melarsoprol causes trypanosome resistance, which may arise from the 
modification of the P2/TbAT1 nucleoside transporter, a transporter for the entry of melarsoprol in 
trypanosome (Babokhov et al., 2013).  
 
Eflornithine  
Eflornithine, also known as alpha-Difluoromethylornithine (DFMO), is effective against both early 
and late stage of T. b. gambiense HAT. It is, however, ineffective for the T. b. rhodesiense 
infection. It was originally an anti-cancer drug, and its anti-trypanosomiasis characteristic was 
discovered by Cyrus Bacchi in 1980. Eflornithine can inhibit ornithine decarboxylase, thereby 
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intervening the process of cell division and proliferation. Eflornithine can be administered by both 
oral and intravenous infusions. However, oral administration shows low efficacy against HAT 
(Babokhov et al., 2013). Compared to melarsoprol, eflornithine is more effective with a lower 
death rate (Priotto et al., 2008). Eflornithine has a short half-life of up to 5 hs and limited 
permeability across the BBB. Thus it needs a prolonged intravenous infusion, which is expensive 
and inconvenient for patients (Sanderson et al., 2008; Bacchi, 2009). The dose of eflornithine is 
100 mg/kg body weight at intervals of 6 hs for two weeks (Burri and Brun, 2003).  
 
Nifurtimox eflornithine combination therapy 
Nifurtimox was originally used for treating Chagas disease. It has limited efficacy against the late 
stage of HAT. However, the combination of nifurtimox and eflornithine, known as NECT, showed 
lower death rate (0.7%) and a higher cure rate (97.7% at 18 months) for T.b. gambiense. NECT 
is well tolerated among children (Alirol et al., 2013). It is administered by intravenous infusion of 
eflornithine at 200 mg/kg twice a day for one week and oral administration of nifurtimox three 
times a day for ten days (Bacchi, 2009).  
 
Fexinidazole 
Fexinidazole (Faxinidazole Winthrop) is a DNA synthesis inhibitor and was just approved by 
European Medicines Agency (EMA) in 2019 for the treatment of HAT. This is the first and only 
drug available now for the treatment of both haymolymphatic and meningo-encephalitic stage of 
T.b.gambiense and T.b.rhodesiense HAT (Deeks, 2019). Fexinidazole has been designed for oral 
administration therefore it is less invasive for patients and cheaper from a healthcare perspective. 
Studies showed that a dose of 1,800 mg fexinidazole in tablet per day for four days and then 1200 
mg per day for six days provided desired efficacy and was well tolerated by patients. However, 
late relapse has been observed. Therefore, patients are suggested to have a follow-up check 12 














Table 1-1 Current drugs for the treatment of human African Trypanosomiasis. *Log P and charges at pH 
7.4 are predicted using the MarvinSketch software 
 
To summarise, pentamidine is the safest choice for treating HAT because it is well-tolerated and 
less toxic. It is not effective for the late stage of HAT due to its limited ability to cross the BBB. 
Therefore, developing a drug delivery method for increasing pentamidine delivery across the BBB 
would provide a promising treatment option for treating the late stage of HAT. Thus, it is necessary 
to understand the BBB and how drugs cross the BBB.  
 
Drugs Molecular weight 
(g/mol)  
Log P* Charge  
at pH 7.4* 
Pentamidine 340.4 2.32 +2 
Suramin 1297.3 5.58 -6 
Melarsoprol  398.3 2.79 +2 
Eflornithine  182.2 -0.61 +1 
Nifurtimox 287.3 -0.27 0 
Fexinidazole 279.3 2.38 0 
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1.3 The blood-brain barrier  
The neurons in the central nervous system (CNS) play keys roles such as receiving and 
transferring chemical and electrical signals and require a stable environment in which to function. 
The BBB plays a critical role in regulating the exchange of ions and molecules between the blood 
and the brain (Abbott et al., 2010). To maintain the homeostasis of CNS and protect the brain 
from external toxins, there are several interfaces including the blood-brain barrier (BBB) and the 
blood-cerebrospinal fluid barrier (BCSFB) which includes the arachnoid barrier (Cipolla, 2009). 
As the BBB is the interface directly between the blood and the brain tissue, has the largest surface 
area and limits the entry of pentamidine into the CNS, this chapter will be focused on introducing 
the BBB. The BCSFB and the arachnoid barrier will only be briefly summarised.  
 
The blood-cerebrospinal fluid barrier (BCSFB) is a barrier which sits between the blood in the 
choroid plexus capillaries and the cerebrospinal fluid. The walls of the choroidal capillaries are of 
the fenestrated, non-continuous type. There are discontinuous tight junctions between the 
capillary endothelium cells which allow the free movement of small molecules as well as large 
molecules such as horseradish peroxidase. Thus the choroid capillary endothelium does not 
contribute to the actual physical barrier. However, surrounding the choroid plexus capillaries is a 
single layer of epithelial cells which is continuous with the ventricular ependyma (the layer of cells 
between the brain and the CSF). This layer of modified epithelial cells has tight junctions that 
restrict the intercellular movement of molecules and offer a barrier phenotype (Cipolla, 2009). The 
meningeal barrier consists of fenestrated dura and outer cells of the arachnoid membrane with 
tight junctions. The fetal cerebrospinal fluid (CSF)-brain barrier is a membrane between the CSF 
and brain parenchyma. The fetal CSF-brain barrier is active only during early development when 
its neuroependymal cells form the physical barrier to restrict large molecules (Cipolla, 2009). The 
adult (mature) ventricular ependyma does not control the entry of large molecules between the 




Figure 1-5 Barrier interfaces in the adult brain. The image was taken from (Cipolla, 2009). (a) The blood-
brain barrier. (b) The blood-CSF barrier. (c) The meningeal barrier (d) The fetal-CSF barrier (d) The adult 
ventricular ependyma.  
 
The blood-brain barrier (BBB) is part of the neurovascular unit (NVU) and is located at the walls 
of the cerebral capillaries (Figure 1-6). The NVU is composed of the endothelial cells, a basement 
membrane, pericytes, astrocytic endfeet, neurons, microglia, and oligodendrocytes (Warren, 
2018). The BBB can regulate the entry of external substances into the brain and is a dynamic 
barrier responding to the changes of the CNS, through signalling among brain endothelial cells, 
neurons and astrocytes (Neuwelt et al., 2011; Banks, 2016). The BBB impedes the majority of 
small molecules and almost all big molecules from entering the central nervous system (CNS) in 




Figure 1-6 Components of the NVU. The image was taken from (Daneman and Prat, 2015). (A) The dense 
CNS vascular network; (B) and (C) Cross-section image captured by electron micrograph of the endothelial 
cells (EC) with tight junctions (TJ), pericytes (PC), astrocyte endfeet (AE); (D) The neurovascular unit (NVU); 
(E) Pericytes (orange) and endothelial cells (green) captured by immunofluorescence. (F) Astrocytes (red) 
and unstained blood vessels captured by immunofluorescence. 
 
1.3.1 Endothelial Cells (ECs)  
The walls of the capillaries are composed of a monolayer of endothelial cells (ECs). The ECs in 
CNS are 39% thinner than ECs in muscles (Coomber and Stewart, 1985) with a thickness of 0.3-
0.5 mm (Zlokovic, 2009). There is a paucity of vesicles and fenestrations found in brain endothelial 
cells compared to non-cerebral endothelial cells. Endothelial cells are joined together at the 
paracellular cleft by both tight and adherens junctions. These junctions are intermingled and 
continuous throughout the paracellular cleft. The BBB tight junctions are complex and restrict the 
paracellular movement of ions and molecules with electrical resistance (TEER) of ~ 2,000 Ω.cm2 
compared to ~30 Ω.cm2 in other tissues (Stamatovic, Keep and Andjelkovic, 2008) (Grieb et al., 
1985; Sumpio, Riley and Dardik, 2002; Ballabh, Braun and Nedergaard, 2004; Weiss et al., 2009). 
The endothelial cells at the BBB have a higher density of mitochondria compared to non-cerebral 
endothelial cells. The electron micrographs of different sections of the rat brain revealed that 8-
11% of the endothelial cytoplasmic volume accommodated the mitochondrial content of the BBB, 
whilst non-BBB tissues had a mitochondrial content of 2-5%. The higher expression of 
mitochondria is related to the role of the BBB in exchanging ions and molecules between the 
plasma and the brain and the homeostasis of the CNS fluids. These roles of the BBB require the 
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use of energy in the form of ATP, which is generated by the mitochondria. ATP is hydrolysed to 
ADP to provide the energy for primary active transporters to move solutes and ions against their 
concentration gradients. Primary active transporters set up the ion gradients needed by 
secondary active transporters to drive solutes and ions against their concentration gradients. 
Thus secondary active transporters also require ATP, albeit indirectly (Oldendorf, Cornford and 
Brown, 1977). 
 
There are multiple membrane transporter proteins which are expressed in the endothelial cell 
plasma membranes and select molecules to cross the endothelial cells and enter the brain and 
also to cross the endothelial cell and enter the blood. A detailed introduction of these transporters 
can be found in sections 1.4.2 and 1.4.3. In addition to the membrane transporters, there are a 
number of metabolising enzymes expressed at the BBB including alkaline phosphatase, γ-
glutamyl transpeptidase, and cytochromes P450 (CYP) enzymes (Correale and Villa, 2009). 
Alkaline phosphatase is used as a biomarker to differentiate capillary endothelial cells in the brain 
from those in the periphery. It also mediates the transport of compounds across the BBB. When 
alkaline phosphatase was inhibited with levamisole, the permeability of the BBB to Lucifer Yellow 
was increased (Deracinois et al., 2015). Both γ-glutamyl transpeptidase and alkaline phosphatase 
are expressed at the luminal side of the endothelial cells (Persidsky et al., 2006). Cytochromes 
P450 are situated at mitochondrial membranes or endoplasmic reticulum. They are involved in 
the metabolism of xenobiotics and endogenous compounds (Ghosh et al., 2011).  
 
1.3.2 Tight junctions (TCs) 
The BBB endothelial cells are connected by tight junctions (TJs). These TJs are responsible for 
regulating the paracellular transport of molecules, preventing the lateral movement of lipids and 
membrane proteins, and intracellular signalling. The TJs are composed of transmembrane 
proteins and membrane-associated cytoplasmic proteins (Luissint et al., 2012).  
 
1.3.2.1 Transmembrane proteins  
Transmembrane proteins including claudins, occludins, and junctional adhesion molecules 
(JAMs) form the backbone of the tight junctions of the BBB.  
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Claudins (20-27 kDa) have over 25 family members and are vital for the paracellular barrier 
formation. Claudin-3, claudin-5, and claudin-12 are expressed at the BBB. Claudin-3 and claudin-
5 are crucial for the formation and integrity of the tight junctions of the BBB (Luissint et al., 2012). 
It was found that the permeability of small molecules with less than 800 Da was affected in 
claudin-5 deficient mice, indicating that claudin-5 was vital for the integrity of the BBB (Nitta et al., 
2003). Study on claudin-12 knocked out mice revealed that claudin-12 is not essential for the 
establishment of the integrity of tight junctions of the BBB (Castro Dias et al., 2019) 
 
Occludin (60 kDa) is expressed on both epithelial and endothelial cells in CNS. It contributes to 
the function of barriers. It is a member of TJ-associated marvel proteins with marvelD2 and 
marvelD3, both of which consist of four transmembrane helices and coiled-coil cytosolic C-
terminus. The structure of occludin contributes to the assembly and redox regulation of tight 
junctions of the blood-brain barrier (Luissint et al., 2012).  
 
Junctional adhesion molecules (JAMs) are not essential to the tight junctions. They are 
immunoglobulin proteins that mediate leukocyte extravasation and paracellular permeability 
(Daneman and Prat, 2015).  
 
1.3.2.2 Membrane-associated cytoplasmic proteins 
Cytoplasmic proteins contribute to the integrity of brain endothelial cells and epithelial cells. 
Among these, the membrane-associated guanylate kinase (MAGUK) family, including zonula 
occludens (ZO) proteins, disks large homolog 1 (DLG1), and membrane protein palmitoylated 
(MPP) 1, 5 and 7 have been identified on the tight junctions of brain endothelial cells. The ZO 
proteins have been extensively studied. ZO proteins are composed of zonula oocludens-1 (ZO-
1), zonula oocludens-2 (ZO-2), and zonula oocludens-3 (ZO-3). ZO proteins have a SH3 domain, 
a guanylate cyclase, and PDZ domains. The SH3 domain interacts with signalling proteins and 
cytoskeletal elements. The guanylate cyclase is responsible for transforming GMP to GDP. The 
PDZ domains bind to the C-terminal cytoplasmic ends of transmembrane proteins (Stamatovic et 
al., 2016). The functions of ZO proteins distinct within their C-terminus. The PDZ-1 domain of ZO 
proteins interacts with the C-terminal of claudins, the PDZ-3 of ZO proteins interacts with JAMs, 
the GUK domains of ZO proteins connects with occluding. ZO proteins are vital to the assembly 
of claudins, occludin, and JAMs which constitute the backbone of the BBB tight junctions (Luissint 
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et al., 2012). ZO proteins also coordinate the multimolecular complex to the actin cytoskeleton. 
ZO proteins bind to F-actin binding proteins (cortactin, α-catenin, protein 4.1, and fodrin) which 
affect the assembly and maintenance of tight junctions. A study on Madin-darby canine kidney 
(MDCK) cells confirmed that ZO-1 interacts with F-actin and plays an important role in the 

















Figure 1-7 Zonula oocludens-1 (ZO-1), zonula oocludens-2 (ZO-2), and zonula oocludens-3 (ZO-3). (A) The structure of ZO-1, ZO-2, and ZO-3. They consist of PDZ domains, SH3, 
GK (catalytically inactive GUK domain), and various ZO-specific U or P regions. ZU5 is a region that is specifically found on ZO-1. (B) ZO-1 and ZO-2 contain structural and signalling 
molecules. Proteins that are known to interact with ZO-1 and ZO-2 in endothelial and epithelial cells are shown in the figure. The image was taken from (Bauer et al., 2014)
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1.3.3 Pericytes  
Pericytes were first identified in the 19th century, but their role was not elucidated until the 21st 
century, thanks to the development of more sensitive technologies. In CNS, pericytes share a 
common basement membrane with endothelial cells. Pericytes regulate cerebral blood flow, 
maintain the stability of the BBB, and perform immune cell functions (Brown et al., 2019). 
Pericytes are associated with microvasculature and possess antigen properties. Thus they are 
regarded as the first line of defence in the CNS. In the presence of antigens, pericytes can trigger 
pro-inflammatory response in the brain, which induces monocyte and lymphocyte recruitment. 
This process is associated with the increased expression of adhesion molecules on the apical 
side of brain endothelial cells. A previous study on mouse brains revealed that pericytes produce 
cytokines, nitric oxide, chemokines and react to immune stimulator lipopolysaccharide. The 
immune functions of pericytes are crucial for communication within NVU and the 
neuroinflammatory process in response to infections and neurodegenerative diseases (Kovac, 
Erickson and Banks, 2011). Pericytes can also produce chemo-attractants and contribute to the 
transmigration of immune cells to the brain. In addition, pericytes can directly produce multiple 
inflammatory mediators such as interleukin (IL)-1β, IL-6, and nitric oxide. These inflammatory 
mediators can potentially cause pericytes to detach and disrupt the BBB (Hurtado-Alvarado, 
Cabañas-Morales and Gómez-Gónzalez, 2013). Pericytes might directly regulate the BBB. 
Armulik (et al., 2010) found that in pericyte-deficient adult mice, the BBB permeability of water 
and a variety of molecular mass tracers was increased, indicating the critical role of pericytes in 
regulating the BBB. Also, it was shown that a lack of pericytes might lead to disorders such as 
hypoxia and/or stroke (Liu et al., 2012). Recent studies suggested that pericytes could be a 
potential drug target for HIV-1 infection (Bertrand, Cho and Toborek, 2019).  
 
1.3.4 Astrocytes  
Astrocytes are glial cells in CNS whose endfeet completely enclose the brain microvessels 
(Mathiisen et al., 2010). Astrocytes serve multiple functions in CNS including facilitation of 
neurovascular coupling, regulation of brain microenvironment, CNS development and repair, and 
among others (Cabezas et al., 2014; Oksanen et al., 2019). Astrocytes were shown to induce 
BBB characteristics, as the tight junctions of endothelial cells were enhanced both in length and 
width when they were co-cultured with astrocytes (Janzer and Raff, 1987; Tao-Cheng, Nagy and 
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Brightman, 1987). Astrocytes endfeet are an integral component of the BBB. It provides nutrients 
from blood vessels to neurons and helps maintain the integrity of the BBB. In a previous study, 
the role of astrocytic endfeet was observed in a mouse brain. When astrocytes were partially 
removed by a laser, the remaining astrocytic endfeet contributed to angiogenesis. This indicated 
that damage to astrocytes caused signalling factors to be secreted, which stimulated the growth 
of new vessels from existing blood vessels (Kubotera et al., 2019).   
 
1.3.5 Basement membrane 
The basement membrane (BM) is a 50-100 nm protein layer that provides structural support, 
mediation for cell signalling, and maintenance of tight junctions. (Persidsky et al., 2006; Liu et al., 
2012; Daneman and Prat, 2015). The BM is composed of type IV collagen, laminin, nidogen and 
heparan sulfate proteoglycans proteins (LeBleu, Macdonald and Kalluri, 2007). There are two 
forms of basement membrane in the brain: the inner endothelial BM and the outer parenchymal 
BM. The two types of BM are isolated by pericytes (Liu et al., 2012), and they have different 
protein components. A detailed protein components of the endothelial BM and the parenchymal 
BM can be found in Thomsen, Routhe and Moos (2017). 
 
1.3.6 Microglia 
Microglia are immune cells in CNS. In healthy brain, microglia and neurons promote the stability 
of the brain. Microglia are activated by brain injury and this process includes microglia 
proliferation, chemotaxis, morphological alternations, and immunomodulatory molecules 
generation (Yenari et al., 2006; da Fonseca et al., 2014). It was found that the introduction of 
microglia in the co-culture of endothelial cells and astrocytes double the cell death rate. The 
increasing cell death rate was avoided by the addition of minocycline, a microglial inhibitor. This 
suggested that microglial inhibitors could be a potential measure to protect the brain after 
ischemic stroke and fibrinolysis (Yenari et al., 2006). 
 
1.4 Drug delivery across the blood-brain barrier  
Drug molecules can cross the BBB through various routes including passive diffusion, ATP-
binding cassette (ABC) transporters, solute carrier (SLC) transporters, and transcytosis (Bhowmik 
et al., 2015).  
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Figure 1-8 Drug transport across the BBB. The image was taken from (Abbott et al., 2010) 
 
1.4.1 Passive diffusion  
Passive diffusion is the transport of substances along the concentration gradient across 
membranes without utilising energy or the assistance of membrane transporters (Sanchez-
Covarrubias et al., 2014). Physicochemical properties such as charge and lipophilicity affect the 
passive transport of drugs across the BBB (Mikitsh and Chacko, 2014). The charge state of a 
molecule can be predicted by its pKd value and the pH of the medium where the molecule is 
dissolved. For lipophilicity, the octanol-water partition coefficient (log P) is a traditional parameter 
to determine the lipophilicity of neutral molecules. For ionised molecules, the distribution 
coefficient (log D) is utilised as an indicator for lipophilicity (Avdeef, 2012). Generally, small 
unionized compound (molecular weight < 400-500 Da) with relatively high lipophilicity (log P ~2) 
and fewer hydrogen bonds (< 8-10 hydrogen bonds with water) are more likely to cross the BBB 
(Pardridge, 2012; Kasinathan et al., 2015). A detailed explanation of physicochemical properties 
can be found in chapter 2. 
 
1.4.2 ABC efflux transporters  
Theoretically, the more lipid a drug is, the more likely a drug can cross the lipid membrane. 
However, many lipid drugs have much lower permeability across the BBB according to their 
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lipophilicities as they are substrates of ATP-binding cassette (ABC) efflux transporters at the BBB 
(Löscher and Potschka, 2005b). The transport of substances by ABC transporters is energy-
dependent and uses energy from the hydrolysis of ATP. Substances can be moved across the 
BBB against the concentration gradient (Sanchez-Covarrubias et al., 2014). ABC transporters are 
categorised into seven subfamilies from A to G. ABC transporters need energy from ATP 
hydrolysis to pump a broad range of lipophilic and amphipathic drug substrates across the BBB 
(Qosa et al., 2015). In human, ABCB, ABCC, and ABCG subfamilies efflux metabolic waste, 
xenobiotics, and drugs out of the brain. The ABC transporters expressing at the BBB include the 
multidrug resistance proteins (ABCB1, MDR1, P-gp), multidrug resistance-associated proteins 
(ABCC; MRPs), and breast cancer resistance protein (ABCG2, BCRP) (M.S. Hartz and Bauer, 
2011; Miller, 2015; Qosa et al., 2015). ABC transporters have similar ATP-hydrolysing nucleotide-
binding domains and a common “coupling helix” which is responsible for conformational changes. 
It has been suggested that the binding of ABC transporters to ATP causes outward-facing 
conformation changes while hydrolysis of ATP triggers inward-facing conformation changes 
(Hollenstein, Dawson and Locher, 2007).  
 
Figure 1-9 Localization of main ABC transporters at the blood-brain barrier. The image was taken from 
(Löscher and Potschka, 2005a)  
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Table 1-2 ABC transporters at the BBB  
ABC Transporter Gene encoded  Localization   Substrates References  
P-glycoprotein (P-
gp; MDR1/ ABCB1) 
ABCB1 Apical/luminal Methotrexate, cyclosporin A, 
dexamethasone, corticosterone, cortisol, 
aldosterone, morphine, colchicines, 
amprenavir, indinavir, saquinavir, 
loperamide, ivermectin, abamectin, 
cimetidine, verapamil, phenytoin, 
carbamazepine, lamotrigine, digoxin 
(Schinkel and Jonker, 2003; Sun et al., 2003; 
Löscher and Potschka, 2005a) 
MRP1 ABCC1 Basolateral Etoposide, teniposide, vincristine, 
doxorubicine, daunorubicine, methotrexate 
(Löscher and Potschka, 2005a) 
MRP2 ABCC2 Apical/luminal Similar to MRP1 (Löscher and Potschka, 2005a) 
MRP3 ABCC3 Basolateral Similar to MRP1 (Löscher and Potschka, 2005a) 
MRP4 ABCC4 Apical/luminal Methotrexate, 6-mercaptopurine, 
thioguanine 
(Löscher and Potschka, 2005a) 
MRP5 ABCC5 Basolateral cGMP, cAMP, 6-mercaptopurine, 
thioguanine, fluorescein 
(Löscher and Potschka, 2005a) 
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BCRP/MXR ABCG2 Apical/luminal Prazosin, anthracyclines, mitoxantrone, 
estrone 3-sulfate, methotrexate, 
sulfasalazine, glyburide, hematoporphyrin, 
7-ethyl-10-hydroxycamptothecin (SN-38), 
SN-38-glucuronide 
(Löscher and Potschka, 2005a; Ni et al., 2010) 
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1.4.2.1 P-gp transporter  
P-glycoprotein (P-gp, MDR1, ABCB1) was first discovered in the 1970s and the first efflux 
transporter identified in the brain capillary endothelial cells. P-gp is found in both animals and 
humans (Tsuji and Tamai, 1997). P-gp is encoded by ABCB1 in humans and two isoforms 
(Abcb1a and Abcb1b) in rodents (DeMars et al., 2017). The human type of P-gp has a molecular 
weight of 170 kDa and was found in in the apical (luminal) side of the BBB (Löscher and Potschka, 
2005b). The human P-gp is a phosphorylated glycoprotein. It is situated on chromosome 7 and 
contains 28 exons (Löscher and Potschka, 2005b). It consists of 1280 amino acids. The structure 
of P-gp is separated into two hydrophobic domains. Each domain has 6 transmembrane 
segments as well as 2 cytoplasmic nucleotide-binding domains. Also, on the first extracellular 
loop there are 3 glycosylation sites (Loo and Clarke, 1999; Ramakrishnan, 2003).  
 
The main function of P-gp at the BBB is to protect the brain from external substances and toxins, 
however, the defensive function of P-gp has made it one of the major obstacles for drug 
development. For example, HIV-1 protease inhibitors indinavir, nelfinavir, and saquinavir have 
limited entry into the brain. The plasma concentrations of these HIV-1 protease inhibitors were 
elevated by 2-5 times in P-gp knocked-out (mdr1a (-/-)) mice after oral administration and 7-36 
folds in brain after intravenous administration (Kim et al., 1998). Also, interactions of P-gp with 
drugs makes it difficult to be predicted in terms of its permeability across the BBB. For example, 
the permeability of doxorubicin, vincristine, epipodophyllotoxin and cyclosporin A across the BBB 
was found to be much lower than predicted by octanol-water partition coefficient. This was mainly 
because P-gp was involved in the transport of these compounds (Levin, 1980). Therefore, 
understanding the role and interaction of drugs with P-gp is crucial for developing safe and 
effective drugs for brain diseases.   
 
1.4.2.2 Breast cancer resistance protein (BCRP, ABCG2) 
The breast cancer resistance protein (BCRP, ABCG2) was discovered in 1998 using RNA 
fingerprinting identification in a multidrug-resistant human breast cancer cell line (MCF-7/AdrVp) 
(Doyle et al., 1998). In the brain, the function of BCRP is to protect the brain from the accumulation 
of neurotoxic amyloid and carcinogen PhIP (ZHANG et al., 2003; Mahringer and Fricker, 2010). 
BCRP is localized on the apical (luminal) side of brain capillaries endothelial cells in rats (Hori et 
al., 2004) and humans (Cooray et al., 2002). The sequence of mouse BCRP and human BCRP 
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is 81% identical, making mouse BCRP comparable to human BCRP studies (Allen et al., 1999). 
Human BCRP has 657 amino acids and around 75 kDa for its protein size (Ni et al., 2010). BCRP 
is a half-transporter which is composed of 6 transmembrane helices and 1 ATP-binding site 
(Nakanishi and Ross, 2012).  
 
BCRP has a wide range of substrates some of which are also substrates for P-gp.  A list of BCRP 
substrates is summarized in table 1-1. As BCRP inhibits many drugs from crossing the BBB, a 
few strategies have been developed to overcome this. One method is to use BCRP inhibitors. For 
example, the accumulation of dasatinib (a substrate for BCRP) was increased in brain of BCRP-
knocked out (Abcg2(-/-)) mice compared to wild-type mice. A similar increase of dasatinib was 
also observed by co-administration of dasatinib and BCRP inhibitor elacridar in wild-type mice 
brain (Lagas et al., 2009). The other approach of interest is by intervening the signalling 
mechanisms of BCRP. Mahringer and Fricker (2010) found that both BCRP protein expression 
and mRNA level were decreased with 17ß-estradiol in isolated rat brain capillaries, suggesting 
the down-regulation of BCRP by 17ß-estradiol. Other evidence suggested that BCRP may also 
be regulated by Akt - a regulator of cell survival. It was found that BCRP was regulated by Akt 
signalling in mice bone marrow (Mogi et al., 2003).  
 
1.4.2.3 Multidrug resistance proteins (MRPs; ABCCs) 
Multidrug resistance associate protein (MRPs, ABCCs) is a member of the ABC superfamily 
transport proteins with a protein size of 190 kDa. The structure of MRP is quite different from P-
gp and they only share 15% of amino acid homology. MRPs maintain the homeostasis of the BBB 
and regulates the transport activity of opioids (Huai-Yun et al., 1998; Su and Pasternak, 2013). In 
the brain, MRP1, MRP2, MRP4 and MRP5 are particularly important in the transport of drugs 
(Abbott et al., 2010). The substrates of MRPs are usually organic anions and their metabolites. 
The expression and localization of MRPs at the BBB are still under examinations, and conflicting 
results have been reported (Fan and Liu, 2018). Quantitative PCR analyses showed the existence 
of MRP1-5 in human brain samples, but MRP2 and MRP3 proteins could not be detected under 
immunofluorescence microscopy. The MRP1, MRP4, and MRP5 were found to be on the apical 
side of the human brain endothelial cells (Nies et al., 2004). In contrast, other studies showed that 
the MRP1 was not found on the luminal side of the human and mouse BBB (Cisternino et al., 
2003; Daood et al., 2008). 
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1.4.3 Solute carrier (SLC) transporters 
Solute carrier (SLC) transporters are facilitated transporters or secondary active transporters 
that transport endogenous substances and nutrients such as amino acids, glucose, vitamins, 
and hormones across the BBB without ATP (Sanchez-Covarrubias et al., 2014; Bhowmik et al., 
2015). Up to now, 65 subfamilies (SLC1-SLC65) with 439 members have been discovered (Hu 
et al., 2019). SLC transporters that are expressed at the BBB include amino acid transporters, 
monocarboxylate transporters, nucleoside transporters, organic anion transporters, organic 
anion transporting polypeptides, organic cation transporters, and peptide transporters (Morris, 
Rodriguez-Cruz and Felmlee, 2017). Generally, SLC transporters are uptake transporters, 
although some of the SLC transporters can transport substances bidirectionally (Sanchez-
Covarrubias et al., 2014). 
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Table 1-3 Solute transporters expressed at the BBB. The table was taken from (Ohtsuki and Terasaki, 2007) with modifications.  
Transporter system  Transporters  Substrates Localization  Direction 
Energy transport system  GLUT1 D-glucose Luminal, abluminal  Blood-to-brain  
MCT1 L-Lactate, monocarboxylates Luminal, abluminal  Blood-to-brain 
CRT Creatine Luminal, abluminal  Blood-to-brain 
Amino acid transport system LAT1/4F2hc[system L] Large neutral amino acids To be confirmed  Blood-to-brain 
CAT1 [system y+] Cationic amino acids To be confirmed  Blood-to-brain 
EAAT1, 2, 3 Anionic amino acids Abluminal Brain-to-blood 
ASCT2 L-Asp, L-Glu Abluminal Brain-to-blood 
ATA2 [System A] Small neutral amino acids To be confirmed Brain-to-blood 
xCT/4F2hc [System xc−] L-Cystine/L-Glu To be confirmed Blood-to-brain 
TAUT [System β] Taurine, β-alanine To be confirmed Both brain-to-blood and 
blood-to-brain 
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System ASC/system B0+ L-Ala and others To be confirmed Brain-to-blood 
Neurotransmitter transport 
system 
GAT2/BGT1 γ-Aminobutyric acid To be confirmed Brain-to-blood  
SERT Serotonin Luminal, abluminal To be confirmed 
NET Norepinephrine Abluminal To be confirmed 
Organic anion transport 
system 
OAT3 PAH, HVA, indoxyl sulfate Abluminal Brain-to-blood 
oatp2 Digoxin, organic anions Luminal and abluminal Blood-to-brain and brain-
to-blood 
oatp14 Thyroid hormones To be confirmed Blood-to-brain 
OCTN2 Carnitine To be confirmed Blood-to-brain 







1.4.3.1 L-Alpha Amino Acid Transporters 
L-alpha amino acid transporters (LATs) belong to SLC7 and SLC43 subfamilies and 4 L-alpha 
amino acid transporters have been identified: LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 
(SLC43A1), and LAT4 (SLC43A2) (Morris, Rodriguez-Cruz and Felmlee, 2017). LAT1 was cloned 
in 1998. Its cDNA was extracted from rat C6 glioma cells. It transport neutral amino acids and the 
process is Na+-independent (Kanai et al., 1998). It exists in brain, placenta, and tumours and 
transports amino acids into cells across endothelial and epithelial membranes. LAT1 was found 
expressing on both apical and abluminal sides at the human BBB using immunofluorescence 
staining method (Geier et al., 2013). The cDNA of LAT2 was first isolated from rat small intestine 
in 1999. LAT2 and LAT1 share an identical of 45-50% DNA sequence, but the transport by LAT2 
is not dependent on Na+-concentrations (Segawa et al., 1999). It mainly exists in the colon, 
intestine, and kidney. LAT2 has much lower expression at the BBB than LAT1 and barely affects 
the transport of substrates at the BBB. It transports both large and small amino acids (Morris, 
Rodriguez-Cruz and Felmlee, 2017).  
 
1.4.3.2 Monocarboxylate Transporters 
Monocarboxylate transporters belong to SLC5 and SLC16 subfamilies. There have been 14 
members in the proton-dependent family (SLC16; MCTs) and 2 members of the sodium-
dependant family: SLC5A8 and SLC5A12 (SMCTs) identified. Only 2 isoforms of MCTs (MCT1 
and MCT8) express on the brain capillary endothelial cells (Morris, Rodriguez-Cruz and Felmlee, 
2017). MCT1 (SLC16A1) is expressed in almost all tissues, and its main function is to transport 
L-lactic acid in or out of cells depending on the proton gradient. The substrates of MCT1 include 
GHB (define), XP13512, butyrate, acetoacetate, lactate, pyruvate, β-hydroxybutyrate (Vijay and 
Morris, 2014). The amount of MCT1 in the brain was found to be age-related. The amount of 
MCT1 in the cerebral cortex of suckling and adult rats was quantified using electron microscopic 
immunogold approach. Furthermore, results showed that the amount of MCT1 in brain capillary 
endothelial cells suckling rats was 25-fold more than adult rats (Leino, Gerhart and Drewes, 






brain (Gerhart et al., 1997). Immunoelectron microscopy revealed that MCT1 was expressed on 
both apical and basolateral sides of brain endothelial cells in rats (Gerhart et al., 1997). MCT8 
(SLC16A2) is a high-affinity thyroid hormones membrane transporter, and its substrates include 
tri-iodothyronine and pro-hormone thyroxine. In humans, modifications of the SLC16A2 gene 
could result in Allan-Herndon-Dudley syndrome (AHDS) (Lee et al., 2017).  
 
1.4.3.3 Nucleoside Transporters 
Nucleoside transporters regulate the uptake of physiologic nucleosides and play important roles 
in the disposition and intracellular transport of nucleoside analogues of drugs for cancer and anti-
viral drugs. There are two nucleoside transporters: equilibrative nucleoside transporters (ENTs) 
and concentrative nucleoside transporters (CNTs) (Kong, Engel and Wang, 2004). ENTs belong 
to SLC29A subfamilies and 4 isoforms have been identified in humans: ENT1 (SLC29A1), ENT2 
(SLC29A2), ENT3 (SLC29A3), and ENT4 (SLC29A4). ENT1-4 are expressed in liver, kidney, 
colon, intestine, placenta and brain. ENT1, ENT2 and ENT3 transport purines and pyrimidines 
and they have common substrates (Morris, Rodriguez-Cruz and Felmlee, 2017). In the brain, the 
location of ENT1 is yet to be determined. ENT2 is situated on the apical side of the BBB. Reversed 
transcriptase PCR and Western blot results showed that ENT1 and ENT2 mRNA and their 
proteins existed in rat brain endothelial cells. Drug permeability assay confirmed the transport of 
ENT1 was Na+ independent (Redzic et al., 2005). CNTs belong to SLC28A subfamilies, and they 
have 3 isoforms in humans: CNT1 (SLC28A1), CNT2 (SLC28A2), and CNT3 (SLC28A3). CNT1 
mainly transports pyrimidine while CNT2 mainly transports purine nucleosides. CNT3 transports 
pyrimidine and purine nucleosides. All the 3 isoforms of CNTs transport nucleosides against 
concentration gradients. CNTs are mainly found in epithelial cells in the kidney and liver. The 
expression of CNTs in the human brain was extremely low and may have very limited functions 
of transporting nucleosides in human brains (Kong, Engel and Wang, 2004; Morris, Rodriguez-







1.4.3.4 Organic Anion Transporters 
The organic anion transporters (OATs/oats) take up approximately half of the SLC22 subfamilies. 
The OATs have 11 members: OAT1 (SLC22A6), OAT2 (SLC22A7), OAT3 (SLC22A8), OAT4 
(SLC22A11), Oat5 (Slc22a19), OAT6 (SLC22A20), OAT7 (SLC22A9), Oat8 (Slc22a9), Oat9 
(Slc22a27), OAT10 (SLC22A13), and URAT1 (SLC22A12). OATs are expressed in many tissues 
including kidney, liver, olfactory mucosa and brain (Nigam et al., 2015). OATs have a broad range 
of substrates for endogenous and exogenous compounds with a negative charge at physiological 
pH condition (Morris, Rodriguez-Cruz and Felmlee, 2017). In humans, OAT1 and OAT3 were 
found in the cytoplasmic membrane and cytoplasm of human choroid plexus using 
immunohistochemical analysis. OAT1 mediates the transport of a range of neurotransmitter 
metabolites such as vanilmandelic acid (VMA) and melatonin (Alebouyeh et al., 2003). At the 
human BBB, the expression of OAT1 was not identified while low expression of OAT3 was found 
using proteomic analysis. OAT3 expression at the human BBB was over 5-fold smaller than its 
expression at the mouse BBB (Hoshi et al., 2013). 
 
1.4.3.5 Organic Anion Transporting Polypeptides 
Organic anion transporting polypeptides (OATPs) belong to the SLCO (SLC21A) subfamilies. 
OATPs have 11 isoforms in humans, 14 isoforms in mice, and 15 isoforms in rats. The OATPs 
mediated transport is ATP and Na+ independent. The endogenous substrates of OATPs include 
bile salts, polypeptides, and thyroid hormones. In human brains, a few isoforms of OATPs were 
identified: OATP1A2 (SLCO1A2), OATP1C1 (SLCO1C1), and OATP2B1 (SLCO2B1) (Morris, 
Rodriguez-Cruz and Felmlee, 2017). OATP1A2 is expressed at neurons and neuronal processes. 
OATP2B1 is highly expressed in brain endothelial cells (Gao et al., 2015). In rat brain, Oatp1 and 
Oatp2 were found at both luminal and abluminal side of the choroid plexus epithelium. The Oatp2 
is highly expressed at the rat BBB (Gao et al., 2000).  
 
1.4.3.6 Organic Cation Transporters 
Organic cation transporters (OCT) belong to SLC22 subfamilies and three of them have been 






three orthologs in rats, mice and humans: OCT1 (SLC22A1), OCT2 (SLC22A2) and OCT3 
(SLC22A3). OCT1 is expressed in liver and brain. It is situated at the apical/ luminal side of the 
brain capillary endothelial cells. OCT2 is expressed in kidney and brain. It is also found at the 
apical/ luminal side of the brain capillary endothelial cells. OCT3 has a wider distribution, and it is 
found in liver, heart, kidney, lung, muscle, brain, and placenta (Morris, Rodriguez-Cruz and 
Felmlee, 2017). A detailed explanation about OCT transporters can be found in Chapter 3.  
 
Three isoforms of OCTN transporters (OCTN1, OCTN2, and OCTN3) have been identified. OCTN 
transporters are responsible for the transport of organic cations and amino acid carnitine. OCTN1 
and OCTN3 have not been identified in human CNS. OCTN2 was found at the luminal side of the 
BBB in the brain. Its transport of substrates is dependent on Na+ concentrations (Sanchez-
Covarrubias et al., 2014). 
 
1.4.3.7 Plasma Membrane Monoamine Transporter (PMAT) 
Plasma membrane monoamine transporter (PMAT) is a polyspecific organic cation transporter 
that mainly transport amines and xenobiotic cations (Figure 1-10). It was highly expressed in the 
brain. Human PMAT cDNA is composed of 530 amino acid with 11 membrane-spanning domains. 
It has an intracellular N-terminus and a C-terminus (Wang, 2016). It was found that the expression 
of PMAT at the BBB in Alzheimer’s patients was reduced compared to healthy patients (Sekhar 








Figure 1-10  Proposed structure of PMAT. The image was taken from (Wang, 2016).  
 
1.4.3.8 Multidrug and toxic compound extrusion (MATE) transporters  
Multidrug and toxic compound extrusion (MATE) transporters were first identified as a bacterial 
drug transporter. It was identified in prokaryotes and eukaryotes. MATE transporters are 
responsible for eliminating metabolic waste and xenobiotics. It is important for maintaining the 
homeostasis of the CNS (Moriyama et al., 2008; Sekhar et al., 2019). MATE1 (SLC47A1) was 
primarily found in human brain microvessels > 10 µm in diameter by western blotting and 
immunohistochemistry (Geier et al., 2013).  
 
1.4.3.9 Peptide transporters  
Peptide transporters belong to the SLC15A superfamily. There are 4 members of SLC15A 
superfamily: peptide transporter-1 (PEPT1; SLC15A1), peptide transporter-2 (PEPT2; SLC15A2), 
peptide/histidine transporter-1 (PHT1; SLC15A4), and peptide/histidine transporter-2 (PHT2; 






transport peptides across membranes. PEPT1 has not been found in the CNS while PEPT2 has 
been identified in the cerebral cortex, cerebellum, astrocytes, and choroid plexus. PHT1 was 
found in rat brain at hippocampus, cerebral cortex, and cerebellum. PHT2 has a high affinity for 





1.5 Drug delivery strategies across the BBB 
1.5.1 Invasive approaches  
In order to increase drugs permeability across the BBB, invasive methods such as intracerebral 
implants and intraventricular infusion of drugs have been used in the past. Another approach is 
to open the BBB temporarily with an intracarotid infusion of hypertonic solutions containing 
mannitol or arabinose. However, these methods can expose the CNS to toxins and may lead to 
severe side effects (Sanchez-Covarrubias et al., 2014).  
 
1.5.1.1 Disrupting BBB 
The BBB can be opened by intracarotid infusion of hypertonic solutes such as arabinose and 
mannitol solutions. This is also known as the osmotic opening of the BBB. The process is 
regulated by vasodilation and shrinkage of brain endothelial cells. The inter-endothelial tight 
junctions can be widened and let therapeutic drugs cross the BBB (Rapoport, 2000).  
 
Figure 1-11 Osmotic modification of the BBB. (a). Brain capillary endothelial cells with tight junctions without 
anatomic space (b) Osmotic modification induces retractions of the cell membrane and the BBB was 
physically opened. The image was taken from (Bellavance, Blanchette and Fortin, 2008). 
 
Rapoport, Hori and Klatzo (1972) applied several concentrated solutions of electrolytes and 
nonelectrolytes to the pia-arachnoid surface of rabbit brain. It was found that the less lipophilic 
electrolytes opened the blood-brain barrier in a reversible manner, while lipophilic propylene 
glycol opened the barrier irreversibly. Greenwood (et al., 1988) investigated the impacts of 
hyperosmolar solutions of arabinose and mannitol on the permeability of the BBB. He perfused 
hyperosmolar solutions into rat brain and he found that within 1 min of perfusion, the BBB was 
consistently opened. Also, [14C]mannitol and Evans blue were used as indicators of membrane 
integrity. The accumulation of radiolabeled hyperosmolar solutions, which was expressed as the 
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ratio of brain tissue to perfusate radioactivity for cerebrum, increased with the increasing 
concentration of arabinose. He concluded that the opening of BBB by osmotic barrier is caused 
by the passive shrinkage of brain endothelial cells. Fredericks and Rapoport  (1988) infused 1.8 
M arabinose in water into the internal carotid artery of mice brain. The process of osmotic opening 
is concentration-dependent and can be revered within 4 hs with no long-term neurologic deficit. 
 
1.5.1.2 Increasing the permeability of BBB with pharmacological agents   
Some pharmacological agents such as histamine and vasoactive peptides can temporarily 
increase the permeability of the BBB by targeting inflammatory mechanisms. These agents can 
disrupt the BBB temporarily and create pores that are large enough to let molecules cross 
through. Disrupting the BBB often cause severe side effects and damage neurons (Kasinathan 
et al., 2015). Cereport is a bradykinin analogue can increase the permeability of the BBB for 
chemotherapy drugs. However, clinical studies on patients did not show the improvement of the 
efficacy of the chemotherapy drug carboplatin by using cereport (Prados et al., 2003). 
Regadenoson is an adenosine receptor agonist which could disrupt the BBB and increase the 
BBB permeability of dextran and temozolomide in rodents. However, clinical studies on humans 
did not exhibit improved permeability of BBB by regadenoson (Jackson et al., 2017).  
 
1.5.1.3 Focused ultrasound 
Focused ultrasound with intravenously injected microbubbles can disrupt the BBB and open its 
tight junctions at the specific location. This method is also known as sonoporation. The injected 
microbubbles have a diameter of 1-10 µm, wrapped by lipid or protein with heavy gases inside. 
Compared to other invasive approaches to opening the BBB, focused ultrasound is less invasive 
because it is focused on specific areas of the brain, does not damage intermediary tissues, and 
the disrupted membrane integrity of the BBB can recover within a few hs. The disadvantage of 
the focused ultrasound may cause inflammatory reactions to the targeted area of the brain 
(Kovacs et al., 2017; Bors and Erdő, 2019). Using focused ultrasound with intravenously injected 
microbubbles, the BBB in rabbit brain was opened. Trypan blue was injected to rabbits 
intravenously before the rabbit was killed and could be identified at the sonicated sites in rabbit 




Figure 1-12 Sonoporation with focused ultrasound. Microbubbles can target the specific area in brain and 
improve the efficiency of sonoporation. The image was taken from (Bors and Erdő, 2019).  
 
1.5.2 Non-invasive methods  
1.5.2.1 Changing the solubility of drugs  
Improving the lipid solubility of a drug can enhance its passive diffusion across the BBB. Although 
the octanol-water shake flask method has been a traditional method to determine the lipophilicity 
of a drug, the number of hydrogen bonds may be a better determinant. Low hydrogen bonds 
indicate high lipophilicity. Chikhale (et al., 1994) investigated the permeability of a series of model 
peptides using an in vitro model of the BBB - bovine brain microvessel endothelial cell (BBMEC) 
monolayers and in situ method with rat brain perfusion. The results indicated that there was no 
correlation between the octanol-water partition coefficients of those peptides and BBB 
permeability; instead, inverse correlations (r=0.837 in vitro and r=0.906 in situ; P<0.05) were 
found between the hydrogen bonds of peptides with permeability. 
 
With medicinal chemistry methods, the hydrogen bond on drug molecules can be modified or 
removed in order to improve their lipophilicity. Modifying hydrogen bond account number is in 
effect generating a new drug entity. For example, heroin shares a similar structure with morphine, 
but the hydroxy groups of morphine were acetylated to form heroin. This resulted in a higher log 
P of heroin at 2.3 versus the log P of morphine at 0.99 consequently the brain uptake of heroin 
was 100 times higher than that of morphine (Oldendorf et al., 1972; Pardridge, 2012; Mikitsh and 
Chacko, 2014). However,  modifying the hydrogen bond may also reduce the efficacy of the drugs 
and can increase the instability of the hydrogen blocking groups (Pardridge, 2012). Also, 
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increasing the lipophilicity of drugs will also increase its permeation into other tissues rather than 
brain (Tsuji and Tamai, 1997).   
 
1.5.2.2 Prodrug  
Prodrugs are bioreversible derivatives of drug molecules that exhibit pharmacological action after 
enzymatic or chemical biotransformation. Depending on how the prodrug is designed, the release 
rate of active drug can be controlled. As many parent drugs are unstable after administration into 
the human body or suffer from poor solubility issues, using a prodrug can resolve these issues. It 
is possible to design a prodrug which can modify the distribution, toxicity and affect the efficacy 
of the parent drugs (Rautio, Laine, et al., 2008). 
 
Figure 1-13 Concept of prodrug (Rautio, Kumpulainen, et al., 2008; Rautio, Laine, et al., 2008). Promoiety 
is an inactive component of a prodrug. The figure was taken from (Rautio, Laine, et al., 2008). 
 
1.5.2.3 Viral vectors 
Viral vectors can infect genes including small-interfering RNA, short-hairpin RNA, and decoy RNA 
into cells and change the expression of proteins for the treatment of diseases (Mohammed et al., 
2018). The transfection of viral vectors is high at around 80% (Pérez-Martínez, 2012). Several 
viral vectors including herpes simplex virus, adenovirus, lentivirus, and adeno-associated virus 
vectors have achieved gene transduction in the brain. The major concerns of using viral vectors 
are their safety issues and high cost. As viruses normally cannot cross the BBB by passive 
diffusion, invasive approaches such as stereotaxic injection and direct injection into the 
cerebrospinal fluid are needed for the delivery of viral vectors. These delivery methods are 
invasive to patients and can result in severe side effects (Dong, 2018). 
 
Among the viral vectors developed, adeno-associated viral 9 (AAV9) is a promising one as it is 
well-tolerated and is able to cross the BBB through active transport while not damaging the 




Figure 1-14 The transport of Adeno-associated viral 9 (AAV9) and adeno-associated viral 2 (AAV2) across 
the BBB. AAV9 can cross the BBB by active transport. AAV2 cannot cross the BBB by itself. It can be 
provided with a receptor for the ligand in order to use the receptor-mediated transport. The image was taken 
from (Bors and Erdő, 2019).  
 
1.5.2.4 Nanoparticles  
Nanoparticles are colloidal carriers which originated naturally or have been synthesised. Their 
sizes vary ranging from 1 nm to 1000 nm (Saraiva et al., 2016). Nanoparticles offer several 
advantages for drug delivery across the BBB such as chemical and biological stability, flexibility 
to be administered via different routes and the capability of containing both water and lipid-soluble 
drug molecules. Nanoparticles have a large surface-area-to-volume ratio so they can also be 
conjugated with antibodies for targeted drug delivery. Commonly used nanoparticles include lipid-
based nanoparticles (liposomes, solid lipid nanoparticles) and polymer-based nanoparticles 
(polymeric nanoparticles, polymeric micelles, dendrimers) (Masserini, 2013). Nanoparticles can 
cross the BBB through interendothelial diffusion, transcytosis and endocytosis. How a 
nanoparticle passes through the BBB is dependent on the design of its size, charge, and surface 







1.5.2.5 Drug delivery by adsorptive-mediated transcytosis 
Adsorptive-mediated transcytosis (AMT) does not involve specific receptors but requires a net 
positive charge on the molecule to make it cationic, to allow interaction with negative charges on 
the cell surface binding sites. This interaction induces endocytosis and subsequent transcytosis 
(Hervé, Ghinea and Scherrmann, 2008). With the growing evidence of successful drug delivery 
across the BBB through cationic proteins and cell-penetrating peptides, adsorptive-mediated 
transcytosis has gained more attention in recent years. Cell-penetrating peptides are 
amphipathic. They can pass through cells without generating any cytolytic effects, so they can be 
used to deliver drugs without being effluxed by efflux transporters across the BBB (Chen and Liu, 
2012). One of the examples of utilising AMT for drug delivery across the BBB is the synthesis of 
chimeric peptides (CP). CP can be used to deliver peptides across the BBB. CPs are composed 
by coupling a non-transportable peptide to a peptide through covalent binding that can transport 
across the BBB by receptor mediated-transcytosis or absorptive-mediated transcytosis. For 
example, β-endorphin can be coupled to cationised albumin via its disulfide linkage and get 
transported across the BBB through adsorptive-mediated transport (Pardridge, Kumagai and 
Eisenberg, 1987).  
 
1.5.2.6 Drug delivery by receptor-mediated transcytosis 
Drug delivery strategy using receptor-mediated transcytosis (RMT) involves the production of a 
complex between the drug of interest and a ligand or an antibody that can target an endogenous 
receptor at the BBB (Pulgar, 2019). Receptor-mediated transcytosis is an important pathway to 
enter the brain for peptides, including insulin and transferrin (Chen and Liu, 2012). Common 
targets for drug delivery via RMT include the transferrin receptor (TfR), insulin receptor (IR), low-
density lipoprotein receptor (LDLR), FC5, Rabies Virus Glycoprotein among others (Lajoie and 
Shusta, 2015). An interesting example of drug delivery by RMT is ANG2002, a  conjugate of 
Angiopep-2 and neurotensin. Neurotensin is a strong analgesic with limited ability to cross the 
BBB. However, combining neurotensin, with the brain delivery vehicle, angiopep-2 to form 
ANG2020 improves brain delivery by 10 fold. This is due to the interaction of Angiopep-2 with 
low‐density lipoprotein receptor-related protein-1. (Demeule, Currie, et al., 2008; Demeule, 
Régina, et al., 2008; Demeule et al., 2014). By developing a brain shuttle of an anti-Aβ antibody 
which binds to the TfR,  the efficiency of the antibody targeting the β-amyloid in a mouse model 
of Alzheimer’s was enhanced by 55 times (Niewoehner et al., 2014). Inhibitors of β-secretase and 
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γ-secretase APP processing enzymes for treating Alzheimer’s disease have limited transport 
across the BBB. By developing an antibody that targets BACE1 (an inhibitor of the β-secretase), 
it reduced Aβ concentrations in vitro and in vivo of mouse brains (Atwal et al., 2011). IgG fusion 
protein can be used as Trojan horse to transport proteins across the BBB into brain. AGT-181 is 
an engineered protein against the human insulin receptor. It can be used to treat Hurler’s 
Syndrome in humans. AGT-181 is currently studied in Phase II clinical trials by ArmaGen  (Boado 
et al., 2009). 
 
1.5.2.7 Target influx and efflux membrane transporters  
Both influx and efflux membrane transporters can be targeted for drug delivery. As endogenous 
substances could pass through the BBB with the assistance of SLC transporters, the structure of 
a drug compound can be modified to mimic the substrates of SLC transporters. For example, 
levodopa used to Parkinson’s disease is a prodrug of dopamine. Dopamine cannot cross the BBB 
while levodopa can pass the BBB through using an amino acid transporter (Oldendorf and Szabo, 
1976). The limitation of this method is that the drug has to be a similar size and structure of the 
SLC transporter substrate (Patel and Patel, 2017).  
 
For drugs that are substrates of efflux transporters at the BBB, a transporter inhibitor can be co-
administered with substrate drugs. The third generation of P-gp inhibitors including tariquidar, 
zosuquidar, laniquidar, and ONT-093 have been used in chemotherapy regimens (Thomas and 
Coley, 2003). Co-administration of probenecid, an inhibitor of OAT, MRP, and OATP transporters, 




1.6 Ion-pairing method for pentamidine  
A drug can be paired with a counterion to form an ion pair. Ion-pair drugs are formed non-
covalently by a positively charged therapeutic drug and a negatively charged counterion or a 
negatively charged therapeutic drug and a positively charged counterion. This ion-pairing method 
is a useful strategy to facilitate the delivery of ionised hydrophilic therapeutic drugs across 
biological membranes. The ion-pair formation could improve the lipid solubility of the therapeutic 
drug thereby enhancing its permeability across biological membranes (Neubert, 1989). At the 
molecular level, the positively charged group of the therapeutic drug is masked and coated by the 
hydrophobic group on the counterion through ion-pairing (Ristroph and Prud’homme, 2019).  
 
The ion-paring method has advantages of improving the lipophilicity of drugs while not affecting 
their efficacies (Suresh and Paul, 2011a). For a therapeutic drug to be suitable for ion-paring, the 
drug needs at least one charged group on its structure, such as compounds with positively 
charged amine groups or negatively charged carboxylic acid groups at physiological pH. It is 
straightforward to pair with molecules with only positive or only negative charges. For a 
zwitterionic molecule with both positive and negative charges on its structure, ion-pairing could 
be complicated. One way to make it easier is to change the pH environment so that only one type 
of charge is shown. In addition to the charges on molecules, the charge density which is 
calculated by the charge per molecular weight would also affect ion-pairing. Normally, pairing a 
counterion with a single charged molecule with smaller molecular weight will be more effective 
than pairing the same counterion to a single charged molecule with an extremely large molecular 




Figure 1-15 The concept of ion-pairing method. The image was taken from (Ristroph and Prud’homme, 
2019). (A) Common charged groups (left) and hydrophobic moieties for counterions (B) Stoichiometry of ion 
pairs, 1:1 charge ratio (C) Non-stoichiometric ion pairing. (D) Reverse of ion-pairing with inadequate binding 
or hydrophobicity 
 
The ion-pairing strategy has successfully improved delivery across transdermal, ocular, oral, 
parenteral and nasal routes (Suresh and Paul, 2011a). Tan (et al., 2009) found that the 
permeation of glipizide across rat skin was enhanced by ion-pairing with amine counterions such 
as diethylamine and triethylamine. This study showed that ion-pairing was a useful method to 
enhance the skin permeation of glipizide. Miller (et al., 2010) selected 1-hydroxy-2-naphthoic acid 
(HNAP) as the counterion to pair with the antiviral drugs, zanamivir heptyl ester and guanidino 
oseltamivir, and increased the log P of antiviral drugs by up to 3.7 log units. He also found that 
ion-pairs with stronger binding were more likely to be effective in vivo, as the rat jejunal of 
zanamivir heptyl ester-HNAP ion-pair with higher binding affinity had higher permeability than the 
guanidino oseltamivir-HNAP ion-pair with lower binding affinity. 
 
Studies on ion-pairing had been focused on the physicochemical properties of drugs until the last 
decade. In recent years, the involvement of membrane transporters in the transport of ion pairs 
has been examined. ElShaer, Hanson and Mohammed (2014) found that the lipophilicity of 
indomethacin was increased by forming ion-pairs with the counterions, arginine and lysine, as 
measured by octanol-water partitioning. An in vitro study on Caco-2 monolayers revealed that the 
transcellular uptake of indomethacin was saturable when counterions were present, with the 
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highest accumulation being observed at the 60-min time-point.  This suggested a transporter 
could be involved, although the specific transporter was not identified. Benaouda (et al., 2018) 
showed that theophylline ion-pairing with a polyamine transporter system substrate spermine 
could increase theophylline delivery to the lungs. A 3.6-fold increase in the accumulation of 
theophylline in lungs was observed after vascular administration by ion-pairing theophylline with 
spermine. She also suggested that the ion-pair formation could change dramatically with pH as 
the ion-pair dissociated completely when the pH dropped from 9.6 to 7.4 according to in silico 
simulation. 
 
In this study, we selected pentamidine as a drug for reformulation. Pentamidine has pKd1 and pKd2 
of 12.13 and 11.53 (MarvinSketch version 17.28, ChemAxon). It can be classed as a strong basic 
and has two positive charges at physiological pH. The two amidine groups on pentamidine have 
the potential to pick up protons from acids in solutions, which makes pentamidine an ideal drug 
candidate for the ion-pairing method. 
 
1.7 Summary  
• Pentamidine is a safe and effective drug for treating sleeping sickness. However, it cannot 
be used for the late-CNS stage of HAT due to its inability to cross the BBB. 
• Ion-pairing method is a cost-effective and non-invasive method to improve drug transport 
across biological membranes. This method, however, has not previously been used to 
improve drug delivery across the blood-brain barrier. 
 
The physicochemical characterisation of pentamidine ion-pairs will be discussed in Chapter 2. In 
Chapter 3 and Chapter 4, we will examine the influence of OCT1 and P-gp, respectively on the 





1.8 General aim and hypothesis of this PhD project  
The aim of this study was to investigate if reformulating pentamidine with a counterion to form an 
ion pair would improve the ability of pentamidine to cross the BBB by passive diffusion and/or by 
interaction with specific transporters (i.e. hOCT1 and P-gp). There were three hypotheses tested 
in this project:  
 
1. The passive diffusion of pentamidine across the blood-brain barrier is improved by ion pairing.  
2. The ion-pairing of pentamidine increases the transport of pentamidine by hOCT1.  
3. Pentamidine ion-pairs inhibit the efflux of pentamidine by P-gp transporter expressed at the 
blood-brain barrier.  
 












Chapter 2 Physicochemical Characterisation of Pentamidine 
Ion-pairs  
2.1 Chapter overview  
In this chapter, we will discuss the selection of counterions to form ion pairs with pentamidine to 
improve the delivery of pentamidine to the CNS and examine the specific physicochemical 
characteristics of the pentamidine ion-pairs by various methods.   
 
2.2 Introduction  
Physicochemical properties are crucial in predicting the pharmacokinetics process, which 
involves Absorption, Distribution, Metabolism, Elimination and Toxicity (ADMET) of compounds. 
The understanding of physicochemical properties of molecules, including lipophilicity, molecular 
weight (MW), hydrogen bonding and charges enables scientists to develop drugs with high 
efficacy and minimal side effect. Drugs with optimal ADMET properties are potent molecules that 
can reach target tissues selectively with adequate concentrations (Guan et al., 2019). 
 
2.2.1 Physicochemical characteristics for drug development  
2.2.1.1 Lipophilicity 
One of the most important physicochemical characteristics is lipophilicity. Lipophilicity reflects the 
ability of compounds to permeate from the aqueous phase to the organic phase and thus serves 
as an indicator for passive transport of drugs across lipid membranes. Lipophilicity is often 
measured by partition coefficient (log P) for unionised compounds, or by distribution coefficient 
(log D) for pH-dependent ionised solutes between octanol and water using the shake-flask 
method (Arnott, Kumar and Planey, 2013). According to literature reviews, compounds with a log 
P at 1-3 have optimal ADMET properties. Therefore they are more likely to progress through the 
different stages of the drug development process (Lipinski et al., 2001; Gleeson, 2008; Waring, 
2010). Compounds with too low log P values often have poor ADMET; If the lipophilicity of a 
compound is too high (log P > 5), it will have poor solubility, a higher chance of eliciting toxicity, 




2.2.1.2 Molecular Weight 
Drugs with molecular weight > 500 Da generally have poor absorptions, according to the “Rule of 
Five” (Lipinski et al., 2001). It was found that the permeation of drugs at the blood-brain barrier 
decreased 100-fold when the molecular weight increased by 150 Da from 300 Da (Pardridge, 
2012). 
 
2.2.1.3 Hydrogen bonding 
Hydrogen bonding reflects the water solubility of molecules. The higher the number of hydrogen 
bonds, the lower the membrane permeability. It has been shown that an increase of one pair of 
hydrogen bonds will decrease membrane permeability 10 fold (Pardridge, 2012). Lipinski (et al., 
2001) suggested that the drug membrane permeation was poor when hydrogen accepter count 
was > 10, or hydrogen donor count was >5. It was also found that the central nervous system 




The charge state of a molecule influences the absorption of drugs across membranes. For drugs 
that can successfully pass through the blood-brain barrier (BBB), most of them have one positive 
charge at pH 7-8. Many CNS drugs share a common tertiary nitrogen on their structure which 
allows them to be positively charged at physiological pH environment (Clark, 2003). As brain 
endothelial cells have a negatively charged glycocalyx (Ribeiro et al., 2012), drugs molecules with 
one positive charge at physiological pH are facilitated across the BBB as their charges are 
neutralised when they cross the BBB. Molecules that are classed as a strong base or as a strong 
acid have a limited ability to cross the BBB (Pajouhesh and Lenz, 2005). The charge state of 
drugs could be predicted by its dissociation constant pKd (Avdeef, 2012). It was found that 






2.2.2 Pentamidine ion-pairing strategy  
In this study, we selected pentamidine as a drug for reformulation. Pentamidine is an aromatic 
diamidine and has been used for treating early-stage of gambiense HAT since the 1940s (Yang 
et al., 2014). Pentamidine has pKd1 and pKd2 of 12.13 and 11.53 (MarvinSketch version 17.28, 
ChemAxon). It has a molecular weight of 340.19 g/mol. It can be classed as a strong base and 
has two positive charges at physiological pH (See Table 2-1 for pentamidine structure and 
characteristics). The two amidine groups on pentamidine have the potential to pick up protons 
from acids in solutions, which makes pentamidine an ideal drug candidate for ion-pairing method.  
 
In this study, we tested the hypothesis that a -1 charged counterion can bind to the +2 pentamidine 
and form a +1 charged ion-pair and in doing so make pentamidine more lipophilic and more likely 
to be transported across the BBB by passive diffusion.  
 
2.2.2.1 Counterions for pentamidine ion-pairs  
We selected four counterions which have -1 charge at pH 7.4. They included taurodeoxycholate, 
octanoate, quercetin and xinafoate. They are described in more detail in the following section and 
their physicochemical properties are summarized in Table 2.1. 
 
(1) Taurodeoxycholate: is an anionic bile salt and has been used to treat multiple diseases such 
as neurological disorders (Gronbeck et al., 2016), ocular diseases (Boatright et al., 2009), 
regulate apoptosis (Amaral et al., 2009) and relieve inflammation in throat (Wang and Carey, 
2014). Taudeoxycholate has previously been used for ion-pairing. For example, Lee (et al., 1988) 
used taurodeoxycholate to pair with isopropamide iodide. The partition coefficient of isopropamide 
iodide which was measured using the n-octanol and phosphate buffer shake flask method at pH 
7.4 was improved through ion-pairing with isopropamide iodide. The octanol-phosphate buffer 
(pH 7.4) shake flask method was also used to confirm the increased partition coefficient of 
methylene blue with sodium taurodeoxycholate (Shim 1986). Also, when sodium 
taurodeoxycholate with methylene blue was infused into rats, the systemic distribution of 
methylene blue in the whole blood of rats was increased. 
 
(2) Octanoate (octanoic acid), also called caprylic acid: has been found in coconut, babassu and 
milk fat (Beare-Rogers, Dieffenbacher and Holm, 2001). It has been proven to be a cheap option 
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to treat frequent urination. It also has the potential to treat infections, ageing and cancer  (Omura 
et al., 2011). Salbutamol is a beta2-adrenergic receptor antagonist to treat asthma and chronic 
obstructive pulmonary disease. It is rapidly eliminated after being administered, so patients have 
to take it several times a day. Octanoate has been explored as a counterion for the ion-pair drug 
delivery of salbutamol to the lung. The ion-pair formation of salbutamol-octanoate has been 
confirmed by Fourier Transformed infra-red spectroscopy. In vivo study indicated that ion-pairing 
salbutamol with octanoate could prolong half-life by extending the duration of salbutamol to stay 
in the lung (Dutton, 2018).  
 
(3) Quercetin: is a natural flavonoid that has been found extensively in vegetables, fruits, and 
herbs. It has been used to treat rheumatoid arthritis and reduce the risk of infections (Davis, 
Murphy and Carmichael, 2009; Ji et al., 2013). Quercetin is also an anticancer agent as it can 
suppress cyclin-dependent kinases, induce apoptosis, inhibit enzymes that cause 
carcinogenesis, modify signal transduction pathways, among others (Pangeni et al., 2018).  
 
(4) Xinafoate (1-hydroxy-2-naphthoic acid): has been used to form a salt with salmeterol, a beta-
adrenergic agonist, for chronic obstructive pulmonary disease. This salt form can improve the 
lipophilicity of salmeterol and extend the time at the site of action (Ticehurst and Marziano, 2015; 
Gupta et al., 2018). Xinafoate has also been used for ion-pairing with antivirals which have poor 
oral absorption and limited intestinal permeability. It was found that the use of xinafoate to form 
ion-pairs with two antiviral compounds heptyl ester and guanidino oseltamivir could enhance their 
lipophilicity (log P) by up to 3.7 log units. In addition, the permeability of heptyl ester and guanidino 
oseltamivir across Caco-2 cell monolayers was enhanced by the increasing concentration of 
xinafoate (Miller et al., 2010). (Patel et al., 2016) found salbutamol-xinafoate ion-pairs exhibit 
significant bronchodilator effect compared to salbutamol base. When salbutamol-xinafoate ion-
pair was tested on guinea pig tracheal parts, a faster (p<0.05) distribution rate was observed than 
salbutamol alone.  
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*Log D and Log P were predicted using MarvinSketch (version 17.28, ChemAxon) 
Compound MW (g/mol) *Predicted  






Pentamidine  340.4 -2.50 2.32 +2 
 
Taurodeoxycholate 521.7 2.23 2.33 -1 
 
      
Octanoate 166.2 2.70 2.70 -1 
 
 
Quercetin 302.2 2.16 2.16 -1 
 




The hypothesis of this chapter is that the passive diffusion of pentamidine across the blood-brain 
barrier is improved by ion pairing. The aim of this chapter is to examine the physicochemical 
properties of pentamidine ion-pairs.  The specific objectives are as follows:  
• To measure the lipophilicity (Log D) of pentamidine alone and when bound to a 
counterion (i.e. the ion-pair) by shake-flask and fluorescence methods; 
• To investigate the binding site of the counterion with pentamidine with 13C-NMR and 1H-
NMR by assessing the chemical shift of H and C assigned to pentamidine in the 
presence of counterions;   
• To determine the association constants (binding constants, pKa) of pentamidine ion-
pairs using HPLC and fluorescence methods;  
• To estimate the percentage of pentamidine (%) bound with counterions 
(taurodeoxycholate, octanoate and xinafoate) in solutions using Hyperquad Simulation 
and Speciation (HySS) software; 
• To further confirm the presence of pentamidine ion-pairs and understand the 
dissociation (pKd) of pentamidine ion-pairs with fluorescence-lifetime imaging 





2.3 Materials and methods 
2.3.1 Materials  
Pentamidine isethionate (>=98%), xinafoate (1-Hydroxy-2-naphthoic acid) (>=97.0%), Dimethyl 
sulfoxide-d6 (>=99.9 atom % D), sodium chloride (>=99.5%), phosphoric acid (ACS reagent, 
>=85%, wt % in H2O)  were purchased from Sigma-Aldrich (Dorset, UK), sodium octanoate 
(>=99.0%), quercetin (>=95.0%), sodium taurodeoxycholate hydrate (>=95.0%) were from Sigma 
Life Science, deuterium Oxide (>=99.90%) was purchased from Fluorochem Ltd (Derbyshire, 
UK), DAPI (hydrochloride) was purchased from Cayman Chemical (Cambridge, UK). Tris base 
(for Molecular Biology) was purchased from Fisher Scientific (New Jersey, US). 1-Octanol (99%, 
pure) was purchased from Acros Organics UK. Potassium phosphate monobasic for HPLC 
(>=99.5%), hydrochloric acid (p.a.>=32%), sodium hydroxide standard solution (1.001 mol/L) 
were purchased from Fluka, Japan. Acetonitrile (>=99.9%) was purchased from Honeywell 




Table 2-2 Concentrations of pentamidine used in different methods 
Methods Concentrations of pentamidine  
HPLC calibration curves 0 - 168.9 µM 
Chemical stability by HPLC 0 - 168.9 µM 
*Octanol-saline shake-flask  *Pentamidine was used at two concentrations 
depending on the solubility of the counterion. 33 µM of 
pentamidine was used with taurodeoxycholate and 
octanoate and 8 µM of pentamidine was used for 
quercetin and xinafoate. The molar ratios of 
pentamidine: counterion are 1:0 - 1:20 
Fluorescence Pentamidine was utilised at a concentration of 8 µM for 
xinafoate 
NMR Pentamidine was utilised at a concentration of 11.2 mM 
for xinafoate 
HySS Pentamidine was set at 9 nM, 8 µM, or 8 mM with equal 
or 20 times molar ratio of each counterion 
FLIM  The concentration of pentamidine was 8 mM or 8 µM 
with 20 times molar ratio of xinafoate 
* The solubility of the counterions was estimated by dissolving each of the counterions in saline and then 
increasing the amount of counterions gradually until sediment was visually seen in the solution.  
* Quercetin and xinafoate have limited solubility (< 200 µM) in saline, therefore, the concentrations of 
quercetin and xinafoate utilised were 8 - 160 µM, which were much lower than taurodeoxycholate and 
octanoate (33 - 660 µM) used in the octanol-saline shake-flask method.  
* In order to compare the results, the concentrations of pentamidine were 1/20 - 1 folds of the molar 
concentration of each counterions. So, 33 µM of pentamidine was used with taurodeoxycholate and 
octanoate and 8 µM of pentamidine was used for quercetin and xinafoate.  
 
2.3.2 High Performance Liquid Chromatography (HPLC) analysis of pentamidine 
Pentamidine was quantified isocratically by HPLC (Spectra-Physics P4000 Quaternary Pump, 
WatersTM 996 Photodiode Array Detector, Waters 717plus Auto Sampler) with an Bondapak C18 
Column (Waters, 3.9 mm X 300 mm). The mobile phase consisted of 0.025M monobasic 
potassium phosphate and acetonitrile (76%:24%, v/v; pH 3.2 regulated by phosphoric acid). The 
solution was filtered through a 0.45 m pore size membrane filter (Hewlett Packard®, Germany) 
and then degassed by sonication. The flow rate was set at 1 ml/min. The UV determination 
wavelength was set at 264 nm. The injection volume was 50 l. The experiment was conducted 




In order to evaluate the suitability of HPLC method for the quantification of pentamidine in the 
following saline-octanol shake flask method, pentamidine standard solutions in different 
concentrations ranging from 2 µg/ml (3 µM) to 100.0 µg/ml (168.9 µM) were prepared in mobile 
phase and in physiological saline saturated with octanol. The samples were measured in 
triplicates by HPLC. Then a calibration curve was generated by plotting the peak area from HPLC 
(y-axis) against the concentrations of pentamidine. The results were fit into a regression model in 
GraphPad7, where an equation for the relationship between peak area and concentrations of 
pentamidine, and R-squared value were acquired. The Limit of Detection (LOD), the Limit of 








            (Equation 2-2) 
In the above equations, σ and S represent the standard deviation of the response and the slope 
of the calibration curve, respectively.  
 
The coefficient of variance (CV) was calculated as follows: 
CV% = 100% * standard deviation of peak area / mean of peak area         (Equation 2-3) 
 
2.3.3 Chemical stability of pentamidine solutions  
The standard pentamidine solutions (5.88 M - 293.75 M) in HPLC capped vials were kept at 
both room temperature and 37°C water bath. After 2, 7, 14 and 28 days, the concentrations of 
pentamidine in these samples were measured in triplicates by HPLC as described in 2.3.2. Data 
were analysed by two-way ANOVA with GraphPad 7. Results were compared to the initial 
concentrations of pentamidine (control) and expressed as a percentage of recovery:  
 
Recovery (%) = Pentamidine Conc(t) / Pentamidine Conc(Initial), where (t) is sampling times at 2, 7, 




2.3.4 Octanol-saline shake flask method  
2.3.4.1 Ion-pairing theory 
Miller (et al., 2009) established the quasi-equilibrium mass transport analyses for hydrophobic 
molecules in octanol-buffer shake-flask method. Based on his theory, we assume that 
pentamidine and the counterion could form ion-pairs in the aqueous phase (saline) and these ion-
pairs are in equilibrium with pentamidine and the counterion alone (Figure 2-1). Also, it is assumed 
that the pentamidine in the organic phase (octanol) exists in the form of ion-pairs only, since the 




Figure 2-1 The equilibrium of pentamidine, counterions and ion-pairs in octanol and saline.  
 
The logarithm distribution coefficient (Log D) of pentamidine can be calculated as follows: 
Log D = Log [([PEN]In - [PEN]aq) / [PEN]aq]          (Equation 2-5) 
[PEN]In represents the initial concentrations of pentamidine added to the octanol-saline system; 
[PEN]aq stands for the total concentration of pentamidine in the aqueous phase. The result of 
([PEN]In - [PEN]aq) is the concentration of pentamidine in octanol. The [PEN]aq is measured by 
HPLC following the shake-flask method. HPLC is a precise, convenient and well-established 
method. However, the limitation of using HPLC in this study is that it can only detect free 
pentamidine rather than pentamidine ion-pairs in the aqueous phase saline.  
 
2.3.4.2 Shake-flask method 
In order to determine the lipophilicity of pentamidine and pentamidine ion pairs, the shake-flask 
method was utilised. 2 ml of 0.9% saline (pH=7.4) was pre-saturated with 2 ml of octanol for 48 
hs before experiments. Pentamidine and the counterions were dissolved in 2 ml of octanol 
saturated saline (pH 7.4) at the following molar ratios: 1:0, 1:1, 1:2, 1:4, 1:8, 1:12 and 1:20. The 
pentamidine concentration was 20 µg/ml (33 µM) for ion-pairing with taurodeoxycholate and 
octanoate, or 5 µg/ml (8 µM) for pairing with xinafoate and quercetin. The ion-pairs in pre-
saturated saline solutions were equilibrated with an equal volume of pre-saturated octanol at 37 
°C shaker for 24 hs. After the equilibrium, the bottom aqueous layer was carefully extracted by a 
fine tip glass pipette and measured by HPLC. Each sample was measured by HPLC for three 
times. The concentration in the octanol layer was calculated by mass balance method. Then the 
Pentamidine (PEN) + Counterions (CI) ⇌ Ion-pairs (PENCI)            Ion-pairs (PENCI) 








distribution coefficient of pentamidine (Log D) was calculated as Equation 2-5 by dividing the 
concentration of pentamidine in the octanol phase by the concentration in the aqueous phase, 
saline, and converted to the logarithm. The experiments were repeated (n=3) and results were 
expressed as the mean ± standard deviation.  
 
2.3.5 1H NMR and 13C NMR spectroscopy  
Nuclear magnetic resonance (NMR) can provide information on the binding sites of pentamidine 
with the counterion to form the ion pair. Since xinafoate has the largest predicted Log P value 
among the four counterions, it was selected as a template compound in the NMR method to study 
pentamidine ion-pairs. NMR spectra were measured by Bruker AscendTM 400 MHz 
Spectrometer at 298.0 K. Data were processed and analysed by TopSpin 3.5pl7 software. 
Samples were loaded into the Wilmad® 5 mm Thin Wall Precision NMR tubes.  The chemical 
shifts were relative to the DMSO residual signal at 2.5 ppm for 1H-NMR and at 39 ppm for 13C-
NMR.  
 
The concentration of pentamidine was 11.2 mM with or without equal or 20 times molar ratios of 
xinafoate. Xinafoate has very low solubility in pure D2O. Only 228.7 mg/l xinafoate can dissolve 
in water at 25°C. Therefore, DMSO-d6 and mix solution of DMSO-d6 and D2O (1%) were used 
as the solvent instead. This allows us to determine if there were the differences in the pentamidine 
spectra with the presence of water. A volume of 700 µl for each sample was loaded into NMR 




2.3.6 Fluorescence spectroscopic characterisation of ion-pairs  
2.3.6.1 Method validation for DAPI and Pentamidine  
The NMR study described above revealed that the amidine groups on pentamidine interacted 
with the counterion, xinafoate. In order to confirm the binding sites and to determine the binding 
constants of pentamidine - xinafoate ion-pairs, both DAPI (4′,6-diamidino-2-phenylindole) and 
pentamidine were used to form an ion-pair with xinafoate for the fluorescence study. DAPI (4’,6-
diamidino-2-phenylindole) has been used as a useful DNA-specific fluorescent probe for decades 
(Kapuscinski, 1995). It has a similar structure as pentamidine with two amidine groups and +2 










The fluorescence intensity of DAPI and pentamidine was measured by Cary Eclipse fluorescence 
spectrophotometer with Hellma fluorescence ultra-micro cuvette (path length 3x3 mm) with a 
200-2500 nm spectra range. Samples were dissolved in 50 nM Tris-buffer at pH 7.4. Each 
sample’s pH was checked by Hanna Checker pH Meter and regulated at 7.4 for measurement.  
 
DAPI was excited at 358 nm and the maximum emission was at 461 nm. The excitation slit and 
emission slit were set at 5 nm. The scan rate was set at 600 (nm/min) with averaging time at 0.1 
s and data interval at 1.0 nm. The detector voltage was set at 800 v. Pentamidine was excited at 
270 nm and its maximum emission was at 340 nm. The excitation slit and emission slit were set 
at 5 nm. The scan rate was set at 120 (nm/min) with an averaging time of 0.5 s and 1 nm data 
interval. The detector voltage was set at 800 v. Standard solutions (2-10 g/ml) of DAPI and 
pentamidine were prepared and calibration curves were plotted using the maximum fluorescence 
intensity against the concentrations of drugs. The R-squared value, Limit of Detection (LOD) and 
Limit of Quantification (LOQ) were acquired by regression analysis.  
 
2.3.6.2 Fluorescence quenching in the presence of xinafoate 
DAPI was utilised as an alternative for pentamidine in order to confirm the binding of amidine 
groups with xinafoate. The fluorescent intensity for a concentration of 4 g/ml (11.4 M) DAPI in 
50 nM Tris buffer (pH 7.4) was measured with equal and 20 times molar ratios of xinafoate at 358 
nm excitation wavelength. The concentration of pentamidine in 50 nM Tris buffer was 8 µM with 
different molar ratios (1:2,1:4, 1:6, 1:8, 1:16,1:20) of xinafoate at pH 7.4. The sample was excited 
at 270 nm and the maximum emission intensity of pentamidine was measured. 
 
2.3.7 Binding constants of pentamidine ion-pairs 
The binding constants here measure how tightly pentamidine is bound to each of the counterions. 
The binding constants (pKa) of ion-pairs were generated by (a) HPLC and (b) fluorescence 
spectroscopy. As pentamidine has two amidine groups which could allow it to bind to one or two 
-1 charged counterion, both 1:1 and 1:2 stoichiometries were assumed: 
PEN+αCI ⇌PEN•CI                                                                       (Equation 2-6) 




2.3.7.1 The binding constants of pentamidine-taurodeoxycholate, pentamidine-octanoate, 
pentamidine-xinafoate, and pentamidine-quercetin ion-pairs determined by HPLC 
The percentage bound of pentamidine with different molar ratios of counterions was estimated 
based on the lipophilicity (distribution coefficients) of pentamidine determined by HPLC. It is 
assumed that the two potential binding sites on pentamidine are fully bound when there are 20 
times molar ratio of counterions in the solution.   
 
The percentage bound of pentamidine: 
PENBOUND% = (LogD1- LogD0) * 100% / (LogD20 - LogD0)                (Equation 2-7) 
where LogD1 represents the logarithm distribution coefficients of pentamidine with different molar 
ratios of counterions (1:1,1:2, 1:4, 1:8, 1:12, 1:20), LogD0 represents the logarithm distribution 
coefficients of pentamidine without any counterion, LogD20  represents the logarithm distribution 
coefficient of pentamidine with 20 molar ratios of counterions. 
 
To calculate the percentage bound of counterions to pentamidine: 
(a) under the 1:1 stoichiometry assumption,  
CIBound% = PENBound%                                                (Equation 2-8) 
(b) under the 1:2 stoichiometry assumption, 
CIBound% = PENBound% / 2                                           (Equation 2-9) 
where PENBound% and CIBound% represent the percentage bound of pentamidine and percentage 
bound of counterions, respectively. 
 
Then the free unbound concentrations of counterions are calculated by subtracting the 
counterions bound to pentamidine: 
[CI]free= [CI]Initial*(1- CIBound%)                                  (Equation 2-10) 
where [CI]Initial is the initial concentration of counterions added in the solution and CIBound% is the 
percentage bound of counterions. 
 
Then the percentage bound of pentamidine (PENBound%) and the concentrations of free unbound 
counterions ([CI]free) were fit into the Sigmoidal model where the binding constants of pentamidine-
counterion ion pairs were generated. 
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2.3.7.2 Fluorescence binding studies of pentamidine - xinafoate ion pairs 
The percentage bound of pentamidine with different molar ratios of xinafoate was calculated 
based on the change of fluorescence intensity of pentamidine with xinafoate. It is assumed that 
pentamidine is fully bound when there is 20 times molar ratio of counterions in the buffer.   
 
The percentage binding of pentamidine: 
PENBound % = (I0- I1) * 100% / (I0 - I20)                                 (Equation 2-11) 
where I0 represents the fluorescence intensity of pentamidine without xinafoate, I1 represents the 
fluorescence intensity of pentamidine with certain molar ratios (1, 2, 4, 8, 12, or 20) of xinafoate, 
I20 represents the fluorescence intensity of pentamidine with 20 molar ratios of xinafoate.  
 
The percentage binding of counterions was calculated by Equations 2-8, 2-9. The free unbound 
concentrations of xinafoate are calculated by subtracting the counterions bound to pentamidine: 
[CI]free= [CI]Initial*(1- CIBound%)                                         (Equation 2-12) 
where [CI]Initial is the initial molar concentration of xinafoate added in the solution and CIBound% is 
the percentage bound of xinafoate 
 
Then the percentage bound of pentamidine (PENBound%) and the concentrations of free unbound 
counterion xinafoate ([CI]free) were fit into Sigmoidal model in GraphPad 7 to calculate the binding 
constants of pentamidine-xinafoate ion pairs. 
 
2.3.8 Hyperquad Simulation and Speciation (HySS)  
The percentage of pentamidine bound with the selected counterions (taurodeoxycholate, 
octanoate and xinafoate) in the various physiological compartments was predicted using 
Hyperquad Simulation and Speciation (HySS2009, Protonic Software), a computer programme 
for titrations and speciation (Alderighi et al., 1999). This software has been developed for the 
determination of stability constants and is a powerful tool to estimate ratios of multiple 
microspecies when complexes are formed in solutions. For example, Benaouda (et al., 2018) 
estimated the microspecies of spermine-theophylline ion-pair complexes for drug delivery to the 
lungs. Fazary & Ramadan (2014) utilised HySS to gain equilibria information on complexes of 




The HYSS computer program requires the following information: the pH range used for 
determination of microspecies, knowledge of the molar concentrations and molar ratios of 
pentamidine to counterion, and binding constants for each pentamidine-counterion complex. 
 
2.3.8.1 Pentamidine: counterion ion-pair complexes 
For the purposes of our study, microspeciation was determined over the pH range of 2-12. 
Pentamidine concentration was set at 9 nM or 8 µM, while the concentrations of 
taurodeoxycholate, octanoate, xinafoate were set at equal (i.e. 1:1 molar ratio) and 20 times molar 
ratios of pentamidine (i.e. 1:20 molar ratio). The counterions were assumed to bind with 
pentamidine at 1:1 molar ratio to one of the amidine groups of pentamidine. Binding constants 
were determined experimentally by HPLC for each pentamidine-counterions complex (Section 
2.3.7.1). 
 
In order to utilise the HySS software for simulations, three requirements need to be met and they 
are: (1) A chemical model needs to be hypothesised. (2) The logarithms of the overall stability 
constants (log β) of the complexes and any micro-species formed need to be determined. (3) The 
experimental procedure needs to be defined (Alderighi et al., 1999). As for the pentamidine 
complexes in our study, our assumptions for each requirement are explained as follows:  
 
(1) Requirement 1: A chemical model needs to be hypothesised.  
For the pentamidine ion-pairs, we assumed that one 2+ ionised pentamidine (PENH2) bound 
to one negatively charged counterion (CI) and formed an ion-pair (PENCIH2) at pH 7.4. In 
addition to the ion-pair complexes (PENCIH2) in solution, the +2 ionised pentamidine 
(PENH2) self-dissociates and exists in the forms of +1 ionised pentamidine (PENH) and 
uncharged pentamidine (PEN). Therefore, the stepwise association equilibria of pentamidine 




Figure 2-3 The stepwise association equilibria of pentamidine ion-pairs.  (a). Unionised pentamidine (PEN) 
and one proton from water form into +1 ionised pentamidine (PENH). The association constant (Ka1) of this 
step Ka1=(PENH)/[(PEN)x(H)].  (b). The +1 ionised pentamidine (PENH) further binds with one proton 
from water and then forms into +2 ionised pentamidine (PENH2). Its association constant 
Ka2=(PENH2)/[(PENH)x(H)]. (c). The +2 ionised pentamidine (PENH2) further binds to negatively charged 
counterions (CI) and become ion-pair complex (PENCIH2). The association constant 
Ka3=(PENCIH2)/[(PENH2)x(CI)]. 
 
Thus, it is assumed that pentamidine exists in four microspecies in solution (i.e. unionised 
pentamidine (PEN), +1 ionised pentamidine (PENH), +2 ionised pentamidine (PENH2) and 
pentamidine ion pair (PENCIH2). The association constant (Ka), or binding constant, is a special 
form of the dissociation constant (Kd), a measure of the strength of an acid in solutions, and has 
an inverse relationship with dissociation constants of complexes.  
 
The pKd values are the logarithm of dissociation constant (pKd = -log10Kd). The higher the pKd, 
the stronger the base is. For the pentamidine, its self-dissociation pKd1 (i.e. 12.13) and pKd2 (i.e. 
11.53) in solutions are known values acquired from MarvinSketch (version17.28, ChemAxon), as 
shown at the two amidine groups of pentamidine in the figure below. Therefore, the amidine group 
with 12.13 pKd has a higher binding affinity with counterions in solutions. The 3-D structures of 
pentamidine and taurodeoxycholate, octanoate, and xinafoate are shown in the discussion 




Figure 2-4 The self-dissociations of pentamidine in water. The pKd1 and pKd2 of the two amidine groups on 
pentamidine are 12.13 and 11.53, respectively.  
 
(2) Requirement 2: The logarithms of the overall stability constants (log β) of the complexes 
and any micro-species formed need to be calculated or determined. 
For HySS simulation, the logarithms of the overall stability constants (log β) are required for the 
HySS software. From the three equilibria (a) (b) and (c) in Figure 2-3, we can deduct the 
logarithms of the overall stability constants (log beta also called log β). And then the logarithms 
of the overall stability constant (log β1) of +1 ionised pentamidine (PENH) from unionised 
pentamidine (PEN) and a proton (H+) is calculated by Equation 2-13, the logarithms of the overall 
stability constant (log β2 ) of +2 ionised pentamidine (PENH2) from unionised pentamidine (PEN) 
and two protons (H+) can be calculated by Equation 2-14, and the logarithms of the overall stability 
constant (log β3 ) of pentamidine ion-pairs (PENCIH2) from unionised pentamidine (PEN) and two 
protons (H+) and counterions (CI) can be calculated by Equation 2-15. 
Log β1=pKa3=12.13                                                               (Equation 2-13) 
Log β2=pKa3+pKa2 =12.13+11.53=23.65                      (Equation 2-14) 
Log β3= pKa3+pKa2+ pKa1=12.13+11.53+pKa1                  (Equation 2-15) 
 
In the above equations, log β1, log β2, log β3 represent the logarithms of the overall stability 
constants (log β) of +1 ionised pentamidine (PENH), +2 ionised pentamidine (PENH2), and 
pentamidine ion-pairs (PENCIH2). pKa1, pKa2, pKa3 are the logarithm of binding constants of +1 
ionised pentamidine, +2 ionised pentamidine and pentamidine ion-pairs, respectively.  
 
For the pentamidine ion-pairs, the binding constants of pentamidine ion-pairs (pKa3) were 







The log β1, log β2, log β3 were then inputted in the HYSS software, as shown in Figure 2-5. The Log 
Beta for PENH, PENH2, H-1 is the same for different counterions, while the PENCIH2 is calculated 
by Equation 2-15. H-1 represents the measured pKa value of water and is a set value for ion-pair 
HySS simulations.  
 
Figure 2-5. HYSS screen to input the log beta and formula information 
 
(3) Requirement 3: The experimental method needs to be considered  
The pH range and the range of pentamidine concentrations that would be used in the studies 
need to be defined and these values inputted into the simulation software (Figure 2-6).  For the 
simulation of ion-pairs speciation, the pH limits were set at 2 and 12. Then the result of the 
percentage of pentamidine bound to the counterion was extracted at pH 7.4, corresponding to the 
experimental and physiological conditions used in this study. The range of pentamidine 
concentrations was set at 4 nM - 9 mM and the ratios of each counter ion to pentamidine were 
fixed at 20:1 and 1:1 for comparison. A screenshot of the experimental conditions inputted into 
HYSS is shown as follows: 
 
Figure 2-6. A screenshot of the HYSS simulation software. Experimental conditions for HySS modelling. 
PEN and XIN represent pentamidine and the counterion (CI) xinafoate (XIN), respectively. The molar 




2.3.9 Measurement of dissociation constants of pentamidine - xinafoate ion pairs using 
fluorescence-lifetime imaging microscopy (FLIM) 
2.3.9.1 Multiphoton fluorescence lifetime measurement microscope system 
The experiment was performed in the Rutherford Appleton laboratory of the science and 
technology facilities council in Didcot. All the samples were dissolved in 50 nM Tris buffer, pH 7.4. 
The experiments were undertaken with an existing FLIM system based on a Nikon E-C2 confocal 
system. Excitation sources for multiphoton lifetime measurements was achieved using a Mira 
900F Ti-sapphire laser pumped by a CW Verdi 532 nm laser (Coherent Ltd) (tunable 700-980 nm, 
pulse length 180-200 fs) pumping an OPO (Optical Parametric Oscillators APE, Germany) with a 
selectable centre wavelength-tunable between 550-650 nm, pulse length 180 fs. Photons were 
detected by a Becker and Hickl, SPC 830 TCSPC unit. Briefly, multiphoton excitation using 
580 ± 5 nm or 600 ±5 nm was used in this study from a tunable mode-locked titanium sapphire 
(Ti: Sapphire) laser (Mira 900, Coherent Lasers, UK) that generated 180 fs pulses at 76 MHz 
pumped by a 532 nm solid-state Neodymium Vanadate laser source (Verdi, Coherent Lasers). 
Excitation was performed using an x60 water immersion objective, NA 1.2. Collected fluorescence 
emission was passed through a UV filter, U340 to eliminate the visible excitation wavelength. A 
high-speed hybrid detector (HPM-100) with a sense in the UV was used, connected to a Time-
Correlated Single Photon Counting (TCSPC) module, SPC830 (Becker-Hickl, GmbH).  Excitation 
laser power was controlled using a circular Neutral Density (ND) filter, and the setup is depicted 
in the figure below.  
 




2.3.9.2 Post image processing and analysis 
Time-correlated Single Photon Counting (TCSPC) decay traces were exported to a Becker and 
Hickl SPCImage software and fluorescence lifetime analysed using an internally generated 
instrument response function.  
 
2.3.10 Data analysis 
Data were expressed as the mean ± standard deviation. Statistics were performed by ANOVA or 




2.4 Results  
2.4.1 Verification of HPLC analysis for pentamidine  
The calibration curve (Figure 2-8, 2-9) for pentamidine shows a high degree of linearity 
(R2=0.9999). The Limit of Detection (LOD) and Limit of Quantification (LOQ) for pentamidine 
assay are 2.30 µg/ml (3.88 µM) and 6.98 µg/ml (11.78 µM), respectively.  
 
Figure 2-8 Calibration curve of pentamidine (0-100 µg/ml; 0-168 µM) in mobile phase (0.025 M monobasic 
potassium phosphate: acetonitrile = 76%: 24%, v/v; pH 3.2 regulated by phosphoric acid). Data represent 
the mean ± standard deviation (n=3). The standard deviation of some points in the figure was too small to 
be visualised.  
 
Figure 2-9 Calibration curve of pentamidine (0-100 µg/ml; 0-168 µM) in 0.9% saline (pH 7.4) saturated with 
octanol. Data represent the mean ± standard deviation (n=3). The standard deviation of some points in the 




The peak for pentamidine appeared within 4.68-4.72 mins as indicated by the retention time in 
the table 2-3. The peak area of pentamidine increased in proportion with the concentrations of 
pentamidine. The coefficient of variance (CV), a measure of precision, varied from 0.32 - 2.90%, 
although the majority is within 2%.  
 
Table 2-3 Retention time, peak area and Coefficient of Variance (CV ) of pentamidine dissolved in the HPLC 
mobile phase (0.025 M monobasic potassium phosphate: acetonitrile = 76%: 24%, v/v; pH 3.2 regulated by 
phosphoric acid) was measured by HPLC. The results represent the mean ± standard deviations (n=3). CV 
was calculated by the standard deviations/ mean of peak areas.  
Concentrations 
(µg/ml) 





100 4.70 13148678 ± 111752 0.85 
50 4.68 6402594 ± 185439 2.90 
20 4.70 2581060 ± 25262 0.98 
10 4.71 1285323 ± 4162 0.32 
5 4.71 616741 ± 3833 0.62 
2 4.72 242165 ± 1534 0.63 
 
 
The peak for pentamidine appeared within 4.77-4.86 mins as indicated by the retention time in 
the table 2-4 for pentamidine dissolved in octanol saturated saline. The peak area of pentamidine 
increased in proportion with the concentrations of pentamidine. The coefficient of variance (CV) 
varied from 0.33 - 3.47%.  
 
Table 2-4 Retention time, peak area and Coefficient of Variance (CV) of pentamidine dissolved in octanol 
saturated saline and then measured by HPLC. The results represent the mean ± standard deviations (n=3). 
CV was calculated by the standard deviations/ mean of peak areas.  
Concentrations 
(µg/ml) 





100 4.86 13653188 ± 209946 1.54 
50 4.81 6747010 ± 27371 0.41 
20 4.84 2654747 ± 13771 0.52 
10 4.84 1300928 ± 15902 1.22 
5 4.81 606280 ± 2011 0.33 




2.4.2 Chemical stability of pentamidine solutions  
The stability of pentamidine solutions (2-100 µg/ml, pH 7.4) at both room temperature and 37 °C 
was assessed by HPLC for up to 28 days. At room temperature (Table 2-5), there were no 
significant degradations at the lower concentrations and degradation could only be detected when 
the pentamidine concentration was initially 100 µg/ml (168 µM) and dropped to 94.60% (P<0.001). 
At 37 °C (Table 2-6), the pentamidine solutions at 50 µg/ml (84 µM) and 100 µg/ml (168 µM) 





Table 2-5 Stability of pentamidine standards in 0.9% saline (pH 7.4) saturated with octanol. Samples were 






Retention time  
(min) 
(n=3 ± SD) 
Peak area (µV*s) 





0 4.48 ± 0.03 11945414 ± 37126  100.00% 
2 4.48 ± 0.02 11939444 ± 17978 99.95% 
7 4.40 ± 0.00 11890057 ± 11107 99.54% 
14 4.51 ± 0.07 11760900 ± 481279 98.46% 
28 4.49 ± 0.02 11300331 ± 524264 94.60% 
50 µg/ml  
(84 µM) 
0 4.48 ± 0.00 5930977 ± 12227 100.00% 
2 4.49 ± 0.03 5932881 ± 23250 100.03% 
7 4.46 ± 0.04 5942533 ± 49969 100.19% 
14 4.46 ± 0.03 5810347 ± 63036 97.97% 
28 4.50 ± 0.03 5884931 ± 80213 99.22% 
20 µg/ml 
(33 µM) 
0 4.51 ± 0.02 2327521 ± 14771 100.00% 
2 4.50 ± 0.01 2331281 ±17252 100.16% 
7 4.42 ± 0.04 2358955 ± 7055 101.35% 
14 4.48 ± 0.03 2361669 ± 8711 101.47% 
28 4.52 ± 0.02 2364060 ± 3130 101.57% 
10 µg/ml 
(16 µM) 
0 4.51 ± 0.02 1154026 ± 19326 100.00% 
2 4.55 ± 0.03 1166975 ± 4926 101.12% 
7 4.44 ± 0.03 1167062 ± 3511 101.13% 
14 4.46 ± 0.01 1175839 ± 8647 101.89% 
28 4.52 ± 0.02 1159798 ± 19805 100.50% 
5 µg/ml 
(8 µM) 
0 4.53 ± 0.04 566584 ± 2424 100.00% 
2 4.54 ± 0.02 575535 ± 3365 101.58% 
7 4.45 ± 0.06 575969 ± 2958 101.66% 
14 4.46 ± 0.01 594522 ± 2013 104.93% 
28 4.52 ± 0.02 589663 ± 8407 104.07% 
2 µg/ml 
(3 µM) 
0 4.51 ± 0.02 227108 ± 2299 100.00% 
2 4.58 ± 0.02 225923 ± 2128 99.48% 
7 4.43 ± 0.01 227798 ± 860 100.30% 
14 4.51 ± 0.07 230204 ± 1016 101.36% 





Table 2-6 Stability of pentamidine standards in 0.9% saline (pH 7.4) saturated with octanol. Samples were 






Retention time  
(min) 
(n=3 ± SD) 
Peak area (µV*s) 
(n=3 ± SD) 
% Recovery 
100 µg/ml 0 4.48 ± 0.03 11945414 ± 37126 100.00% 
(168 µM) 2 4.53 ± 0.05 11923725 ± 75496 99.82% 
 7 4.40 ± 0.02 11517138 ± 74832 96.41% 
 14 4.44 ± 0.04 11413168 ± 232233 95.54% 
 28 4.49 ± 0.02 10808348 ± 179213 90.48% 
50 µg/ml  0 4.48 ± 0.00 5930977 ± 12227 100.00% 
(84 µM) 2 4.50 ± 0.01 5885856 ± 57257 99.24% 
 7 4.41 ± 0.03 5659399 ± 6879 95.42% 
 14 4.47 ± 0.06 5567208 ± 23125 93.87% 
 28 4.50 ± 0.01 5515947 ± 6544 93.00% 
20 µg/ml 0 4.51 ± 0.02 2327521 ± 14771 100.00% 
(33 µM) 2 4.23 ± 0.44 2351282 ± 9481 101.02% 
 7 4.44 ± 0.02 2284371 ± 19071 98.15% 
 14 4.46 ± 0.02 2293498 ± 15963 98.54% 
 28 4.54 ± 0.03 2241901 ± 1165 96.32% 
10 µg/ml 0 4.51 ± 0.02 1154026 ± 19326 100.00% 
(16 µM) 2 4.51 ± 0.04 1151453 ± 7586 99.78% 
 7 4.45 ± 0.02 1094396 ± 3532 94.83% 
 14 4.48 ± 0.02 1096031 ± 3313 94.97% 
 28 4.54 ± 0.02 1072813 ± 18515 92.96% 
5 µg/ml 0 4.53 ± 0.04 566584 ± 2424 100.00% 
(8 µM) 2 4.53 ± 0.03 576866 ± 4090 101.81% 
 7 4.45 ± 0.06 547407 ± 2083 96.62% 
 14 4.48 ± 0.01 543093 ± 13314 95.85% 
 28 4.54 ± 0.03 541672 ± 10154 95.60% 
2 µg/ml 0 4.51 ± 0.02 227108 ± 2299 100.00% 




2.4.3 Octanol-water distribution coefficient  
The lipophilicity (log D, 7.4) of pentamidine (33 µM of pentamidine was used with 
taurodeoxycholate and octanoate and 8 µM of pentamidine were used for quercetin and 
xinafoate) in the presence of 20 times molar ratio of taurodeoxycholate, octanoate, quercetin, and 
xinafoate increased by 1.15, 1.06, 0.06 and 0.82 compared to pentamidine respectively.  
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Counterion Concentrations of 
counterion (µM) 





33 Taurodeoxycholate 0 -1.192 0.093 
33 -0.774 0.023 
66 -0.573 0.009 
132 -0.368 0.015 
264 -0.158 0.002 
396 -0.091 0.001 
660 -0.042 0.001 
33 Octanoate 0 -1.194 0.091 
33 -0.927 0.028 
66 -0.785 0.016 
132 -0.632 0.054 
264 -0.388 0.005 
396 -0.238 0.010 
660 -0.133 0.010 
8 Xinafoate 0 -1.194 0.091 
32 -1.022 0.041 
64 -0.811 0.023 
96 -0.557 0.008 
160 -0.371 0.016 
0 Quercetin 0 -1.194 0.091 
  32 -1.136 0.175 
  64 -1.272 0.079 
  96 -0.920 0.077 






For taurodeoxycholate (Figure 2-10), the log D7.4 of pentamidine improved continually when 
increasing the concentration of taurodeoxycholate in the solution. Compared to the log D7.4 of 
pentamidine without taurodeoxycholate, it was 96.5% higher when adding 20 times molar ratio 
(660 µM) of taurodeoxycholate.  
 
Figure 2-10 Distribution coefficient of pentamidine at pH 7.4 with the presence of taurodeoxycholate. The 
experiment was performed at 37 °C. Results were expressed as mean ± standard deviation at each point 
(n=3, with 3 replicates each). Some of the error bars were too small to be seen in the figure.  
 
























For octanoate (Figure 2-11), the distribution coefficient of pentamidine at pH 7.4 also increased 
with the presence of octanoate, although the magnitude of change was not as significant 
compared to taurodeoxycholate. The log D7.4 of pentamidine was 89.1% higher when adding 20 
times molar ratios (660 µM) of octanoate.  
 
Figure 2-11 Distribution coefficient of pentamidine at pH 7.4 with the presence of octanoate. The experiment 
was performed at 37 °C. Results were expressed as mean ± standard deviation at each point (n=3, with 3 
replicates each). Some of the error bars were too small to be seen in the figure. 
 
 
The log D7.4 of pentamidine dramatically fluctuated when introducing quercetin to the solution, 
and no significant increase was observed. This indicated that quercetin did not form a stable ion 




Figure 2-12 Distribution coefficient of pentamidine at pH 7.4 with the presence of quercetin. The experiment 
was performed at 37 °C. Results were expressed as mean ± standard deviation at each point (n=3, with 3 
replicates each).  
 














































For xinafoate (Figure 2-13), the lipophilicity of pentamidine increased proportionally when adding 
1-12 times molar ratios of xinafoate. After that, the magnitude of change was milder, and the log 
D7.4 of pentamidine reached 68.9% higher compared to the original value without xinafoate when 
adding 20 times molar ratios (160 µM) of xinafoate. 
 
Figure 2-13 Distribution coefficient of pentamidine at pH 7.4 with the presence of xinafoate. The experiment 
was performed at 37 °C. Results were expressed as mean ± standard deviation at each point (n=3, with 3 
replicates each). Some of the error bars were too small to be seen in the figure.  
 
2.4.4 Nuclear magnetic resonance (NMR) spectroscopy  
The binding site of the counterion with pentamidine is determined by assessing the chemical shift 
of H and C assigned to pentamidine in the presence of the counterion xinafoate using nuclear 
magnetic resonance (NMR) spectroscopy. The principle of NMR explained in detail can be found 
(Koutcher and Burt, 1984). In simple terms, nuclei in different chemical structures share electrons 
with other electrons. Thesis electrons have magnetic fields and resonate different frequencies. 
When nuclei samples are excited, they generate signals with different frequencies which are 
reflected as different chemical shift on NMR spectra. The NMR spectra can be used to identify 
chemical structures of molecules (Chatham and Blackband, 2001). 
 
2.4.4.1 13C NMR spectra 
13C-NMR measures the spin changes of carbon nuclei. The number of protons carbons and the 
backbones of molecules can be directly observed from 13C-NMR spectra. Although 13C-NMR is 
less sensitive than 1H-NMR, it has the advantage of specificity. The chemical shifts of 13C-NMR 
spectra range from 0 to 240 ppm and are not sensitive to the change of environment. Thus the 
























protons for carbons are easier to be distinguished and specified to carbons of molecules (Pieters 
and Vlietinck, 1989; Thompson, 1990). 
 
For the carbons of pentamidine in DMSO-d6 (Figure 2-15), an upfield shift was observed on the 
carbon (P6, P7, P8) near the C-O-C linkage. A minor upfield shift was also seen on the carbons 
assigned to the two benzene rings (P2, P3, P4, P5). The carbons (P1) located in the amidine 
groups experienced a downfield shift with the presence of xinafoate at 1:20 molar ratio. For the 
carbons of xinafoate in DMSO-d6, no obvious carbon shift was observed.  
 
Similar shifts in the majority of carbons were observed when pentamidine and xinafoate were 
dissolved in DMSO-d6 with 1% D2O (Figure 2-16). Exceptions included the carbon (P2) adjacent 
to the amidine groups assigned to the benzene ring of pentamidine shifted downfield and the 












Figure 2-15 The 13C NMR spectra of pentamidine free, and pentamidine xinafoate mixture (1:1 and 1:20) and xinafoate free dissolved in DMSO-d6  
(a) Pentamidine alone 
(b) Pentamidine: xinafoate = 1:1 
(c) Pentamidine: xinafoate = 1:20 





Figure 2-16 The 13C NMR spectra of pentamidine free, and pentamidine xinafoate mixture (1:1 and 1:20) and xinafoate free dissolved in DMSO-d6 (99%) with D2O (1%) mixed solution
(a) Pentamidine alone 
(b) Pentamidine: xinafoate = 1:1 
(c) Pentamidine: xinafoate = 1:20 
(d) Xinafoate alone 
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Table 2-8 Chemical shifts (δ, ppm) of pentamidine from 13C-NMR spectra dissolved in DMSO-d6 
Molar ratio 
(Pentamidine:Xinafoate) 
Chemical shift, δ(ppm) 
P1 P2 P3 P4 P5 P6 P7 P8 
1:0 (pentamidine only) 165.04 119.85 130.65 115.26 163.54 68.51 28.65 22.54 
1:1 165.04 119.85 130.65 115.25 163.54 68.50 28.65 22.53 
1:20 165.10 119.80 130.61 115.15 163.51 68.39 28.62 22.48 
  
Table 2-9 Chemical shifts (δ, ppm) of xinafoate from 13C-NMR spectra dissolved in DMSO-d6 
Molar ratio 
(Pentamidine:Xinafoate) 
Chemical shift, δ(ppm) 
X1 X2 X3 X9 X10 
0:1 (xinafoate only) 173.47 106.45 160.80 137.19 118.78 
1:1 173.42 106.48 160.72 137.20 118.86 
1:20 173.47 106.45 160.79 137.18 118.77 
 
Table 2-10 Chemical shifts (δ, ppm) of pentamidine from 13C-NMR spectra dissolved in DMSO-d6 (99%) 
with D2O (1%) mixed solution  
Molar ratio 
(Pentamidine:Xinafoate) 
Chemical shift, δ(ppm) 
P1 P2 P3 P4 P5 P6 P7 P8 
1:0 (pentamidine only) 164.89 119.71 130.67 115.28 163.56 68.52 28.64 22.53 
1:1 164.92 119.78 130.66 115.27 163.56 68.51 28.64 22.53 





Table 2-11 Chemical shifts (δ, ppm) of xinafoate from 13C-NMR spectra dissolved in DMSO-d6 (99%) with 
D2O (1%) mixed solution 
Molar ratio Chemical shift, δ(ppm) 
(Pentamidine:Xinafoate) X1 X2 X3 X9 X10 
0:1 (xinafoate only) 173.37 106.40 160.70 137.45 118.80 
1:1 173.25 106.41 160.57 137.20 119.72 
1:20 173.39 106.41 160.72 137.18 119.72 
 
2.4.4.2 1H NMR spectra 
1H-NMR is more sensitive than 13C-NMR. The information on the total number and types of the 
chemical environment of protons can be acquired from the 1H-NMR spectra. Its chemical shift 
ranges from 0 to 14 ppm. 1H-NMR spectra are generally more complicated than 13C-NMR spectra, 
and it is affected by proton resonance with water (Pieters and Vlietinck, 1989; Thompson, 1990). 
 
The protons on pentamidine and xinafoate were labelled, as shown in Figure 2-17. The chemical 









For 1H-NMR, the pentamidine concentration was 11.2 mM without or with different molar ratios of 
xinafoate (1:1, 1:20). As shown in Figure 2-18 and Figure 2-19, the peak for the proton (L2) 
assigned to the amidine groups on pentamidine split into two peaks with both equal and 20 times 
molar ratio of xinafoate, and another peak for the proton on amidine groups (L1) disappeared with 
the presence of xinafoate. No chemical shift changes were observed for protons on the benzene 
rings or carbon chains of pentamidine with xinafoate at a 1:1 molar ratio. However, at a 1:20 molar 
ratio of xinafoate the protons (L4, L5, L6, L7) shifted upfield while the proton located near the 
amine groups shifted downfield. For xinafoate, it was expected to see a chemical shift of protons 
-COOH (M1) and -OH (M2) on xinafoate. Unfortunately, these signals were not detected. For the 
rest of the protons on xinafoate, only a slight upfield shift was observed for the proton (M6) of 
naphthalene. The 1H-NMR spectra in both DMSO-d6 and DMSO-d6/D2O mixed solutions showed 





Figure 2-18 The 1H NMR spectra of pentamidine free, and pentamidine xinafoate mixture (1:1 and 1:20) and xinafoate free dissolved in DMSO-d6 (99%) and D2O (1%) mixed solution. 
The concentration of pentamidine was 11.2 mM in (a) (b) (c). The concentration of xinafoate alone was 224 mM in (d). The peak for the proton assigned to the amidine groups on 
pentamidine (L2) split into two peaks, and another proton peak on pentamidine (L1) disappeared with the presence of xinafoate.  
(a) Pentamidine alone 
(b) Pentamidine: xinafoate = 1:1 
(c) Pentamidine: xinafoate = 1:20 




Figure 2-19 The 1H NMR spectra of pentamidine free, and pentamidine xinafoate mixture (1:1 and 1:20) and xinafoate free dissolved in DMSO-d6 (99%) and D2O (1%) mixed solution. 
The concentration of pentamidine was 11.2 mM in (a) (b) (c). The concentration of xinafoate alone was 224 mM in (d). The peak for the proton assigned to the amidine groups on 
pentamidine (L2) split into two peaks, and another proton peak on pentamidine (L1) disappeared with the presence of xinafoate.
(a) Pentamidine alone 
(b) Pentamidine: xinafoate = 1:1 
(c) Pentamidine: xinafoate = 1:20 




Table 2-12 1H NMR chemical shifts of pentamidine protons in DMSO-d6  
Molar ratio 
(Pentamidine:Xinafoate) 
 Chemical shift, δ(ppm) 
L1 L2 L3 L4 L5 L6 L7 
1:0 (pentamidine only) 4.48 8.93 7.81 7.16 4.13 1.83 1.59 
1:1 disappeared split into 2 peaks 
(8.74, 9.13) 
7.81 7.16 4.12 1.83 1.59 
1:20 disappeared split into 2 peaks 
(8.79, 9.14) 
7.82 7.14 4.09 1.79 1.56 
 




 Chemical shift, δ(ppm) 
L1 L2 L3 L4 L5 L6 L7 
1:0 (pentamidine only) 4.49 8.94 7.81 7.16 4.12 1.83 1.59 
1:1 disappeared split into 2 peaks  
(8.75, 9.14) 
7.81 7.16 4.12 1.83 1.59 
1:20 disappeared split into 2 peaks  
(8.79, 9.16) 
7.82 7.14 4.08 1.79 1.56 
 
Table 2-14 1H NMR chemical shifts of xinafoate protons in DMSO-d6  
Molar ratio 
(Pentamidine:Xinafoate) 
Chemical shift, δ(ppm) 
M3 M4 M5 M6 M7 M8 
0:1 (xinafoate only) 8.29 7.67 7.58 7.90 7.39 7.76 
1:1 8.29 7.69 7.59 7.91 7.40 7.76 
1:20 8.29 7.67 7.58 7.89 7.39 7.76 
 
 
Table 2-15 1H NMR chemical shifts of xinafoate protons in DMSO-d6 (99%) and D2O (1%) mixed solution 
Molar ratio 
(Pentamidine:Xinafoate) 
Chemical shift, δ(ppm) 
M3 M4 M5 M6 M7 M8 
0:1 (xinafoate only) 8.29 7.67 7.58 7.89 7.39 7.76 
1:1 8.29 7.69 7.59 7.91 7.41 7.76 




2.4.5 Fluorescence spectroscopic characterisation of ion-pairs  
2.4.5.1 Method validation for DAPI  
The maximum emission of DAPI appeared at 460 nm, and its intensity increased proportionally 
with the concentrations of DAPI (Figure 2-20).  
 
Figure 2-20 Fluorescence spectra of 2-10 g/ml (7-36 M) DAPI (emission spectra from bottom to top) in 50 
nM Tris-buffer at pH 7.4.  The excitation was set at 358 nm, and the emission was scanned for the full range 





















































































As shown in Figure 2-21, the standard curve of DAPI has an R-squared value of 0.9902. Its Limit 
of Detection (LOD) is 1.25 g/ml (3.57 M) and its Limit of Quantification (LOQ) is 3.80 g/ml 
(10.85 M).  
 
Figure 2-21 Calibration curve of DAPI in Tris buffer at pH 7.4. The average fluorescence intensity (n=3, 
background value subtracted) was plotted as a function of 2-10 g/ml (7-36 M) DAPI. Data were expressed 
as mean  S.D (n=3 samples/ replicates). The S.D. of some points is too small to be seen in the figure.  
 
 
Table 2-16 Statistical parameters for DAPI linearity with regression analysis 
Parameters Value 
Wavelength(nm) of excitation  358 
Wavelength(nm) of emission 460 
Linear range (g/ml) 2-10 
Intercept 13.42 
Slope 35.31 
R-squared  0.9902 
LOD  1.25 g/ml (3.57 M) 
LOQ  3.80 g/ml (10.85 M) 
 




























2.4.5.2 Method validation for pentamidine 
The maximum emission of pentamidine was at 340 nm, and its intensity was enhanced with the 
increasing concentrations of pentamidine (Figure 2-22).  
 
Figure 2-22 Fluorescence spectra of 2-10 g/ml (3-17 M) pentamidine (emission spectra from bottom to 
top) in 50 nM Tris-buffer at pH 7.4. The excitation was set at 270 nm, and the emission was scanned for the 
full range from 200 to 600 nm (maximum emission at 340 nm). 
 
As shown in Figure 2-23, the standard curve of pentamidine in tris buffer has an R-squared value 
of 0.9979. Its Limit of Detection (LOD) is 0.58 g/ml (0.98 M) and its Limit of Quantification (LOQ) 
is 1.76 g/ml (2.97 M).  
 
 
Figure 2-23. Calibration curve of 2-10 g/ml (3-17M) pentamidine in 50nM Tris buffer at pH 7.4. The 
average fluorescence intensity (n=3, background value subtracted) was plotted as a function of the 















































































































Table 2-17 Statistical parameters for pentamidine linearity with regression analysis 
Parameters Value 
Wavelength(nm) of excitation  270 
Wavelength(nm) of emission 340 
Linear range (g/ml) 2-10 
Intercept -0.30 
Slope 7.58 
R-squared  0.9979 
LOD (g/ml) 0.58 
LOQ (g/ml) 1.76 
 
2.4.5.3 Fluorescence spectra of DAPI-xinafoate and pentamidine-xinafoate ion-pairs 
The fluorescence intensity of DAPI quenched slightly when adding an equal molar ratio of 
xinafoate (Figure 2-24). When adding a 20 times molar ratio of xinafoate, the emission intensity 
of DAPI increased. This occurred as xinafoate itself had a wavelength of emission overlapping 
with the emission of DAPI. There was also a blue shift of the DAPI’s peak when adding equal and 
20 times molar ratio of xinafoate. The new peaks of DAPI appeared when xinafoate was 
presented in the solution. This indicated that ion-pairs of DAPI and xinafoate were formed.  
 
Figure 2-24 Fluorescence excitation and emission of 11.4 M DAPI (4 g/ml), 11.4M Xinafoate and DAPI-
Xinafoate ion-pairing solution (DAPI: xinafoate = 1:1 and 1:20). The excitation was set at 358 nm and a full 
emission scan at 200-600 nm.   
 
The intensity of pentamidine was quenched with the increasing molar ratios of xinafoate (Figure 
2-25). Also, there was a red shift in the spectra of pentamidine with xinafoate. This indicated that 
pentamidine formed ion-pairs with xinafoate.  


































Figure 2-25 Emission spectra of 8 µM pentamidine (PEN) with increasing molar ratios of xinafoate (XIN) in 
50 nM Tris buffer at pH 7.4. The excitation was set at 270 nm and a full emission scan at 200-600 nm.  The 
maximum emission for pentamidine was at 340 nm. 
 
 
2.4.6 Binding constants of ion-pairs  
2.4.6.1 (a) Binding constants of pentamidine ion-pairs determined by HPLC 
Binding constants were determined by measuring the concentrations of pentamidine in the saline 
phase with increasing concentrations of counterions using the octanol-saline shake flask method 
followed by HPLC. The R-squared values for pentamidine – taurodeoxycholate, pentamidine – 
octanoate, and pentamidine – xinafoate are > 0.99, which suggested a good fit for the regression 
curves (Figure 2-26, Figure 2-27, Figure 2-29). The regression curve for pentamidine – quercetin 
showed a poor fit, which could be caused by multiple steps of reactions or non-ion-pairing process 
between pentamidine and quercetin (Figure 2-28). Among pentamidine – taurodeoxycholate, 
pentamidine – octanoate, and pentamidine – xinafoate, pentamidine has the strongest binding 
with taurodeoxycholate (pKpen-tau = 4.1), followed by xinafoate (pKpen-xin = 3.6), and octanoate 








































































Peak 1: PEN:XIN= 1:0 (341.4nm, 46.8au)
Peak 2: PEN:XIN= 1:2 (342.0nm, 45.0au)
Peak 3: PEN:XIN= 1:4 (342.4nm, 43.2au)
Peak 4: PEN:XIN= 1:6 (343.4nm, 41.8au)
Peak 5: PEN:XIN= 1:8 (339.7nm, 40.5au)
Peak 6: PEN:XIN= 1:16 (347.4nm, 35.5au)







Figure 2-26 The binding constants of pentamidine with taurodeoxycholate based on 1:1 (a) and 1:2 (b) 
stoichiometry determined by HPLC. Data were expressed as mean  S.D. (n=3) and fit into the Sigmoidal 
regression model in GraphPad7.  






















pKPEN-TAU= 4.045 ± 0.08
R2 = 0.9970






























Figure 2-27 The binding constants of pentamidine with octanoate based on 1:1 (a) and 1:2 (b) stoichiometry 


























pKPEN-OCT= 3.144 ± 0.122
R2 = 0.9902






























Figure 2-28 The binding constants of pentamidine with quercetin based on 1:1 (a) and 1:2 (b) stoichiometry 
determined by HPLC. Data were expressed as mean  S.D. (n=3) and fit into the Sigmoidal regression model 
in GraphPad7. The regression curve for pentamidine – quercetin shows poor fit, which could be caused by 
multiple steps of reactions or non-ion-pairing process between pentamidine and quercetin. 
 






















pKPEN-QUE= 4.477 ± 0.202
R2 = 0.6113































Figure 2-29 The binding constants of pentamidine with xinafoate based on 1:1 (a) and 1:2 (b) stoichiometry 


























pKPEN-XIN= 3.597 ± 0.028
R2 = 0.9944


























2.4.6.2 (b) Binding constants determined by fluorescence spectroscopy 
The binding constants of pentamidine – xinafoate ion pairs calculated from fluorescence 
quenching method are 3.922  0.234 and 3.959  0.238 for 1:1 and 1:2 binding ratios of 





Figure 2-30 The binding constants of pentamidine with xinafoate based on 1:1 (a) and 1:2 (b) stoichiometry. 


























pKPEN-XIN= 3.922 ± 0.234
R2 = 0.9761


























These binding constants calculated from fluorescence method are around 0.3 higher than the 
binding constants acquired from the previous HPLC method, as shown in Table 2-17.  
 
Table 2-18 A comparison of the binding constants of pentamidine-xinafoate ion-pairs (pKpen-xin) determined 
by HPLC and fluorescence methods 
 pKpen-xin 
(Pentamidine:xinafoate = 1:1) 
pKpen-xin 
(Pentamidine:xinafoate = 1:2) 
HPLC 3.597  0.028 3.611  0.032 
Fluorescence  3.922  0.234  3.959  0.238 
Difference  0.325 0.348 
*Statistical significance?   No No 




2.4.7 HySS micro-speciation of pentamidine ion-pairs  
2.4.7.1 HySS micro-speciation of pentamidine and taurodeoxycholate  
As simulated by HySS, when pentamidine and taurodeoxycholate were added into the solution, 
+2 ionised pentamidine (PENH2), +1 ionised pentamidine (PENH), +2 ionised pentamidine 
(PENH2), and pentamidine-taurodeoxycholate ion pair formation (PENTAUH2) were present in 
the equilibria (Figure 2-31). The concentration of pentamidine was set at 9nM (representing the 
concentration in the brain) or 8µM (representing the concentration in plasma) (Bronner et al., 
1991), and taurodeoxycholate was set at equal or 20 times molar ratios of pentamidine.  
 
When the concentrations of pentamidine and taurodeoxycholate were both at 9nM, pentamidine 
was predicted to be in the form of +2 ionised (almost 100.0%) at pH 2-8, and there would be 
almost no (0.01%) ion-pairs in the solution (Figure 2-31a).  In the 8-12 pH range, +2 ionised 
pentamidine would start to decrease, while +1 ionised pentamidine and non-charged pentamidine 
would increase gradually with the increase of pH. No pentamidine (<0.01%) would be in the form 
of ion-pairs at pH 8-12. When pentamidine was fixed at 9nM and taurodeoxycholate was 
increased to 180nM, 0.22% of pentamidine would be in ion-pairs, and the rest vast majority of 
pentamidine (>99%) would be +2 ionised at pH 2-9. +2 ionised pentamidine would start to 
decrease from pH above 9 and until 20% at pH 12, while the total of +1 ionised pentamidine and 




When the concentration of pentamidine was increased to 8µM and taurodeoxycholate was 
increased to 8 µM or 160 µM, the main forms of pentamidine would be ion-paired and +2 ionised 
(Figure 2-31c and d). At pH 7.35-7.45, there would be 8.4% of pentamidine and 66.1% of 
pentamidine in ion-pairs for 8 µM and 160 µM taurodeoxycholate, respectively (Table 2-19). Both 
ion-pairs and +2 pentamidine would start to decrease from pH above 10, while unionised and 
uncharged pentamidine decreased. 
(a)                                                                  (b) 
  
(c)                                                                   (d) 
  
Figure 2-31 HySS speciation plots of (a) 9 nM pentamidine and 9 nM taurodeoxycholate, (b) 9 nM 
pentamidine and 180 nM taurodeoxycholate, (c) 8µM pentamidine and 8µM taurodeoxycholate, (d) 8 µM 
pentamidine and 160 µM taurodeoxycholate in solutions as a function of pH range at 2-12.  Microspecies 
of +2 ionised pentamidine (PENH2), +1 ionised pentamidine (PENH), and pentamidine-taurodeoxycholate 
ion pair formation (PENTAUH2) are present in the equilibria. 
 
2.4.7.2 HySS micro-speciation of pentamidine and octanoate  
There would be almost no ion-pairs (<0.01%) in the solution for pentamidine (9 nM) – octanoate 
(9 nM), and only 0.2% for pentamidine (9 nM) – octanoate (180 nM) in the solution at pH 7.4. 





























































































































Almost 100% of pentamidine was +2 ionised at pH 2-9. From pH above 9, +2 pentamidine started 
to decrease while non-charged and +1 pentamidine started to increase in the solution. The 
percentage of ion-pairs was too low (<0.3%) throughout pH 2-12 therefore it remained invisible in 
Figure 2-35. 
 
When both pentamidine and octanoate were increased to 8 µM, there were 0.99% of pentamidine 
in ion-pairs and 99% of pentamidine in +2 ionised form at pH 2-9. More ion-pairs (16.6%) and 
less +2 ionised pentamidine (83.4%) were present in the solution (pH 2-9) when the concentration 
of octanoate was increased to 160 µM. Both ion-pairs and +2 ionised pentamidine started to 
decrease at pH above 9, and until pH 12 where the majority (80%) of pentamidine were neutral 
or +1 ionised.  
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(a)                                                                   (b) 
  
(c)                                                                     (d) 
  
Figure 2-32 HySS speciation plots of (a) 9 nM pentamidine and 9 nM octanoate, (b) 9 nM pentamidine and 
180 nM octanoate, (c) 8 µM pentamidine and 8 µM octanoate, (d) 8 µM pentamidine and 160 µM 
octanoate in solutions as a function of pH range at 2-12. Microspecies of +2 ionised pentamidine (PENH2), 
+1 ionised pentamidine (PENH), and pentamidine-octanoate ion pair formation (PENOCTH2) are present 
in the equilibria. 
 
 
2.4.7.3 HySS micro-speciation of pentamidine and xinafoate  
There were almost no ion-pairs (<0.01%) for pentamidine (9 nM) – xinafoate (9 nM) and only 
0.07% for pentamidine (9 nM) – xinafoate (180 nM) at pH 2-10. Within this pH range, over 99% 
of pentamidine were +2 ionised. From pH 10-12, the +2 ionised pentamidine and ion-pairs 
decreased, while +1 ionised and uncharged pentamidine increased. 
 
For pentamidine (8 µM) – xinafoate (8 µM), there were 3.0% ion-pairs formed and the rest 97.0% 
of pentamidine +2 ionised at pH 2-10. These two forms started to decrease in the solution at pH 




























































































































above 10, and +1 and uncharged pentamidine were formed. When changing the concentration of 
xinafoate from 8 µM to 160 µM, the percentage of ion-pairs increased from 3.0% to 38.5% at pH 
2-10. The major forms of pentamidine existed in +2 ionised for pH 2-10, and in +1 ionised and 
uncharged for pH 10-12.  
(a)                                                              (b) 
  
(c)                                                               (d) 
  
Figure 2-33 HySS speciation plots of (a) 9nM pentamidine and 9nM xinafoate, (b) 9nM pentamidine and 
180nM xinafoate, (c) 8µM pentamidine and 8µM xinafoate, (d) 8µM pentamidine and 160µM xinafoate in 
solutions as a function of pH range at 2-12. Microspecies of +2 ionised pentamidine (PENH2), +1 ionised 
pentamidine (PENH), and pentamidine-xinafoate ion pair formation (PENXINH2) are present in the 
equilibria. 
 




























































































































2.4.7.4 Simulation of whole-body distribution for pentamidine ion-pairs 
The HySS speciation was also utilised in this study to simulate the clinical body distribution upon 
administration by pentamidine ion-pairs. To treat HAT, pentamidine isethionate (4 mg/kg) is given 
to patients daily for 2-3 weeks by intramuscular injection or intravenous administration (Burri and 
Blum, 2017). Given the average human body weight worldwide is 62 kg (average body weight in 
Africa is 60.7 kg) (Walpole et al., 2012), the dose of pentamidine isethionate on average is 248 
mg. Assuming that the 248mg of pentamidine isethionate is dissolved in 50 ml of saline for 
dilution, then the calculated molar concentration of pentamidine is 8 mM. The detailed calculation 
process was shown below: 
Table 2-19 Simulated concentration of pentamidine in saline for injection  
Conditions 
/assumptions 
Molecular weight of 




isethionate salt = 
592 g/mol 
The volume of 





salt = 248 mg 
Calculation of pentamidine concentration =142 mg/(340 g/mol*50 ml)= 0.142 g/(340 g/mol*0.05 
L)=0.008 mol/L=8 mM 
 
After injection, the plasma concentration of pentamidine peaked at 1 h after administration and 
varied from 0.42 µM (142.8 µg/L) to 13.42 µM (4562.8 µg/L).  The median plasma concentration 
of pentamidine isethionate at day 7 was 4 nM (2.4 µg/L) (Bronner et al., 1991). Pentamidine is 
highly ionized in a physiological environment so will not cross membranes well and therefore, only 
achieves a very limited concentration within the central nervous system (Bardal et al., 2011). 
However, it can be detected within the human cerebrospinal fluid with a concentration of 1.7-3.9 
nM (Bronner et al., 1991). To simulate the process of pentamidine ion pairs distribution within the 
body, the concentration of pentamidine was set at 8 mM (pentamidine in the solution for injection), 
8 µM (pentamidine in the plasma) and 4 nM (pentamidine in the brain) in the presence of 20 molar 
excess of counterions and then analysed by HYSS simulation software.  
 
For pentamidine-xinafoate ion-pairs, the results showed that 99.9% of pentamidine was ion-
paired at 8 mM, 38.5% of pentamidine was in ion-pair formation at 8 µM and no (<0.1%) ion pairs 




(a) Before Injection                        (b) In plasma                             (c) In brain 
 
Figure 2-34. HYSS simulation of microspecies percentage as a function of pH range 2-12. PENCIH2 
represents the pentamidine ion pair formation, PENH2, PENH, PEN represents +2 pentamidine, +1 
pentamidine and uncharged pentamidine respectively. (a) Pentamidine microspeciation in the solution for 
injection with 8 mM pentamidine and 160 mM counter ions (1:20). 99.9% of pentamidine is formed in ion-
pairs at physiological pH. The lines for the PENXINH2 and PENH2 are very close to 100% and 0% in the 
figure, therefore they are too close to be seen. (b) Pentamidine ion pair ratios in the plasma. 
Concentrations were set at 8 µM for pentamidine and 160 µM for counter ions. 38.5% of pentamidine is in 
ion-pair formation at pH 7.4 (c) Pentamidine microspeciation calculated with 4 nM pentamidine and 80 nM 
counterions in the brain. Less than 0.1% of pentamidine is in ion-pair formation.  
 
2.4.8 Measurement of dissociation constants of pentamidine – xinafoate ion pairs using 
fluorescence-lifetime imaging microscopy (FLIM) 
2.4.8.1 Limitation of detection of pentamidine by FLIM. 
Pentamidine was diluted from 8 mM in order to confirm the minimum concentration that could be 
detected by FLIM method. The decrease of the total number of photons (emission) is related to 
the dilution of pentamidine. The fluorescence decay curves suggest that pentamidine at 0.8 µM 
or lower cannot be detected by FLIM (Figure 2-35). In general, the lifetime (τ) does not change 
with the concentration of molecules. The shorter lifetimes (τ) at higher concentrations of 
pentamidine can be explained by the self-quench of pentamidine.  


























































































































































































Figure 2-35 Fluorescence lifetime (τ) of different concentrations of pentamidine dissolved in 50 nM tris buffer 
(pH 7.4). (a) 8 mM pentamidine, 16329 traced photons in 10 ns, τ= 74.17 ps, χ2= 8.42 (b) 800 µM 
pentamidine, 12266 traced photons in 10 ns, τ= 82.42 ps, χ2= 1.55. (c) 80 µM pentamidine, 31672 traced 
photons in 10 ns, τ= 142.56 ps, χ2= 1.24. (d) 8uM pentamidine, 28852 traced photons in 10ns, τ= 171.25, 
χ2= 1.60 (e) 0.8uM pentamidine, 16132 traced photons in 10ns, τ= 3835.59 ps, χ2= 2.46  
 
 






















2.4.8.2 FLIM detection of pentamidine and xinafoate ion-pairs  
The increase of lifetime upon xinafoate addition may suggest a stabilization of the excited state 
of pentamidine, as shown in Table 2-20. This means that the pentamidine is more stable when it 
is bound to a counterion. Either or both of the radiative and non-radiative rates of the electrons in 
the excited state have reduced. The increase of lifetime (τ) for 8 µM/ 8 mM pentamidine and 





Figure 2-36 Fluorescence decay curve of pentamidine with xinafoate. (a) 8 mM pentamidine with 160 mM 
xinafoate in 50 nM Tris buffer (pH 7.4). 21201 traced photons in 10 ns, τ= 147.62 ps, χ2= 1.08. (b) 8 µM 
pentamidine with 160 µM xinafoate in 50 nM Tris buffer (pH 7.4). 40838 traced photons in 10 ns, τ= 1351.67 
ps, χ2= 1.07.  
 
Table 2-20 The lifetime of 8 mM pentamidine with 160 mM xinafoate (pentamidine: xinafoate = 1:20) and 8 
µM pentamidine with 160 µM xinafoate (pentamidine: xinafoate = 1:20) 
Solutions Lifetime τ (ps) 
8 mM Pentamidine 74.17 
8 mM Pentamidine + 160 mM Xinafoate 147.62 
8 µM Pentamidine 171.25 




2.5 Discussion  
2.5.1 Method validation of HPLC  
Pentamidine solutions were measured by HPLC over 10 min at the wavelength of 264 nm. The 
HPLC method was verified by determining the correlation coefficient and the relative standard 
deviations of peak areas. The correlation coefficient for the pentamidine calibration curve is higher 
than 0.9999, which meets the requirement of above 0.99, according to the ICH guideline (ICH, 
1995). The relative standard deviations of peak areas were within the acceptable limit of 5%. 
These results confirmed that the HPLC method was a reliable method to quantify pentamidine in 
aqueous solutions. 
 
2.5.2 Chemical stability of pentamidine solutions  
The chemical stability measurement of pentamidine was critical for the octanol and saline shake-
flask study, as the pentamidine: counterion solutions would be heated at 37 °C for 24 h, and both 
degradations of pentamidine and formation of complexes with counterions would contribute to the 
reduction of pentamidine peak areas by HPLC. The recovery of pentamidine at both 37 °C and at 
room temperature did not significantly decrease until the 7-days point. In addition, the standard 
deviations of the retention time of pentamidine were <0.1 min for all the data points. These results 
confirmed the stability of pentamidine in solutions during the octanol and saline shake-flask study. 
 
2.5.3 Lipophilicity and percentage bound of pentamidine with counterions 
The lipophilicity of pentamidine was determined by octanol-saline shake flask method, and the 
pentamidine concentration was measured in the saline phase by HPLC. The change of 
pentamidine lipophilicity was explored in the presence of 1:1 to 1:20 of counterions over the time 
course of 24 h at 37 °C. The possibility of pentamidine self-degradation was excluded as no 
significant change in pentamidine stability was observed during 7 days. 
 
The result from octanol-saline shake flask experiment revealed that the counterions 
taurodeoxycholate, octanoate, and xinafoate improved the lipid solubility of pentamidine. Its 
magnitude of change was the most significant with taurodeoxycholate, followed by octanoate and 
xinafoate. Also, the increasing concentrations of taurodeoxycholate, octanoate and xinafoate 
increased the distribution coefficient of pentamidine at pH 7.4 gradually. This magnitude of 
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change was likely linked to increases in the percentage of pentamidine bound in ion-pairs, as 
pentamidine ion-pair has higher lipophilicity than pentamidine itself.  
 
Quercetin did not show a similar pattern of change as those three counterions and did not improve 
the lipophilicity of pentamidine. Also, the lipophilicity of pentamidine in the presence of an excess 
of quercetin fluctuated dramatically. This indicated that the change of pentamidine lipophilicity 
with quercetin was a multi-step process and may not result from ion-pairing. Quercetin was 
chosen as a counterion as it was predicted by MarvinSketch (version 17.28, ChemAxon) to have 
one negative charge at pH 7.4. Further evaluation revealed that the negatively charged state of 
quercetin is weak and it is mainly neutral at pH 7.4 (pKd1=7.10 ± 0.12, pKd2=9.09 ± 0.11, 
pKd3=11.12 ± 0.36 (Herrero-Martínez et al., 2005)). This may be the reason why quercetin could 
not form ion-pairs with pentamidine, thereby not being able to improve the lipophilicity of 
pentamidine.  
 
2.5.4 Confirmation of pentamidine-xinafoate ion-pairs with fluorescence method 
In the fluorescence spectroscopy study, the correlation coefficients of DAPI and pentamidine 
standard curves are greater than 0.99, which verified the reliability of the fluorescence method. 
In addition, the calculated Limit of Quantification was necessary for selecting the concentrations 
for pentamidine and DAPI with xinafoate in the quenching study. The fluorescence quenching of 
pentamidine titration with xinafoate further confirmed the formation of ion-pairs. The new peaks 
and the shift in maximum emission wavelength of DAPI in the presence of xinafoate further 
confirmed that the amidine groups could bind to xinafoate and form ion-pairs.  
 
2.5.5 The binding affinity of pentamidine ion-pairs  
The binding constants calculated from HPLC and fluorescence methods are crucial to 
understanding the binding affinity of pentamidine ion-pairs. Pentamidine has the strongest binding 
with taurodeoxycholate, followed by xinafoate, and octanoate. Interestingly, this ranking is 
different from the predicted Log P (pLog P) of these three counterions: Xinafoate (pLog P = 2.97) 
> Octanoate (pLog P = 2.70) > Taurodeoxycholate (pLog P = 2.33).  
 
For taurodeoxycholate, its hydroxyl group and sulfonyl hydroxide can both act as hydrogen bond 
acceptors to attract pentamidine. This may explain the strongest binding of taurodeoxycholate - 
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pentamidine ion-pairs. A predicted 3D molecular modelling for pentamidine and 
taurodeoxycholate is shown in Figure 2-37 (a).  
 
For xinafoate and octanoate, only the carboxyl group on their structures can interact with the 
amidine groups of pentamidine. Xinafoate is more polar than octanoate. Thus it has a stronger 
binding affinity with pentamidine than octanoate. Their predicted 3D pentamidine ion pair 
structures are shown in Figure 2-37 (b) and (c).  
 
It is reasonable to conclude that pentamidine is unable to form significant numbers of ion-pairs 
with quercetin, due to the very limited lipophilicity improvement of pentamidine with quercetin in 
the shake-flask experiment, as well as the unfit regression of pentamidine - quercetin binding 





Pentamidine (MW: 340.4 g/mol) 













Figure 2-37 The predicted 3D structures of (a) pentamidine - taurodeoxycholate, (b) pentamidine - 
octanoate, and (c) pentamidine - xinafoate. The elements were labelled in different colours: red = 
hydrogen (O), blue = Nitrite (N), orange = sulfate (S), light grey = hydrogen (H), dark grey = carbon (C). 
The images of pentamidine ion pairs were manually created by Dr David Barlow and displayed using 
Discovery Studio Visualizer 4.0 (Accelrys Software Inc, San Diego, CA, USA), with the atomic co-ordinates 
for the individual molecules downloaded from the NIH PubChem resource. 
 
The binding constants (pKa) of pentamidine with taurodeoxycholate, octanoate, and xinafoate 
range from 3.1 - 4.1 in this study. Their binding constants much smaller than the reported highly 
stable metal complexes: pKCu2+-EDTA= 18.8, pKMg2+-EDTA= 8.8 (Wang and Tomasella, 2016). 
Therefore, the strength of pentamidine ion-pairs binding is relatively weak. Therefore, it is 
important to understand the dissociation of pentamidine ion-pairs for their potential applications 
in drug development.  
 
Pentamidine (MW: 340.4 g/mol) 
Octanoate (MW: 166.2 g/mol)  
Xinafoate (MW: 188.2 g/mol) 
Pentamidine (MW: 340.4 g/mol) 
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2.5.6 Binding sites of pentamidine-xinafoate ion-pair 
The NMR data provided insight into the specific binding sites information of pentamidine-xinafoate 
ion-pair. In the 1H NMR experiment, the splitting and disappearance of the proton peaks assigned 
to the amidine group of pentamidine provided evidence that pentamidine could bind to xinafoate 
at the site of its amidine group through hydrogen bonding, a strong non-covalent interaction. In 
the 13C NMR study, the down shield shift of pentamidine peaks associated with the carbons on 
the benzene ring indicated that pentamidine might also interact with xinafoate through π-systems 
interaction.  
 
2.5.7  Percentage of pentamidine bound in ion-pairs by HySS simulation 
The HySS simulation results showed that the percentage of ion-pairs (pentamidine in ion-pairs/ 
total pentamidine) varied with the pH of solutions, the binding constant of pentamidine- counterion 
complexes, the concentration of initial pentamidine, and the concentration of initial counterions 
added in the solution. The percentage bound of pentamidine with taurodeoxycholate, octanoate, 
and xinafoate was predicted by HySS. Percentage bound of pentamidine with quercetin was not 
predicted as the lipophilicity and binding studies showed that pentamidine would unlikely to form 
ion-pairs with quercetin. This information will help interpret the results gained from in vitro studies 
in Chapter 3 and Chapter 4. Table 2-21 summarises the percentage of pentamidine bound in ion-




Table 2-21 Summary of percentage of pentamidine bound in ion-pairs with different concentrations of 
taurodeoxycholate, octanoate and xinafoate at pH 7.4 
% Pentamidine bound   






(8 mM)  
Taurodeoxycholate (9 nM)  0.01%   
Taurodeoxycholate (180 nM) 0.22%   
Taurodeoxycholate (8 µM)  8.4%  
Taurodeoxycholate (160 µM)  66.1%  
Octanoate (9 nM)  <0.01%   
Octanoate (180 nM) 0.2%   
Octanoate (8 µM)  0.99%  
Octanoate (160 µM)  16.6%  
Xinafoate (9 nM)  <0.01%   
Xinafoate (180 nM) 0.07%   
Xinafoate (8 µM)  3.0%  
Xinafoate (160 µM)  38.5%  
Xinafoate (160 mM)   99.9% 
 
2.5.8 Dissociation of pentamidine-xinafoate ion-pair 
The florescence lifetime imaging microscopy were utilized in this study to understand the 
dissociation of pentamidine ion-pairs upon dilutions in physiological compartments. Three 
concentrations (8 mM, 8 µM, and 8 nM) of pentamidine were selected for the dissociation of 
pentamidine - xinafoate ion-pair study in order to mimic the concentrations range of pentamidine 
in clinic. For pentamidine, the human plasma concentration of pentamidine peaked at 1 h after 
administration at a varied range from 0.42 µM (142.8 µg/L) to 13.42 µM (4562.8 µg/L) with a 
median plasma concentration of pentamidine isethionate at day 7 was 4 nM (2.4 µg/L) after 
injection (Bronner et al., 1991). Unfortunately, pentamidine at 0.8 µM or less was not detectable 
by fluorescence lifetime imaging microscopy. Nevertheless, the change of lifetime of pentamidine 
upon the addition of xinafoate further proved the formation of pentamidine - xinafoate ion pairs at 




2.6 Conclusion  
The different methods utilised in this study helped us to understand the lipophilicity, binding 
affinity, binding sites, percentage bound, and dissociation of pentamidine upon forming ion-pairs 
with taurodeoxycholate, octanoate, quercetin and xinafoate. A summary of changes to the 
properties of pentamidine is listed in Table 2-22 below.  
 
Table 2-22 The change of pentamidine physicochemical parameters through ion-pairing with 
taurodeoxycholate, octanoate, quercetin, and xinafoate 
Physicochemical parameters Effect 
Lipophilicity (log D) The magnitude of change: taurodeoxycholate > 
octanoate > xinafoate > quercetin 
Binding constants (pKa) Pentamidine-taurodeoxycholate > pentamidine-
xinafoate> pentamidine-octanoate 
Binding sites  
(only xinafoate was assessed) 
The amidine groups on pentamidine could bind to 
xinafoate and form ion-pairs 
Percentage bound The percentage of pentamidine existing as an ion 
pair is extremely low (<1%) when pentamidine is 
at 9 nM, even in the presence of excess 
counterions; The percentage of pentamidine 
bound with counterions ranges from 1% to 66%, 
depending on the type and concentrations of 
counterions. 
Dissociation rate  
(only xinafoate was assessed) 
Not determined due to method limitations, 
however, FLIM confirmed the formation of ion-
pairs  
 
Xinafoate was selected as a model counterion for pentamidine, and it has been extensively 
studied with multiple techniques in this chapter. The HPLC, fluorescence, binding studies and 
NMR results confirmed the formation of pentamidine-xinafoate ion-pairs. Based on the improved 
lipophilicity of pentamidine with taurodeoxycholate, octanoate, and xinafoate in the octanol-saline 
shake-flask study, we can predict that pentamidine could also form ion-pairs with 
taurodeoxycholate and octanoate. The improved lipophilicity of pentamidine by forming ion-pairs 
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with taurodeoxycholate, octanoate, and xinafoate should be able to enhance the passive diffusion 
of pentamidine across lipid membranes. The results from the octanol-saline shake-flask and 
binding studies indicate that quercetin does not improve the lipophilicity of pentamidine and that 
quercetin cannot form ion-pairs with pentamidine.  
 
The results of the transport of pentamidine ion-pairs across biological membranes and their 






Chapter 3 Interactions of Pentamidine Ion-pair Complexes with 
hOCT1 Transporter at the Blood-Brain Barrier  
3.1 Chapter overview 
In this chapter, we will examine the interaction of pentamidine ion-pairs with biological membranes 
using human blood-brain barrier cells and xenopus oocytes expressing hOCT1. We will first 
establish and verify these cell models and then study the accumulation of pentamidine ion-pairs 
across the blood-brain barrier as well as their interactions with hOCT1. 
 
3.2 Introduction  
The blood-brain barrier (BBB) is critical for maintaining homeostasis and preventing toxins from 
entering the central nervous system (CNS). As a result, this protective barrier remains the biggest 
obstacle in the development of effective therapies for treating neurological disorders. It is 
estimated that more than 98% of small molecules (<500 Da) and nearly all large molecules are 
extruded by the BBB. Thus they cannot reach the CNS at an effective therapeutic concentration 
(Pardridge, 2005). Increasing doses of drugs administered systemically could improve the final 
concentrations reached at the CNS. However, this can cause serious side effects and potentially 
irreversible brain damage  (Pardridge, 2012). Therefore, for molecules that are effective but 
unable to reach the CNS at high enough concentrations, the focus of drug development is to 
increase their permeability across the BBB whilst not eliciting toxicity.  
 
As mentioned in Chapter 2, for drugs to reach the CNS in the brain, ideal drug candidates usually 
possess certain physicochemical properties (e.g., sufficient lipid solubility, small size) and a 
preferable pharmacokinetic profile (e.g., low efflux by P-gp transporter).  According to Lipinski’s 
“Rule of Five” (Lipinski et al., 2001; Pajouhesh and Lenz, 2005), for molecules to be successful 
in penetrating the CNS they must have the following physical properties: (1) molecular weight ≤  
500 Da, (2) Log P (lipophilicity) ≤ 5, (3) sum of OHs and NHs ≤ 5, (4) sum of Ns and Os ≤ 10 and 
(5) rotatable bonds ≤ 10.   
 
In addition to the physicochemical characteristics, membrane transporters play crucial roles in the 
pharmacokinetics (absorption, distribution, metabolism, and excretion) of drugs and ultimately 
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influence their therapeutic efficacy. It is often assumed that improving the lipophilicity of molecules 
can enhance their lipid solubility. However, this may inhibit drugs from utilising influx transporters 
such as OCT1 (Ahlin et al., 2008) and therefore decrease their therapeutic efficiencies.  
 
Generally, membrane transporters are divided into two super-families: ATP-binding cassette 
(ABC) transporters and carrier solute (SLC) transporters. Locations and levels of expression of 
membrane transporters vary in different organs. Transporters that have been identified at the 
human BBB are the ABC transporters (P-gp, BCRP, MRPs) and the SLC solute carriers (amino 
acid transporters, glucose transporters, OATPs, OATs, OCTs, OCTNs, nucleosides transporter, 
peptide Transporters, MCTs, MATE, PMAT). A comprehensive description of membrane 
transporters at the BBB can be found in Chapter 1. 
 
Some efflux membrane transporters such as P-gp have been selected as drug targets. For 
example, in order to eliminate the extrusion by P-gp transporter at biological membranes, a P-gp 
inhibitor may be co-administered with a P-gp substrate. Kemper (et al., 2004) found that the 
absorption of paclitaxel into wild-type mice brain was 5-fold higher with LY335979 (a P-gp 
inhibitor), although the process of inhibiting P-gp was reversible and its effect faded rapidly when 
the plasma concentration of the inhibitor declined.  
 
More recently, there has been an increasing interest in selecting SLC transporters as drug targets 
(Lin et al., 2015). One way of enhancing the absorption of drugs is to mimic the structures of influx 
transporter substrates. As dopamine could not cross the BBB, L-DOPA (a prodrug of dopamine) 
was developed to target LAT-1 (SLC3A2) transporter at the BBB for the treatment of Parkinson’s 
disease (Sanchez-Covarrubias et al., 2014). Despite the emerging opportunities in targeting SLC 
transporters for drug delivery, the mechanisms of transport are still being understood.  
 
For pentamidine, its limited efficacy in treating the Trypanosoma brucei gambiense type of Human 
African Trypanosomiasis (HAT) after parasites have invaded the CNS is due to its limited ability 
to cross the BBB. This process involves multiple influx and efflux transporters (L. Sanderson et 
al., 2009). Pentamidine has been found to be effluxed by P-gp and MRP transporters at the BBB 
(L. Sanderson et al. 2009). In addition, Ming (et al. 2009) found that pentamidine is a substrate of 
hOCT1 in transfected Chinese hamster ovary (CHO) cells. Sekhar (et al. 2017) found that 
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pentamidine is influxed across the BBB by the OCT1 expressed in human brain endothelial cells 
(hCMEC/D3) and mouse blood-brain barrier cells (bEnd.3).  
 
Ion-pairing strategy has been shown to improve drug delivery across skin, lung and intestinal 
membranes (Miller et al., 2009b; Suresh and Paul, 2011b; Hui et al., 2016; Song et al., 2016; 
Benaouda et al., 2018). It has been proved in Chapter 2 section 2.4.3 that the selected 
counterions could improve the lipophilicity of pentamidine. However, it is not yet known if the 
presence of the counter ion in the solution or the ion-pair complex itself would also affect the 
ability of pentamidine to interact with the membrane transporter hOCT1. By analysing 26 
published OCT1 substrates (Figure 3-1) we found that the majority of OCT1 substrates have one 
positive charge at physiological pH and a relatively small molecular weight (<400 Da). 
 
Figure 3-1 Charge and molecular weight of 26 published OCT1 substrates (source: NCBI database, 1989-
2016).  
 
In the physicochemical study (Chapter 2 section 2.4.5), we found that one of the selected 
counterions, xinafoate, bound to the amidine group of pentamidine through hydrogen bonding 
and increased its log D7.4 by 68.9%. While the physicochemical profile of ion-pairs seems 
promising for enhancing the permeability of drugs across lipid membranes of the BBB, their 
biological interactions with membrane transporters at the BBB are not understood. In fact, few 
drug molecules that were discovered at the early stage of drug discovery crossed cell membranes 
without interacting with transporters (Lee, Lean and Limenta, 2009). Further clarification of this 
issue will contribute to the design of a safe and effective ion-pair drug delivery method for 
pentamidine and other diamidines across the BBB.   
 
The hypothesis of this study is that the interaction of pentamidine with hOCT1 at the BBB would 
be altered through ion-pairing. The lavies xenopus oocyte system was selected to examine the 















interaction of pentamidine ion-paired complexes with hOCT1. The xenopus oocyte is an 
established single-cell model for expressing heterologous proteins. Its robust translational 
capacity makes it an ideal model to study proteins (e.g., membrane transporters, ion channels 
and receptors (Markovich, 2008a; Lin-Moshier and Marchant, 2013; Marchant, 2018; Pike et al., 
2019).  
 
The overall aim of this chapter is to examine if the ion-pairing of pentamidine increases the 
transport of pentamidine by hOCT1. 
 
The objectives are as follows:  
• To measure the toxicity of pentamidine-taurodeoxycholate, pentamidine-octanoate, 
pentamidine-quercetin, and pentamidine-xinafoate in hCMEC/D3 cells with MTT assay. 
• To determine the retention of [3H]pentamidine with taurodeoxycholate, octanoate, 
quercetin, and xinafoate in hCMEC/D3 cells by measuring the volume of distribution 
(Vd) of [3H]pentamidine with drug accumulation assay and the concentrations of protein 
with bicinchoninic acid (BCA) assay. 
• To simulate the interaction of pentamidine with hOCT1 membrane transporter using in 
silico molecular docking.  
• To establish a hOCT1 single transporter expressing model utilising xenopus oocytes 
• To confirm the identity and functional expression of hOCT1 in xenopus oocytes through 
DNA sequencing, gel electrophoresis of DNA and RNA, and influx of the hOCT1 
substrate - [3H]acetylcholine into xenopus oocytes expressing hOCT1  
• To determine the interaction of [3H]pentamidine ion-pairs with hOCT1 by measuring the 
influx of [3H]pentamidine into xenopus oocytes expressing hOCT1  
 
3.3 Materials and Methods 
3.3.1 Materials 
Ampicillin sodium salt was purchased from Calbiochem, gentamicin sulphate from Apollo 
Scientific, HiSpeed Plamid Midi Kit was purchased from Qiagen (Manchester, UK), mMESSAGE 
mMACHINE T7 Transcription Kit, 3M Sodium Acetate (pH 5.5), 100mm square petri dishes were 
purchased from Thermo Fisher Scientific (Paisley, UK), 100mM Sodium Pyruvate, tris base were 
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purchased from Fisher Scientific (Leicestershire, UK), Collagenase Type IV was purchased from 
Gibco, UltraPure Agarose from Invitrogen Life Technologies, 0.5M EDTA solution was purchased 
from Severn Biotech (Worcestershire, UK), magnesium sulphate heptahydrate (>=99.5%), 
potassium chloride were bought from AnalaR, calcium chloride dihydrate (>=99.0%), sodium 
chloride (>=99.5%), sodium dodecyl sulfate (>=92.5%), quinine were purchased from Sigma-
Aldrich, sodium octanoate (>=99.0%), calcium nitrate tetrahydrate, quercetin (>=95.0%), HEPES 
(>=99.5%), sodium taurodeoxycholate hydrate (>=95.0%), LB Agar, boric acid (>=99.5%) were 
from Sigma Life Science, 1-Hydroxy-2-naphthoic acid (>=97.0%) from Aldrich Chemistry. 
Ethidium Bromide Solution (10mg/ ml) was bought from Alfa Aesar, 3.5’’ tubes from Drummond 
Scientific, Ultima Gold was purchased from PerkinElmer (Bucks, UK), 1kb DNA ladder, 6x loading 
dye, NotI enzyme, HindIII enzyme and EcorI enzyme were purchased from Promega, hydrochloric 
acid and sodium hydroxide standard solution were purchased from Fluka Analytical. 
 
Radiolabelled chemicals 
[14C]sucrose (2.5 mCi in 25 ml, 536 mCi/mmol) was purchased from Moravek Biochemicals and 
[3H]pentamidine (5 mCi in 5 ml, 31.9 Ci/mmol) was custom radiolabelled by Moravek 
Biochemicals, [14C] D-glucose (250-360 mCi/mmol) and [3H]acetylcholine iodide (50-100 
mCi/mmol) were purchased from PerkinElmer (Bucks, UK).  
 
3.3.2 Cell Culture 
The immortalized human brain capillary endothelial cell line, hCMEC/D3 is a commercially 
available in vitro BBB model (Poller et al., 2008; Sekhar et al., 2017, 2019). It was previously 
utilised to explore the transport of pentamidine and its interaction with OCT1 and P-gp (Sekhar et 
al., 2017) as well as the effect of pentamidine reformulation with Pluronics (Sanderson et al., 
2019). To examine if pentamidine, in the presence of counterions, would be able to cross the BBB 
more efficiently, we utilised this well-established BBB model. In order to do this, we first needed 
to confirm that the cells remained viable during the exposure with counterions with a cytotoxicity 
assay. We could then assess the effect of each of the counterions on the human BBB 







All the hCMEC/D3 cells used in this study were between passage 29-35. The hCMEC/D3 cells 
were cultured in T-75 (75 cm2) flasks or 96-well plates in cell medium at 37 °C with 5% CO2. The 
cell media was composed of sterile-filtered Clonetics EGM Endothelial Cell Growth Medium, 1M 
HEPES (1%), Penicillin-Streptomycin (100 units/ml of penicillin, 100 µg/ml of streptomycin), 
Foetal Bovine Serum (2.5%), and growth factors (RhfGF-B, R3-IGF-1, VEGF, rhEGF and 
hydrocortisone). The cell medium was changed every 2-3 days. 
 
For splitting, the hCMEC/D3 cells were passaged when they were 80-90% confluent (areas of 
cells covered/areas of the T-75 flask), judged by visual observation under the microscope. The 
T-75 flasks and 96-well plates were pre-coated with rat collagen type I (0.1 mg/ml) for 2 h at 37 
°C. Then the residual collagen was removed with three times of wash by PBS+. The seeding 
density was 25,000 cells/cm2, and the hCMEC/D3 cells usually reached 80-90% confluency 
around 3-4 days. For cell accumulation assay, the cells were left for further 3-4 days to 
differentiate.  
 
3.3.3 Cytotoxicity Assay  
The viability of hCMEC/D3 cells in the presence of taurodeoxycholate, octanoate, quercetin and 
xinafoate was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay. This assay is a widely used colourimetric assay to determine cell viability or 
cytotoxicity. This assay measures cell viability through the determination of the mitochondrial 
function of cells by measuring the activity of mitochondrial enzymes.  In this assay, MTT is 
reduced to purple formazan by NADH. The purple formazan can be measured by light absorbance 
at a particular wavelength. MTT assay is convenient, reproducible, and safe to use. However, the 
MTT formazan could interfere with the background, which causes overestimation of the cell 
viability (Aslantürk, 2018). To account for the inaccurate estimation of cytotoxicity caused by 
varied numbers of viable cells, the cytotoxicity of hCMEC/D3 cells was investigated by MTT assay 
and BCA assay (see 3.3.5). 
 
Confluent monolayers of hCMEC/D3 cells (passage 29-33) were incubated with different 
concentrations (0, 0.1, 1, 10, 20, 50, 100 and 200 µM) of each of the counterions in the 
accumulation buffer for 2 h at 37 ˚C. At the end of this incubation time, the buffer was aspirated, 
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and the wells were refilled with pre-warmed MTT (1 mg/ml) in DMEM without phenol red and the 
plates placed in an incubator with 5% CO2 at 37 ˚C for 4 h. Following this, the MTT solutions were 
replaced with 100 µl of propan-2-ol. After 5 min, the viability of cells could be determined by 
measuring the absorbance of samples at 540 nm using a Labsystems Multiscan reader with the 
Ascent software. The absorbance was corrected by protein concentrations with BCA assay (See 
section 3.3.5 for details of BCA assay). Cells viability was compared to the control (i.e. 0 µM of 
counterions in the accumulation buffer) and results were expressed as percentage viability. 
 
3.3.4 Accumulation of [3H]pentamidine ion-pairs in hCMEC/D3 cells  
The accumulation of [3H]pentamidine and [14C]sucrose (0.9 µM), was measured by cell 
accumulation assay on a single monolayer of hCMEC/D3 cells in 96-well plates.  The [14C]sucrose 
here acted as a marker for non-specific binding, membrane integrity and measurement of 
extracellular space. Two different test concentrations of pentamidine were utilised in the absence 
and presence of 20 times molar ratios of counterions: a low concentration (9 nM) of just 
[3H]pentamidine in the accumulation buffer and a higher concentration (8 µM) which was 
composed unlabelled and radiolabelled pentamidine together. The buffer was shaken at 120 rpm 
over 2 h at 37°. The selected concentrations of pentamidine were based on the clinical 
concentration of pentamidine achieved in plasma after intramuscular injections at 3.5 - 4.5 mg 
pentamidine base per kg body weight. The plasma concentration of pentamidine peaked at 1h 
after administration, ranging from 0.42 µM (142.8 µg/L) to 13.42 µM (4562.8 µg/L), and the median 
plasma concentration of pentamidine isethionate at day 7 was 4 nM (2.4 µg/L) (Bronner et al., 
1991).  
 
 The accumulation buffer was removed at 5, 20, 30, 60 and 120-min time points, immediately 
followed with three washes with ice-cold PBS+ to terminate the transport. Then the cells were 
lysed in 200 µl 1% Triton x-100 and shaken at 120 rpm for 1 h. The 100 µl of the lysates were 
transferred to a scintillation vial with 4 ml of scintillation solution to count for radioactivity. The 
radioactivity was measured as disintegration per min (dpm) by Packard Tri-Carb 2900TR liquid 
scintillation counter (Perkin-Elmer, Beaconsfield, UK). The radioactivity of the lysates was 
corrected with protein concentrations measured by BCA and background dpm of the 




3.3.5 BCA protein assay 
The bicinchoninic acid assay (BCA assay) was introduced by Paul K. Smith in 1985, and since 
then, this method has become one of the most popular methods to quantify total protein. Basically, 
the chelation of copper with protein formed a blue complex and cuprous cation (Cu1+) in an 
alkaline environment. Then the BCA reagent reacts with Cu1+ and generates a water-soluble 
copper complex in purple colour. This purple complex can be measured at 550-570 nm with less 
than 10% loss signal, and it has the strongest signal at 562 nm (Smith et al., 1985). 
 
A standard curve was generated using the following bovine serum albumin (BSA) concentrations 
(0, 100, 150, 200, 250, 300 g/ml) and prepared in triplicate and absorption measured on a 
Labsystems Multiscan reader at 562 nm. In this study, the rest of the 100 µl cell lysates from the 
accumulation assay were used to quantify the total protein by BCA protein assay. The absorption 
of proteins was measured at 562 nm on a Labsystems Multiscan reader with Ascent software. 
Then the measured absorptions of cells lysates were converted to protein (mg/ml) from the 
standard curve.  
 
3.3.6 Calculations and expression of results  
Results of accumulated radioactivity were expressed as a volume of distribution (Vd), which was 
calculated by the ratio of dpm/mg protein to dpm/µl buffer (Equation 3-1) (Watson et al., 2012; 





                                                                                      (Equation 3-1) 
 
Background values of the accumulation buffer and Vd values of [14C]sucrose were subtracted in 
order to correct the Vd of [3H]pentamidine. The protein amount (mg) was acquired from BCA 
protein assay. The results were expressed as mean values in 6 replicates/wells per 96-well plate 
from at least 3 different passages of cells. The effect of the counterion was expressed as a 
percentage change.  
 
3.3.7 Molecular Docking of pentamidine onto hOCT1  
The Molecular Docking for pentamidine into hOCT1 transporter was completed by Dr Khondaker 
Miraz Rahman’s group from Medicinal Chemistry at King’s College London. Molecular docking 
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was performed using CDOCKER (Discovery studio version 4.0), a CHARMm based docking tool, 
where annealing molecular dynamics were simulated to each orientation. Based on the 
CDOCKER energy, the ligand poses were sorted, and then the most favourable binding (the most 
negative value) was retained. Due to the unavailability of the structure for hOCT1, 4ZW9 (the 
crystal structure for human GLUT3) (Deng et al., 2015) from Protein Data Bank was selected. 
The crystal structure of 4ZW9 is similar to the structure of hOCT1. The binding site of pentamidine 
to 4ZW9 was chosen based on the least energies needed for docking into different binding 
cavities.  
 
Figure 3-2 Crystal structure of human GLUT3 (4ZW9) bound to D-glucose in the outward-occluded 
confirmation  (Deng et al., 2015).  
 
3.3.8 Using xenopus laevis oocytes to functionally characterise the interaction of ion pairs 
with hOCT1 transporter 
Compared to eukaryotic cell lines, the advantages of the xenopus laevis oocytes are: (1) they can 
rapidly express proteins within one week; (2) they can produce a large number of foreign proteins 
through microinjections; (3) they provide a controllable environment with high-signal-to-noise 
ratio; (4) they can clone cDNAs with unknown sequence (Markovich, 2008b; Pike et al., 2019). 
The disadvantages of the xenopus laevis oocytes include: (1) some proteins such as aquaporins 
(van Balkom et al., 2004) affect the viability and will cause swelling or bursting of oocytes; (2) 




3.3.9 Uptake of [14C]D-glucose into rSGLT1 expressing oocytes 
In this study we utilised an established rat sodium-dependent glucose transporter (rSGLT1) 
expressing oocyte method and the radiolabelled substrate D-glucose to act as an internal control. 
The preparation method of rSGLT cRNA has been published in the thesis of Dr Corpe MSc 
student Reshma Suresh (Suresh, 2013). In brief, the prepared rSGLT cRNA and [14C] D-glucose 
(250-360 mCi/mmol, PerkinElmer) were provided by Dr Christopher Corpe from King’s College 
London. Oocytes were injected with 36 nl rSGLT1 cRNA or water and then incubated in MBM 
with 1 mM pyruvate at 20 ˚C. MBM was changed daily, and broken oocytes were disposed of. For 
uptake assay, the 1 mM [14C] D-glucose uptake media was composed of 1 mM unlabelled D-
glucose and 0.2 µCi/ml (~ 1 µM) [14C]D-glucose in MBM. 11-13 rSGLT1 cRNA or water-injected 
oocytes were placed per vial and incubated for 10 min before washed three times with ice-cold 
PBS. Then each of the oocytes was lysed in 500 µl 10% (w/v) sodium dodecyl sulfate (SDS). 4 
ml of scintillation fluid was then added, and the DPM (disintegrations per min) was counted by 
Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK). The DPM 
of 10 µl uptake media was also counted. The results were expressed as the average uptake of 
[14C]D-glucose (pmol) in each of the 11-13 oocytes during the 10 min incubation time. 
 
3.3.10 Laevis xenopus oocyte as a model system to study hOCT1 transporter 
There are a few steps of preparing xenopus oocytes expressing hOCT1. At first, the cDNA of 
hOCT1 vector was amplified and verified through DNA sequencing and restriction enzyme 
digestion. Then the hOCT1 cRNA was synthesised and verified by gel electrophoresis. Finally, 
the hOCT1 cRNA was injected into oocytes, and the functional expression of hOCT1 was 
confirmed by radiotracer uptake assay.  
 
3.3.10.1 Materials  
3.3.10.1.1 Plasmid and inserts  
hOCT1 cDNA was kindly provided by Professor Hermann Koepsell (University of Wurzburg, 
Würzburg, Germany). hOCT1 cDNA (Accession: BC126364) was cloned in vector pOG1 using 
the restriction site 5’HindIII >>>EcoR1 3’ containing a 1861kb insert and an ampicillin selection 




3.3.10.1.2 Oligonucleotides  
The oligonucleotide (sequence: TTA CTC CGC TCT GGT CGA AAT, 25 nmole, desalted) was 
purchased from Sigma-Aldrich Company Ltd (Dorset, UK) for DNA sequencing for the hOCT1 
vector. 
 
3.3.10.2 Preparation of Agar plates 
LB Agar solution (15%) was autoclaved and cooled down to 37 ˚C. Then a small amount of 
ampicillin (100 µg/ml) was mixed into the LB Agar solution. After that, the solution was 
immediately poured into petri dishes and left overnight for the agar to solidify.  
 
3.3.10.3 Amplification of hOCT1 cDNA 
One vial of E.coli cells (Subcloning Efficiency™ DH5α™ Competent Cells from Invitrogen) was 
thawed on ice. Then 100 ng of hOCT1 DNA vector was gently mixed with the cells and left on ice 
for 30 min. After that, the cells went through a heat-shock at 42 ˚C without shaking for 30 s before 
immediately transferred on ice for 2 min. The cells were then added into 250 µl 20% pre-warmed 
LB broth shaken at 225 rpm and incubated at 37 ˚C for 1 h. Following the incubation, 20 µl of 
transformation samples were plated on pre-made selective antibiotics (ampicillin, 100 µg/ml) 
selective LB agar plates and incubated at 37 ˚C for overnight. The next day, a single colony was 
picked up and inoculated in 250 ml of LB medium with 100 µg/ml ampicillin. Then the solution 
was shaken at 225 rpm for overnight at 37 ˚C. After the amplification, the hOCT1 cDNA was 
purified with the HiSpeed Plasmid Midi Kit (Qiagen, Germany).  
 
3.3.10.4 DNA sequencing of hOCT1 vector 
The hOCT1 plasmid was diluted to 100 ng/µl. Then the hOCT1 plasmid and oligonucleotides were 
sent to Beckman Coulter Genomics (Essex, UK) for sequencing. The DNA sequencing result was 
compared to the dataset in the National Center for Biotechnology Information (NCBI) of U.S. 
National Library of Medicine (Link to website: https://www.ncbi.nlm.nih.gov).  
 
3.3.10.5 Restriction Enzyme Digestion of cDNA 
The hOCT1 cDNA plasmid was digested by enzymes to confirm the identity of the insert. hOCT1 
cDNA was digested by EcoRI and HindIII, or Not1 enzymes at 37 ˚C overnight. Then sizes of the 
fragments were checked by agarose gel electrophoresis. The agarose was dissolved in 75 ml of 
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1xTBE buffer at a final concentration of 1% (m/v). Ethidium Bromide (4 µl) was added into the gel 
and used to stain the DNA. 1 kb DNA ladder was loaded in parallel with the samples as a 
reference. 500 ng DNA samples in loading buffer were loaded in each well and run at 100 V for 1 
h. Then results were visualized under UV and images were captured by GeneSnap. 
 
3.3.10.6 Plasmid linearization  
The hOCT1 plasmid was linearized with the restriction enzyme Not1 at 37 ˚C overnight. The 
linearization process was terminated with 1/20th volume of 0.5 M EDTA, 1/10th volume of 3 M Na 
acetate and 2 volumes of ethanol. Then the sample was mixed well and chilled at -20 ˚C overnight 
for precipitation.  
 
3.3.10.7 Synthesis of RNA 
The hOCT1 cDNA was centrifuged at maximum speed (16,000 g) at 4 ˚C for 30 min. Then the 
pellet was washed three times by 70% ethanol before re-suspended in 10µl nuclease-free water. 
The concentration of cDNA was determined by NanoDrop Microvolume Spectrophotometer (ND-
1000 Spectrophotometer). Then the cDNA sample was used for synthesis with the T7 
mMESSAGE mMACHINE kit (Ambion). Briefly, a mixed solution consisting of the precipitated 
hOCT1 cDNA (5 µg), nuclease-free water, 2xNTP/CAP, 10xReaction buffer and Enzyme was 
prepared and then incubated at 37 ˚C for 2 h. Then the reaction was terminated by adding 30 µl 
lithium chloride and 30 µl nuclease-free water. Then the sample was stored at -20 ˚C to precipitate 
for at least 12 h. The sample was then removed from the freezer and left to defrost at room 
temperature (~20 ˚C). It was then centrifuged at 16,000 g at 4 ˚C for 30 min. The supernatant was 
carefully discarded, and the pellet was washed three times with 70% ice-cold ethanol. The pellet 
was left at room temperature for 5 min to air-dry the residual ethanol before re-suspension in 10 
µl of nuclease-free water. The concentration of the RNA was spectrophotometrically determined 
by NanoDrop Microvolume Spectrophotometer (ND-1000 Spectrophotometer). Typically, the yield 
of cRNA was ~10 µg. 
 
Calculation of cRNA yield:  
1000 ng/µl (1 µl of the stock cRNA concentration determined by NanoDrop) x 10 µl (total volume 




3.3.10.8 Verification of hOCT1 RNA                          
The size and integrity of the synthesised hOCT1 total RNA were characterised using Agilent RNA 
6000 Nano Kit and 2100 Bioanalyzer. Firstly, the gel was prepared. The RNA 6000 gel matrix 
(550 µl) was pipetted into a spin filter and then centrifuged at 1,500 g for 10 min. Sly, the gel-dye 
mix was prepared. The RNA 6000 Nano dye concentrate was taken out of the -80 ˚C freezer and 
allowed to equilibrate to room temperature for half an h. Then the dye concentrate was vortexed 
for 10 s and spun down. The gel-dye solution was prepared by mixing 1 µl of the dye concentrate 
into 65 µl aliquot of filtered gel. The solution was vortexed, spun at 13,000 g for 10 min, and used 
within 24 h. Thirdly, the prepared gel-dye mix was loaded into an RNA 6000 Nanochip. The RNA 
6000 Nanochip was placed into the chip priming station and 9 µl gel-mix was loaded into the 
designated well of the chip. The plunger of the chip priming station was pressed from its initial 1 
ml position until it was held by the clip. After 5 s, the plunger was slowly pulled back to its 1 ml 
position. Finally, the gel-dye mix, RNA 6000 Nano marker, ladder and RNA samples were pipetted 
into the wells of the chip. The chip was vortexed horizontally at 2,400 rpm for 1 min before it was 
put into the Agilent 2100 bioanalyzer for analysis.  
 
3.3.10.9 Isolation of Oocytes 
Modified Barth's Medium (MBM) was prepared and it consisted of 88 mM NaCl, 1 mM KCl, 0.82 
mM MgSO4, 0.33 mM Ca (NO3)2, 10 mM HEPES, 0.41 mM CaCl2 (pH 7.4 regulated by HCl/ 
NaOH) and was utilized to store the oocytes. The lavies xenopus oocyte ovary (27 months old) 
was delivered overnight in ice from the European Xenopus Resource Centre (Portsmouth, UK). 
Upon arrival, the ovary was placed into a petri dish and washed 4-6 times with MBM without Ca 
(NO3)2 and CaCl2. The ovary was teased apart and the oocytes were released from the ovary. 
Then the oocytes were incubated in 25 ml of collagenase (2 mg/ml) in MBM without Ca (NO3)2 
and CaCl2 for 30 min and the whole process was repeated. The collagenase activity was 
terminated by washing with MBM for 2-3 times. The intact oocytes at stage V or VI were selected 
under the microscope (Figure 3-3). The oocytes were stored at 19-20 ˚C and protected from light 






Figure 3-3 Stage I-VI of xenopus oocytes. Picture was modified from Allen (et al., 2007). The oocytes in 
stage V or VI were selected for injections.  
 
3.3.10.10 Oocytes injection 
The micropipettes (Drummond Nanoject™ II Replacement Bores, length: 88.9 mm, outer 
diameter: 1.14 mm, inner diameter: 0.53 mm, Alpha Laboratories Limited, UK) for injection were 
prepared by pulling with a needle puller (Sutter Instruments Co. Model-87, Flaming/Brown 
Micropipette puller) as shown in Figure 3-4. These micropipettes were loaded with hOCT1 RNA 
to inject into each oocyte. 
 
Figure 3-4 Sutter Instruments Co. Model-87, Flaming/Brown Micropipette puller with the setting of heat 
(749; range 0-999), pull (63: range 0-255), velocity (45, range 0-255) and time (210 millis). The units of the 
heat, pull, and velocity settings are arbitrary.  Heat setting will affect the length and tip size of the pipette.  
Generally speaking, higher heat settings tend to give longer and finer tips.  Low values of pull strength win 
the range 40-75 will give larger tips appropriate for injection needles, while settings between 120-250 give 
smaller tips appropriate for micropipettes.  Velocity is typically set between 80 to 120 for micropipettes or 
50-80 for microinjection needles. The instruction manual is available here: 
https://www.americaninstrument.com/pdf/3889-PIPETTOR.pdf (accessed 27.5.2020). 
 
Prior to injection, one side of micropipettes was cut by micro tweezers to make the final length 
between 10 to 15 mm. Then hOCT1 RNA was loaded into micropipettes with a micro-loader and 
sealed with mineral oil. Each oocyte was observed under the microscope and the ones that were 
broken or with unclear edges were disposed of. Each oocyte was injected with 50 nl RNA-free 
water or hOCT1 RNA, then placed in MBM solution with 1 mM sodium pyruvate. The injected 
oocytes were stored at 19-20 ˚C for 3 days before the uptake assay. The MBM buffer was 
changed every day and broken oocytes were discarded.  




Figure 3-5 The RNA injector (NanoJect II, Leica) used in this study. The micropipettes were connected to 
the injector. The oocytes were placed under the microscope, and one injection to each oocyte contained 
50 nl of RNA-free water or hOCT1 RNA. 
 
3.3.11 Verification of the method 
3.3.11.1 Uptake of [3H]acetylcholine in hOCT1 expressed oocytes  
In order to confirm the functionality of hOCT1 transporter in oocytes, acetylcholine, an 
endogenous substrate for hOCT1 (Lips et al., 2005), was utilised. In 8-12 of water-injected 
oocytes or hOCT1 expressed oocytes were placed in vials with MBM. The MBM was aspirated 
just before 500 µl of transport buffer (7.6 µM [3H]acetylcholine and 0.9 µM [14C]sucrose in MBM) 
was pipetted into the vials. Each group of oocytes was incubated with the transport buffer for 1, 
30, 60 and 120 min and then stopped with three times of wash with ice-cold MBM containing 100 
µM quinine (hOCT1 inhibitor (Lips et al., 2005)). Each of the oocytes was lysed in 500 µl 10% 
SDS. Then 4 ml of scintillation fluid was added to the each of the oocyte lysates and the DPM 
was counted by Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, 
UK).  
 
3.3.12 Uptake of [3H]pentamidine in oocytes expressing hOCT1   
The uptake of [3H]pentamidine in hOCT1 expressed oocytes was performed in order to confirm 
the role of hOCT1 in the uptake of [3H]pentamidine. Water-injected oocytes and hOCT1 injected 
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oocytes were incubated with 31 nM [3H]pentamidine and 0.9 µM [14C]sucrose in 500 µl MBM for 
1, 20, 30, 60 and 120 min. The uptake was terminated by three times of wash with ice-cold MBM 
containing 100 µM quinine (hOCT1 inhibitor). Then each oocyte was lysed in 500 µl 10% SDS 
solution and 4 ml of scintillation solution. The DPM was counted by Packard Tri-Carb 2900TR 
liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK).  
 
3.3.13 Self-saturation of [3H]pentamidine in hOCT1 expressed oocytes 
 [3H]pentamidine (31 nM) was incubated with unlabelled pentamidine (0, 2, 5,10, 20, 50, 100, 250, 
500 µM) for 1 h. The uptake of [3H]pentamidine in oocytes was terminated by 3 times of wash 
with ice-cold MBM buffer containing 100 µM quinine (hOCT1 inhibitor). Then each oocyte was 
lysed in 500 µl 10% SDS solution and 4 ml of scintillation solution. The DPM was counted by 
Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK). To 
calculate the Km of pentamidine by hOCT1 in oocytes, the molar concentrations of 
[3H]pentamidine (µM) and the net uptake of  [3H]pentamidine (fmol/oocyte) by hOCT1 in oocytes 
were fit into the Michaelis-Menten model in GraphPad 7. 
 
3.3.14 Uptake of [3H]pentamidine ion-pairs in hOCT1 expressed oocytes 
To understand how counterions including taurodeoxycholate, octanoate, quercetin and xinafoate 
affect the uptake of [3H]pentamidine by hOCT1, the uptake of [3H]pentamidine ion-pairs in oocytes 
expressing hOCT1 was performed. Water-injected (sham) or hOCT1 expressed oocytes were 
incubated in transport buffer containing 8µM [3H]pentamidine (8 µM unlabelled pentamidine and 
31 nM [3H]pentamidine), 0.9 µM [14C]sucrose, and 8 µM or 160 µM of each counterion 
(taurodeoxycholate, octanoate, quercetin, and xinafoate) for 60 min. The uptake was terminated 
by 3 times of wash with ice-cold MBM buffer containing 100 µM quinine (hOCT1 inhibitor). Each 
oocyte was lysed in 500 µl 10% SDS solution and 4 ml of scintillation. The DPM was counted by 
Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK). Results 
were expressed as mean ± standard errors of n=21-26 oocytes from 3 different batches/ 
independent experiments. 
 
3.3.15 Calculation methods 
The specific activity of the uptake media was calculated by the moles of the radiolabelled 
compound in 10 µl uptake media. Together with the counted DPM of 10 µl uptake media, the ratio 
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of DPM to the molar amount of each radiolabelled compound was calculated. Then this ratio 
(DPM/moles) was used to determine the uptake of the radiolabelled compound in each oocyte.  
 
3.3.16 Statistical analysis  
Results were expressed as mean ± standard errors (S.E.M). The data of the uptake assay were 
analysed by one-way ANOVA or two-way ANOVA with GraphPad 7. Significant differences were 





3.4.1 Cytotoxicity of taurodeoxycholate, octanoate, xinafoate and quercetin on 
hCMEC/D3 cells 
The four counterions did not cause significant changes on the mitochondrial function or cell 
viability of hCMEC/D3 cells after 120 min exposure when compared to the negative control of 
accumulation buffer only. As expected, the positive control caused a decrease by approximately 
70% (***p<0.001) with 1% triton (Figure 3-6). 
 
 
Figure 3-6 Cytotoxicity of taurodeoxycholate, octanoate, quercetin, and xinafoate (0.1- 200 µM) in 
hCMEC/D3 cells at 2 h incubation time point. Results were corrected by protein from BCA assay and 
expressed as percentage viability of cells ± SEM (n=3 passages from P29-35/ independent experiments 
with 6 replicates per plate) compared to the untreated cells (control). Data were analysed by one-way 




3.4.2 Uptake of [3H]pentamidine with taurodeoxycholate in hCMEC/D3 cells 
The concentration of [3H]pentamidine was set at 9 nM in order to mimic the clinical concentration 
(4 nM) in the brain, as explained earlier. The results in Figure 3-7 (a) indicated that the presence 
of 9 nM and 180 nM of taurodeoxycholate did not improve the uptake of [3H]pentamidine. No 





Figure 3-7 The effect of taurodeoxycholate (9 nM and 180 nM) on the accumulation of [3H]pentamidine (9 
nM) corrected by sucrose, and [14C]sucrose (0.9 µM) in hCMEC/D3 cells. Results were expressed as 
mean ± SEM from 3 passages of cells/ independent experiments (n=3 from passage 31-33) with 6 
replicates per time point. Data were analysed by two-way ANOVA with Dunnett multiple comparison test 
by GraphPad Prism 7. The percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS 
simulations (Chapter 2 Section 2.4.7.1). The Log D was measured by shake flask method and HPLC 
analysis (chapter 2 Section 2.4.3). For ease of comparison, these values have been included in this figure.   
 
The presence of taurodeoxycholate (160 μM) suppressed the uptake of [3H]pentamidine and 
caused significant decrease by 42.4% (p<0.05) at the 120 min time point, but there was no effect 
observed at the earlier time points (Figure 3-8, a). No significant differences of [14C]sucrose with 




































+ 9nM Taurodeoxycholate (0.01% ion-pairs)
+ 180nM Taurodeoxycholate (0.22% ion-pairs)
MW of pentamidine: 340.4 g/mol
MW of sodium taurodeoxycholate: 521.7 g/mol
Log D, 7.4 (PEN-TAU, 1:20) = - 0.04
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160 μM taurodeoxycholate compared to the control were observed within the 2 h incubation time 





Figure 3-8 The effect of taurodeoxycholate (160 μM) on the accumulation of [3H]pentamidine (9 nM 
[3H]pentamidine+ 8 μM unlabelled pentamidine) corrected by sucrose and 0.9 μM [14C]sucrose in 
hCMEC/D3 cells. Results were expressed as mean ± SEM from 3 passages of cells/ independent 
experiments (n=3 from passage 30, 31 and 34) with 6 replicates per time point. Data were analysed by 
two-way ANOVA with Sidak’s multiple comparison test by GraphPad Prism 7 (p*<0.05). P*<0.05 
represents a significant difference between the treatment and control group at a specific time point. The 
percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations (Chapter 2 
Section 2.4.7.1 ). The Log D was measured by shake flask method and HPLC analysis (Chapter 2 Section 
2.4.3). For ease of comparison, these values have been included in this figure.   
 
3.4.3 Uptake of [3H]pentamidine with octanoate in hCMEC/D3 cells 
The presence of 20 times of octanoate (180 nM) significantly increased the accumulation of 
[3H]pentamidine at the 120 min time point (P<0.05) by 98.1% (Figure 3-9, a). No significant 
differences were seen in the uptake of [14C]sucrose over the 120 min incubation time course 
(Figure 3-9, b). 
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MW of sodium taurodeoxycholate: 521.7 g/mol
Log D, 7.4 (PEN-TAU, 1:20) = - 0.04








































Figure 3-9 The effect of octanoate (9 nM and 180 nM) on the accumulation of [3H]pentamidine (9 nM) 
corrected by sucrose and [14C]sucrose (0.9 µM)  in hCMEC/D3 cells. Results were expressed as mean ± 
SEM from 3 passages of cells/ independent experiments (n=3 from passage 31-33) with 6 replicates per 
time point. Data were analysed by two-way ANOVA with Dunnett multiple comparison test by GraphPad 
Prism 7 (p*<0.05). P*<0.05 represents significant difference between the treatment and control group at a 
specific time point. The percentage of [3H]pentamidine in ion pair form was predicted from the HYSS 
simulations (Chapter 2 Section 2.4.7.2). The Log D was measured by shake flask method and HPLC 
analysis (Chapter 2 Section 2.4.3). For ease of comparison these values have been included in this figure.   
 
The 160 μM octanoate significantly decreased the uptake of [3H]pentamidine by 52.1% at the 20 
min (P<0.05) and by 54.4% at the 120 min (P<0.01) time points (Figure 3-10, a). No statistical 
differences were seen in the [14C]sucrose uptake over the 2 hs compared to the control (Figure 
3-10, b).  
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Figure 3-10 The effect of octanoate (160 μM) on the accumulation of [3H]pentamidine (9 nM 
[3H]pentamidine+ 8 μM unlabelled pentamidine) corrected by sucrose and 0.9 μM [14C]sucrose in 
hCMEC/D3 cells. Results were expressed as mean ± SEM from 3 passages of cells/ independent 
experiments (n=3 from passage 30, 31 and 34) with 6 replicates per time point. Data were analysed by 
two-way ANOVA with Sidak’s multiple comparison test by GraphPad Prism 7 (p*<0.05, p**<0.01). 
P**<0.01 represents a significant difference between the treatment and control group at a specific time 
point. The percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations 
(Chapter 2 Section 2.4.7.2). The Log D was measured by shake flask method and HPLC analysis (Chapter 
2 Section 2.4.3). For ease of comparison, these values have been included in this figure.   
 
3.4.4 Uptake of [3H]pentamidine with quercetin in hCMEC/D3 cells 
The presence of 9 nM and 180 nM of quercetin did not cause significant changes in the uptake 
of [3H]pentamidine over the 120 min incubation time (Figure 3-11, a). The uptake of [14C]sucrose 
increased significantly over 2 folds at the 60 min (P<0.05) and the 120 min (P<0.05) time points 
with 9 nM quercetin (Figure 3-11, b). 
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Figure 3-11 The effect of quercetin (9 nM and 180 nM) on the accumulation of [3H]pentamidine (9 nM) 
corrected by sucrose and [14C]sucrose (0.9 µM) in hCMEC/D3 cells. Results were expressed as mean ± 
SEM from 3 passages of cells/ independent experiments (n=3 from passage 31-33) with 6 replicates per 
time point. Data were analysed by two-way ANOVA with Dunnett multiple comparison test by GraphPad 
Prism 7 (p*<0.05). P*<0.05 represents a significant difference between the treatment and control group at 
a specific time point. The Log D was measured by shake flask method and HPLC analysis (Chapter 2 
Section 2.4.3). For ease of comparison, these values have been included in this figure. 
 
3.4.5 Uptake of [3H]pentamidine with xinafoate in hCMEC/D3 cells 
Significant increases of [3H]pentamidine were observed by 9 nM xinafoate at the 60 min (P<0.01) 
and the 120 min (P<0.001) time points (Figure 3-12, a). However, the increases may be explained 
by the damage of membrane integrity as the uptake of [14C]sucrose showed significant increases 
(P<0.05 and P<0.01) at these two time points (Figure 3-12, b).  
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MW of quercetin: 302.2 g/mol 
Log D, 7.4 (PEN-QUE, 1:20) = - 1.14










































Figure 3-12 The effect of xinafoate (9 nM and 180 nM) on the accumulation of [3H]pentamidine (9 nM) 
corrected by sucrose and [14C]sucrose (0.9uM) in hCMEC/D3 cells. Results were expressed as mean ± 
SEM from 3 passages of cells/ independent experiments (n=3 from passage 31-33) with 6 replicates per 
time point. Data were analysed by two-way ANOVA with Dunnett multiple comparison test by GraphPad 
Prism 7 (p*<0.05, p**<0.01). P*<0.05 and P**<0.01 represent a significant difference between the 
treatment and control group at a specific time point. The percentage of [3H]pentamidine in ion-pair form 
was predicted from the HYSS simulations (Chapter 2 Section 2.4.7.3). The Log D was measured by shake 
flask method and HPLC analysis (Chapter 2 Section 2.4.3). For ease of comparison, these values have 
been included in this figure. 
 
There were no significant differences in the uptake of [3H]pentamidine or [14C]sucrose by 180 μM 
xinafoate compared to the control, as shown in Figure 3-13. 
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Figure 3-13 The effect of xinafoate (160 μM) on the accumulation of [3H]pentamidine (9 nM 
[3H]pentamidine+ 8 μM unlabelled pentamidine) corrected by sucrose and 0.9 μM [14C]sucrose in 
hCMEC/D3 cells. Results were expressed as mean ± SEM from 3 passages of cells/ independent 
experiments (n=3 from passage 30, 31 and 34) with 6 replicates per time point. Data were analysed by 
two-way ANOVA with Sidak’s multiple comparison test by GraphPad Prism 7. The percentage of 
[3H]pentamidine in ion-pair form was predicted from the HYSS simulations (Chapter 2 Section 2.4.7.3). 
The Log D was measured by shake flask method and HPLC analysis (Chapter 2 Section 2.4.3). For ease 
of comparison, these values have been included in this figure. 
 
3.4.6 Molecular docking of pentamidine, mannitol and sucrose into hOCT1  
The in silico simulations revealed that the hydrogens on the amidine groups of pentamidine 
interact with the ASN286 of hOCT1 (Figure 3-14). The hydrogen on the chain between the ether 
groups in pentamidine interacts with THR293 of hOCT1. The benzene rings of pentamidine are 
attracted to PHE289 and ILE166 on hOCT1 through hydrophobic interaction.  
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Figure 3-14 Molecular docking of pentamidine into 4ZW9. The green and pink dotted lines in the 3D figure 
represent hydrogen bonds and hydrophobic interactions, respectively. The image was provided by Dr 
Khondaker Miraz Rahman’s group from Medicinal Chemistry at King’s College London. 
 
The docking results showed that the hydroxyls of mannitol interact with the PHE289, THR293, 




Figure 3-15 Molecular docking of mannitol into 4ZW9. The green dotted lines in the 3D figure represent 
hydrogen bonds. The image was provided by Dr Khondaker Miraz Rahman’s group from Medicinal 
Chemistry at King’s College London. 
 
The molecular docking results indicated that the hydroxyls of sucrose interact with the ASN32, 






Figure 3-16 Molecular docking of sucrose into 4ZW9. The green dotted lines in the 3D figure represents 
hydrogen bonds. The image was provided by Dr Khondaker Miraz Rahman’s group from Medicinal 
Chemistry at King’s College London. 
 
 
The free energy with higher negative value implies a more favourable binding between the 
molecule and the transporter. A substrate is defined as one with a free energy binding lower than 
-5 kcal/mol (from personal communication with Dr Miraz Rahman from King’s College London 
December 2019). The best pose of pentamidine interacted with the binding site of 4ZW9 with a 
free energy of -35.22 kcal/mol, while sucrose has a free energy of +19.93 kcal/mol.  
 
3.4.7 Method verification  
The hOCT expressing lavies xenopus oocyte model was verified in three ways: (a) Confirming 
the transporter assay methodology using rSGLT, (b) Confirming the identity of hOCT1 DNA and 
RNA, and (c) Confirming the functional expression of the hOCT1 transporter in lavies xenopus 




3.4.7.1 [14C]D-glucose uptake in established rSGLT expressing oocyte model 
The rat sodium-dependent glucose transporter (rSGLT) RNA injected oocytes saw significant 
increases (P<0.001) in [14C] D-glucose compared to both non-injected and water-injected oocytes 
(Figure 3-17). No significant differences were seen between the non-injected and the water-
injected oocytes, which indicated the intact membrane integrity by injections.  
 
Figure 3-17 [14C]D-glucose (1 mM) uptake in non-injected oocytes, water-injected oocytes, and oocytes 
expressing rSGLT. Oocytes were incubated in transport buffer with [14C] D-glucose for 10 min. Data 
represents mean ± standard errors of 11-13 oocytes (1 batch) per group. Results were analysed by one-
way ANOVA using GraphPad Prism 7.03 (P<0.001***). 
 
3.4.7.2 hOCT1 vector sequencing  
The amino acid sequences of the hOCT1 vector were aligned to the published hOCT1 sequences 
(BC126364.1) from the National Centre for Biotechnology Information (NCBI) database. The 
alignment indicated that the hOCT1 vector sequences were 100% identical to the published cDNA 
sequences which confirmed the identity of the vector (Figure 3-18). After sequencing, this vector 
















































Figure 3-18 Comparison of the hOCT1 vector sequences to hOCT1 sequence (BC126364.1) from the 
NCBI database. A (adenine), T (thymine), C (cytosine), G (guanine) are the four bases of DNA. The upper 
rows of the alignment are the hOCT1 vector cDNA sequences and the lower rows are the sequences from 
NCBI database (BC126364.1).  
 
3.4.7.3 Restriction enzyme digestion of hOCT1 cDNA 
The uncut hOCT1 cDNA ran in the forms of both supercoiled and open-circular thus it appeared 
in two fragments on the gel at around 8 kb (band 2, Figure 3-19). The hOCT1 cDNA linearised by 
NotI had one single band at around 8 kb (band 3, Figure 3-19), while the double digested hOCT1 
cDNA had two bands (band 4, Figure 3-19), of which the first band appeared at around 1.8 kb 
and the other at around 6 kb. The sizes of bands for the uncut, linearised, and double digested 
hOCT1 on the gel were expected. This verified the identity of the hOCT1 vector. 
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                *         *         *         *         *         *         *         *         *         *
     1 GAGCCATCATGCCCACCGTGGATGACATTCTGGAGCAGGTTGGGGAGTCTGGCTGGTTCCAGAAGCAAGCCTTCCTCATCTTATGCCTGCTGTCGGCTGC 100   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
     1 GAGCCATCATGCCCACCGTGGATGACATTCTGGAGCAGGTTGGGGAGTCTGGCTGGTTCCAGAAGCAAGCCTTCCTCATCTTATGCCTGCTGTCGGCTGC 100   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   101 CTTTGCGCCCATCTGTGTGGGCATCGTCTTCCTGGGTTTCACACCTGACCACCACTGCCAGAGTCCTGGGGTGGCTGAGCTGAGCCAGCGCTGTGGCTGG 200   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   101 CTTTGCGCCCATCTGTGTGGGCATCGTCTTCCTGGGTTTCACACCTGACCACCACTGCCAGAGTCCTGGGGTGGCTGAGCTGAGCCAGCGCTGTGGCTGG 200   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   201 AGCCCTGCGGAGGAGCTGAACTATACAGTGCCAGGCCTGGGGCCCGCGGGCGAGGCCTTCCTTGGCCAGTGCAGGCGCTATGAAGTGGACTGGAACCAGA 300   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   201 AGCCCTGCGGAGGAGCTGAACTATACAGTGCCAGGCCTGGGGCCCGCGGGCGAGGCCTTCCTTGGCCAGTGCAGGCGCTATGAAGTGGACTGGAACCAGA 300   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   301 GCGCCCTCAGCTGTGTAGACCCCCTGGCTAGCCTGGCCACCAACAGGAGCCACCTGCCGCTGGGTCCCTGCCAGGATGGCTGGGTGTATGACACGCCCGG 400   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   301 GCGCCCTCAGCTGTGTAGACCCCCTGGCTAGCCTGGCCACCAACAGGAGCCACCTGCCGCTGGGTCCCTGCCAGGATGGCTGGGTGTATGACACGCCCGG 400   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   401 CTCTTCCATCGTCACTGAGTTCAACCTGGTGTGTGCTGACTCCTGGAAGCTGGACCTCTTTCAGTCCTGTTTGAATGCGGGCTTCTTCTTTGGCTCTCTC 500   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   401 CTCTTCCATCGTCACTGAGTTCAACCTGGTGTGTGCTGACTCCTGGAAGCTGGACCTCTTTCAGTCCTGTTTGAATGCGGGCTTCTTCTTTGGCTCTCTC 500   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   501 GGTGTTGGCTACTTTGCAGACAGGTTTGGCCGTAAGCTGTGTCTCCTGGGAACTGTGCTGGTCAACGCGGTGTCGGGCGTGCTCATGGCCTTCTCGCCCA 600   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   501 GGTGTTGGCTACTTTGCAGACAGGTTTGGCCGTAAGCTGTGTCTCCTGGGAACTGTGCTGGTCAACGCGGTGTCGGGCGTGCTCATGGCCTTCTCGCCCA 600   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   601 ACTACATGTCCATGCTGCTCTTCCGCCTGCTGCAGGGCCTGGTCAGCAAGGGCAACTGGATGGCTGGCTACACCCTAATCACAGAATTTGTTGGCTCGGG 700   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   601 ACTACATGTCCATGCTGCTCTTCCGCCTGCTGCAGGGCCTGGTCAGCAAGGGCAACTGGATGGCTGGCTACACCCTAATCACAGAATTTGTTGGCTCGGG 700   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   701 CTCCAGAAGAACGGTGGCGATCATGTACCAGATGGCCTTCACGGTGGGGCTGGTGGCGCTTACCGGGCTGGCCTACGCCCTGCCTCACTGGCGCTGGCTG 800   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   701 CTCCAGAAGAACGGTGGCGATCATGTACCAGATGGCCTTCACGGTGGGGCTGGTGGCGCTTACCGGGCTGGCCTACGCCCTGCCTCACTGGCGCTGGCTG 800   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *         *         *         *         *
   801 CAGCTGGCAGTCTCCCTGCCCACCTTCCTCTTCCTGCTCTACTACTGGTGTGTGCCGGAGTCCCCTCGGTGGCTGTTATCACAAAAAAGAAACACTGAAG 900   
       ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   801 CAGCTGGCAGTCTCCCTGCCCACCTTCCTCTTCCTGCTCTACTACTGGTGTGTGCCGGAGTCCCCTCGGTGGCTGTTATCACAAAAAAGAAACACTGAAG 900   
                *         *         *         *         *         *         *         *         *         *
                *         *         *         *         *         *
   901 CAATAAAGATAATGGACCACATCGCTCAAAAGAATGGGAAGTTGCCTCCTGCTGATTTAAAGATGCTTT 969   
       |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||       
   901 CAATAAAGATAATGGACCACATCGCTCAAAAGAATGGGAAGTTGCCTCCTGCTGATTTAAAGATGCTTT 969   























Figure 3-19 Restriction enzyme digestion of hOCT1. Lane 1: 1 kb DNA ladder, lane 2: uncut hOCT1 cDNA, 
lane 3: hOCT1 linearised by NotI, lane 4: hOCT1 digested by HindIII and EcoRI, lane 5: 1 kb DNA ladder. 
The digestion was repeated each time of cDNA preparation. 
 
3.4.7.4 cRNA Verification by Nano Chip 
The size and integrity of the synthesized hOCT1 cRNA were verified by Agilent RNA 6000 Nano 
Kit with 2100 Bioanalyzer. As shown in Figure 3-20, the size of hOCT1 RNA band on the RNA 
gel was at around 1.7 kb, corresponding to the expected size of the hOCT1 inserted clone (1.75 
kb). The pTRI-Xef, a control RNA provided in the Invitrogen MEGAscript® T7 Kit, appeared at the 
expected transcript size of 1.89 kb on the gel.  
 
  






















































































Figure 3-20 RNA Nano chip electrophoresis of hOCT1 cRNA. (A) Image of the RNA chip. Band 1: RNA 
ladder, band 2: pTRI-Xef control RNA, band 3: hOCT1 RNA; (B) Electropherogram of pTRI-Xef control 
RNA; (C) Electropherogram of hOCT1 cRNA.  
                        1      2        3 
 








3.4.7.5 Uptake of [3H]acetylcholine in oocytes expressing hOCT1 
The function of the hOCT1 transporter was verified using the endogenous substrate, 
acetylcholine. As shown in Figure 3-21, there were significant increases (P<0.05) of 
[3H]acetylcholine uptake in hOCT1 RNA injected oocytes compared to the water-injected oocytes 
(control). The uptake of [3H]acetylcholine in oocytes expressing hOCT1 was 80.7% and 87.1% 
higher than the water-injected oocytes at the 30-min and 60-min time points, respectively.  
 
No significant differences were observed between the non-injected oocytes and water-injected 
oocytes at all the time points tested (1 min, 30 min and 60 min). [14C]sucrose was co-administered 
with [3H]acetylcholine and its uptake was an indicator of passive transport and membrane integrity 
level for the study. No significant differences among the non-injected, water-injected and hOCT1 






Figure 3-21 [3H]Acetylcholine (7.6 µM) corrected by [14C]sucrose and [14C]sucrose (0.9 µM) uptake in non-
injected oocytes, water-injected oocytes and hOCT1 RNA injected oocytes. Data were expressed as the 
mean ± standard errors of 30-40 oocytes from 4 different batches/ independent experiments. Results were 














































































3.4.8 Uptake of [3H]pentamidine in oocytes expressing hOCT1 
Uptake of [3H]pentamidine (31 nM) in oocytes expressing hOCT1 was significantly higher than 
water-injected oocytes (control) at 30 min (P<0.05), 60 min (P<0.05) and 120 min (P<0.01) time 
points (Figure 3-22). [14C]Sucrose uptake between the control group and hOCT1 expressed group 
was not significantly different until the 120 min time point (P<0.05). Based on the results, the 1h 
incubation time was selected for the following studies in order for the hOCT1 to transport 





Figure 3-22 [3H]Pentamidine (31 nM) uptake, and [14C]Sucrose (0.9 µM) uptake in water-injected oocytes 
and oocytes expressing hOCT1. Data represent mean ± standard errors of 23-24 oocytes from 3 different 
batches/ independent experiments. Statistical analysis was conducted by two-way ANOVA with GraphPad 
Prism 7.03 (P*<0.05, P**<0.01). 
 
When 8 µM of unlabelled pentamidine was mixed with 31 nM [3H]pentamidine, the difference of 
[3H]pentamidine uptake in oocytes expressing hOCT1 compared to the water-injected oocytes 
were not statistically significant until the 120-min time point (Figure 3-23). However, the variations 
of [14C]sucrose uptake indicated that the membrane integrity of oocytes might have been 
compromised at the 120-min time point (Figure 3-23). Compared to the results with 
[3H]pentamidine alone (Figure 3-23), the uptake of [3H]pentamidine with unlabelled pentamidine 
in hOCT1 expressed oocytes was less, which may be caused by partially self-saturation of 
pentamidine to the hOCT1 transporter in oocytes.  












































































Figure 3-23 Uptake of [3H]Pentamidine (31 nM [3H]pentamidine + 8 µM unlabelled pentamidine) corrected 
with sucrose, and [14C]Sucrose (0.9 µM) in water-injected oocytes and oocytes expressing hOCT1. Data 
represent mean ± standard errors of 6-8 oocytes from 1 batch of oocytes. Statistical analysis was 










































































































3.4.9 Kinetics of pentamidine uptake by hOCT1 in oocytes  
As shown in Figure 3-24, the Km of [3H]pentamidine uptake by hOCT1 in oocytes was 279.9±112.4 
µM and the Vmax was 93.1±18.3 mM (n=6-8 from one batch of oocytes). [3H]pentamidine (31 
nM) was incubated with different concentrations of unlabelled pentamidine (0, 2, 5,10, 20, 50, 
100, 250, 500 µM) for 1h. Data were fit into the non-linear Michaelis-Menten model using 
GraphPad7.  
 
Figure 3-24 Kinetics of pentamidine uptake in oocytes expressing hOCT1. The uptake of [3H]pentamidine 
in water-injected oocytes was subtracted from oocytes expressing hOCT1. The incubation time was 60 
min. Results were expressed as mean ± standard errors of 6-8 oocytes from 1 batch of oocytes.  
 
3.4.10 Uptake of [3H]pentamidine ion pairs by hOCT1  
To understand how ion-pairs affect [3H]pentamidine to be transported by hOCT1, the uptake 
[3H]pentamidine ion-pairs in oocytes expressing hOCT1 were performed. The concentration of 
pentamidine in the buffer was 8 µM (31nM [3H]pentamidine mixed with 8 µM unlabelled 
pentamidine) with different concentrations of counterions (8 µM and 160 µM) in MBM.  
 
Three sets of comparison were shown for each counterion: (a) Uptake of [3H]pentamidine ion-
pairs in water-injected oocytes, utilised as a control for oocytes expressing hOCT1. This set of 
results is also an indicator of passive permeability properties in simple cell membranes since no 
membrane transporters were involved. (b) Uptake of [3H]pentamidine ion-pairs in oocytes 
expressing hOCT1. This set of results showed the overall results from both passive diffusion and 
active transport with hOCT1 transporter. (c) Net uptake of [3H]pentamidine ion-pairs by hOCT1 in 
oocytes. The net uptake by hOCT1 was calculated by subtracting the uptake of [3H]pentamidine 





































with each counterion in water-injected oocytes from the values in oocytes expressing hOCT1. 
This was calculated so that the net uptake of [3H]pentamidine with counterions by hOCT1 only, 
without the influence of passive diffusion, could be revealed.  
 
3.4.10.1 Uptake of [3H]pentamidine-taurodeoxycholate ion pairs by hOCT1 in oocytes 
Increasing pentamidine-taurodeoxycholate ion-pairs did not affect the influx of [3H]pentamidine in 
either water-injected or oocytes expressing hOCT1 (Figure 3-25). The net uptake of 
[3H]pentamidine by hOCT1 (hOCT1 - water) in oocytes also did not change significantly by the 
different percentage of pentamidine-taurodeoxycholate ion-pairs. 
 
Figure 3-25 The uptake of [3H]pentamidine by hOCT1 transporter. The concentration of pentamidine was 8 
µM (31 nM [3H]pentamidine and 8 µM unlabelled pentamidine) and the concentration of taurodeoxycholate 
was 8 µM or 160 µM. The uptake of [3H]pentamidine in water-injected oocytes was subtracted from 
oocytes expressing hOCT1 in order to compare the net influence of hOCT1 transporter on pentamidine-
taurodeoxycholate ion-pairs. Results were expressed as mean ± SEM, n=24-26 oocytes from 3 different 
batches/ independent experiments. Data were analysed by one-way ANOVA with GraphPad7. The 
percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations (Chapter 2 
Section 2.4.7.1). The Log D was measured by shake flask method and HPLC analysis (Chapter 2 Section 
2.4.3). For ease of comparison, these values have been included in this figure. 
 
3.4.10.2 Uptake of [3H]pentamidine-octanoate ion pairs by hOCT1 in oocytes 
The pentamidine-octanoate ion-pairs did not significantly increase the uptake of [3H]pentamidine 
in both water-injected and oocytes expressing hOCT1 (Figure 3-26). The net effect of hOC1 on 
the uptake of [3H]pentamidine with octanoate was positive, but the values were very close. This 
indicated that the pentamidine-octanoate ion-pairs did not influence the [3H]pentamidine to be 




























































8µM [3H]Pentamidine (0% ion-pairs)
+ 8µM Taurodeoxycholate (8.4% ion-pairs)
+ 160µM Taurodeoxycholate (66.1% ion-pairs)
MW of pentamidine: 340.4 g/mol
MW of sodium taurodeoxycholate: 521.7 g/mol




Figure 3-26 The uptake of [3H]pentamidine by hOCT1 transporter. The concentration of pentamidine was 8 
µM (31 nM [3H]pentamidine and 8 µM unlabelled pentamidine) and the concentration of octanoate was 8 
µM or 160 µM. The uptake of [3H]pentamidine in water-injected oocytes was subtracted from oocytes 
expressing hOCT1 in order to compare the net influence of hOCT1 transporter on different percentages of 
pentamidine-octanoate ion-pairs. Results were expressed as mean ± SEM, n=21-26 oocytes from 3 
different batches/ independent experiments. Data were analysed by one-way ANOVA with GraphPad7. 
The percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations (Chapter 2 
Section 2.4.7.2). The Log D was measured by shake flask method and HPLC analysis (Chapter 2 Section 












































































8µM [3H]Pentamidine (0% ion-pairs)
+ 8µM Octanoate (1.0% ion-pairs)
+ 160µM Octanoate (16.7% ion-pairs)
MW of pentamidine: 340.4 g/mol
MW of Sodium octanoate: 166.19 g/mol
Log D, 7.4 (PEN-OCT, 1:20) = - 0.13
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3.4.10.3 Uptake of [3H]pentamidine-xinafoate ion pairs by hOCT1 in oocytes 
As shown in Figure 3-27, pentamidine-xinafoate ion-pairs increased the uptake of 
[3H]pentamidine in water-injected oocytes, although it was not statistically significant. The net 
uptake of [3H]pentamidine by hOCT1 in oocytes significantly decreased by 154.8%  with 38.5% 
pentamidine-xinafoate ion-pairs compared to 3% of pentamidine-xinafoate ion-pairs. 
 
Figure 3-27 The uptake of [3H]pentamidine by hOCT1 transporter. The concentration of pentamidine was 8 
μM (31 nM [3H]pentamidine and 8 μM unlabelled pentamidine) and the concentration of xinafoate was 8 
μM or 160 μM. The uptake of [3H]pentamidine in water-injected oocytes was subtracted from oocytes 
expressing hOCT1 in order to compare the net influence of hOCT1 transporter on different percentages of 
pentamidine-xinafoate ion-pairs. Results were expressed as mean ± SEM, n=21-26 oocytes from 3 
different batches/ independent experiments. Data were analysed by one-way ANOVA with GraphPad7. 
The percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations (Chapter 2 
Section 2.4.7.3). The Log D was measured by shake flask method and HPLC analysis (Chapter 2 Section 
2.4.3). For ease of comparison, these values have been included in this figure. 
 
3.4.10.4 Uptake of [14C]sucrose in oocytes expressing hOCT1 
The purpose of [14C]sucrose uptake assay in oocytes was to evaluate if hOCT1 would affect the 
membrane integrity of oocytes. The result showed that there were no significant differences of 
[14C]sucrose uptake between water-injected and oocytes expressing hOCT1 for each counterion. 
However, the water-injected oocytes had varied [14C]sucrose uptake for different concentrations 



























































8µM [3H]Pentamidine (0% ion-pairs)
+ 8µM Xinafoate (3.0% ion-pairs)
+ 160µM Xinafoate (38.5% ion-pairs)
MW of pentamidine: 340.4 g/mol
MW of Xinafoate: 188.18 g/mol




























































0.9µM [14C]Sucrose (0% ion-pairs)
+ 8µM Taurodeoxycholate (8.4% ion-pairs)




















































0.9µM [14C]Sucrose (0% ion-pairs)
+ 8µM Octanoate (1.0% ion-pairs)






Figure 3-28 The uptake of [14C]sucrose in water-injected and oocytes expressing hOCT1. The 
concentration of [14C]sucrose was 0.9 µM and concentrations of counterions were 8 µM or 160 µM. 
Results were expressed as mean ± SEM, n=21-26 oocytes from 3 different batches/ independent 




















































0.9µM [14C]Sucrose (0% ion-pairs)
+ 8µM Xinafoate (3.0% ion-pairs)
+ 160µM Xinafoate (38.5% ion-pairs)
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3.5 Discussion  
Human African Trypanosomiasis (HAT) is a neglected disease that affects some of the poorest 
areas in the world and investing in developing an effective treatment has been demotivated by 
the high expenses (Barrett, 2000; Barrett et al., 2007). The current drugs for treating HAT are 
either not effective for late-stage infection when parasites enter the cerebrospinal fluid and brain 
or cause severe side effects (Legros et al., 2002; Baker and Welburn, 2018). Pentamidine is used 
only in early-stage of gambiense HAT as it is highly ionised in physiological pH and does not 
cross the BBB well (Bardal et al., 2011). At the BBB, pentamidine is transported into the brain 
through hOCT1 and effluxed by P-gp (Sekhar et al., 2017). Improving the permeability of 
pentamidine across the BBB could be key to improving treatment effectiveness for last stage HAT. 
The ion-pairing method has been successful in improving the entry of ionised molecules into the 
lung, skin, nasal mucosa and intestinal mucosa (Hatanaka et al., 2000; Benaouda et al., 2018). 
In chapter 2 we demonstrated that selected counterions improve the lipophilicity of pentamidine 
as determined using octanol-saline shake flask and HPLC analysis. In this chapter, we explored 
the possible influence of counterions and ion pair formation on pentamidine transport via passive 
diffusion and OCT1 using both simple and complex BBB models.  
 
The MTT assay of counterions confirmed that taurodeoxycholate, octanoate, xinafoate, and 
quercetin of up to 200 µM in hCMEC/D3 cells during the 2 h incubation time did not affect cell 
viability. This was also assessed by the presence of [14C]sucrose in each of the accumulation 
assays. There was no effect of 8 or 160 µM counterion on [14C]sucrose uptake at time points of 
5, 20, 30 and 60 min, however, there seemed to be loss of membrane integrity at the later time 
point of 120 min with 9 nM and 160 µM xinafoate. Any increase observed by the presence of 
counterion with pentamidine at such timepoints was therefore ignored. 
 
The uptake of [3H]pentamidine in hCMEC/D3 cells was either unchanged or reduced with all the 
counterions, which was contrary to what we expected based on the physicochemical data in 
Chapter 2. Although pentamidine ion-pairs could improve the lipophilicity of pentamidine as 
measured by Log D, the complex did not improve the accumulation of [3H]pentamidine in 
hCMEC/D3 cells. This may be caused by their interactions with other membrane transporters 
such as hOCT1 and P-gp expressed in hCMEC/D3 cells, or inhibited permeation by the larger 
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size of pentamidine ion-pair complex. In order to verify these assumptions, we used the single 
transporter model xenopus oocytes which express hOCT1 and studied the interaction of 
pentamidine ion-pairs with hOCT1. 
 
As the hOCT1 vector had not been used in our lab, the hOCT1 expressed in oocytes model was 
established and then verified by a series of methods in order to confirm the identity and 
functionality of hOCT1 in oocytes. The uptake of [14C]D-glucose in oocytes expressing rSGLT 
was consistent with the results in the thesis of MSc student Reshma Suresh (Suresh, 2013). The 
DNA sequencing and gel electrophoresis of DNA digestions verified the identity of hOCT1 cDNA. 
The RNA chip confirmed the size of hOCT1 RNA. The uptake results of the endogenous hOCT1 
substrate, [3H]acetylcholine, in oocytes expressing hOCT1 were consistent to the published 
results by Lips (Lips et al., 2005),  This data confirmed the functionality of hOCT1 expressed in 
oocytes. In the [3H]pentamidine uptake assay, our data suggested that pentamidine is also a 
substrate of hOCT1, which is consistent to the studies CHO cells and in hCMEC/D3 cells (Xin 
Ming et al., 2009; Sekhar et al., 2017). In our experiments [14C]sucrose data was generated along 
with [3H]pentamidine data but was not used as a baseline value to calculate the Km of 
[3H]pentamidine uptake by hOCT1 in oocytes. Instead, [14C]sucrose was used as an internal 
control to measure the membrane integrity of oocytes throughout and between the experiment( 
The oocytes with extremely high accumulation of [14C]sucrose were excluded from the analyses). 
Further validation experiments could have been performed to improve the rigour and assurance 
of the functional expression of hOCT1 in oocytes. For example, OCT1 inhibitors and/or an OCT1 
mutated transporter could have been used.  
 
The Km of pentamidine by hOCT1 transporter in xenopus oocytes in this study was 279.9±112.4 
µM. This value is higher than 36.4 µM generated by Ming (et al. 2009) utilising transfected 
Chinese hamster ovary (CHO) cells. This discrepancy may be explained by non-identical 
expression levels of the transfected OCT1 as well as the different sizes of the xenopus oocytes 
and CHO cells.  
 
Importantly, as human OCT1 was expressed in xenopus oocytes, the glycosylation of proteins 
may have influenced its transport activity in oocytes.  Glycosylation affecting the transport activity 
of transporters has previously been observed as discussed below for the human erythrocyte anion 
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transporter (band 3) and the proton-coupled amino acid transporter 1 (PAT-1).   Glycosylation is 
a common post-translation modification in protein biosynthesis that affects the thermodynamic 
stabilization, folding, and kinetics of proteins (Shental-Bechor and Levy, 2008). Glycosylation is a 
complex process that involves the formation of the sugar-amino acid linkage of carbohydrate 
components of glycoproteins (Spiro, 2002). Glycosylation affects the membrane expression and 
transport activity of membrane transporters expressing in xenopus oocytes.  The human 
erythrocyte anion transporter (band 3) has a glycosylation site N-glycan at the amino residue. The 
glycosylated band 3 had more band 3 transported chloride into oocytes compared to the 
unglycosylated band 3. This suggested that glycosylation may play an important role in allowing 
the correct folding of protein in oocytes and thereby affecting its transport activity (Groves and 
Tanner, 1994). The proton-coupled amino acid transporter 1 (PAT1, SLC36A1) when expressed 
in xenopus oocytes is glycosylated at asparagine residues. A study has revealed that changes to 
the asparagine residues causes reduced transport and less expression on the plasma membrane 
(Dorn et al., 2009).  
 
The influx of [3H]pentamidine ion-pairs in water-injected oocytes indicated the passive diffusion in 
simple cell membranes as no membrane transporters were involved. Interestingly, the 
improvement of lipophilicity of pentamidine by counterions (taurodeoxycholate> octanoate> 
xinafoate) in octanol-shake flask method (Chapter 2) did not correlate with the influx of 
[3H]pentamidine with these counterions (xinafoate>octanoate>taurodeoxycholate) in water-
injected oocytes. To understand the differences, we compared lipophilicity from the shake-flask 
method and the uptake of [3H]pentamidine with each counterion in water-injected oocytes (Figure 
3-28 below). These comparisons indicate that counterions with larger molecular weight impede 
pentamidine to pass through cell membranes. One thing to be aware of is that the water-injected 
oocyte model is not ideal for studying passive diffusion properties, because injecting water into 
oocytes could damage the integrity of membranes. Thus, drugs could fall into oocytes through 
the hole on the membrane rather than by lipophilicity. 
 
Also, in the octanol-saline shake-flask methods (Chapter 2), the total pentamidine in the octanol 
phase was calculated by mass balance method and the total pentamidine in saline phase was 
quantified by HPLC. The increased log D meant there were more pentamidine in the octanol 
phase compared to the saline phase, with the introduction of counterions. It did not, however, 
163 
 
reflect the percentage of pentamidine in ion-pair complexes. In other words, more pentamidine 
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Figure 3-29 Comparisons of the distribution coefficient of pentamidine at pH 7.4 measured by octanol-
saline shake flask and HPLC methods (left) and uptake of [3H]pentamidine in water-injected oocytes (right) 
with counterions (taurodeoxycholate, octanoate, xinafoate). The percentage labels on the figures are 
percentage of pentamidine in ion-pairs predicted from the HYSS simulations (Chapter 2 Section 2.4.7). For 
the distribution coefficient of pentamidine, the pentamidine concentration was 20 µg/ml (33 µM) for ion-
pairing with taurodeoxycholate and octanoate, or 5 µg/ml (8 µM) for pairing with xinafoate. Results were 
expressed as mean ± standard deviation at each point (n=3, with 3 replicates each). Some of the error 
bars were too small to be seen in the figure. For the uptake of [3H]pentamidine in water-injected oocytes, 
the concentration of pentamidine was 8 µM (31 nM [3H]pentamidine and 8 µM unlabelled pentamidine) and 
the concentration of counterions was 8 µM or 160 µM. Results were expressed as mean ± SEM, n=21-26 
oocytes from 3 different batches/ independent experiments. Data were analysed by one-way ANOVA with 
GraphPad7.  
 
The net influence of hOCT1 on the uptake of [3H]pentamidine was significantly lower for 
pentamidine-xinafoate ion pairs in oocytes, which suggested that pentamidine-xinafoate ion-pairs 
interacted with hOCT1 and this new formation may have impeded the uptake of [3H]pentamidine. 
This may be related to the change of binding site of pentamidine with hOCT1 when forming 
pentamidine-xinafoate ion-pairs. The molecular docking simulation indicated that the hydrogen in 
the amine group of pentamidine interacted with hOCT1. The amidine group on pentamidine is 
also the binding site of pentamidine with xinafoate, as suggested in the NMR results (chapter 2). 
Therefore, it is likely that xinafoate blocked the binding site of pentamidine to the hOCT1 influx 
transporter in oocytes expressing hOCT1. 
   
hOCT1 of the SLC22 transporter family is a polyspecific facilitated transporter that mediates the 
absorption and the clearance of xenobiotics in liver, kidney, brain (Couroussé and Gautron, 2015). 
Most of the hOCT1 substrates are cations, although some neutral and weak anionic compounds 
are also transported by hOCT1 (Koepsell, 2013). A previous study demonstrated that relatively 
elongated cationic molecules might have stronger binding to hOCT1 (Bednarczyk, 2003). This is 
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consistent with our finding that pentamidine ion-pair made the chemical structure “fatter” and 
therefore less likely to be transported by hOCT1. Also, as shown in the literature review in Chapter 
2, half of the 26 published OCT1 substrates have a molecular weight in 101-200 g/mol, and with 
the further beyond 200 g/mol molecular weight, the less likely the molecules to be substrates of 
hOCT1. Pentamidine has a molecular weight of 340 g/mol, while pairing with the selected 
counterions in this study would deviate the molecular weight of complexes from the ideal range 
for hOCT1 substrates. 
 
3.6 Conclusion  
The data generated in this chapter confirmed the role of hOCT1 in the uptake of pentamidine. 
For pentamidine ion-pairs, we proposed that the transport of pentamidine ion-pairs across the 
BBB was a dynamic process. When there were no counterions, pentamidine was taken across 
the BBB by hOCT1. When pentamidine was in the ion-pair complexes, more pentamidine could 
be taken across the BBB by passive diffusion due to improved lipophilicity, but only if the 
counterion had a small molecular weight. For example, xinafoate and octanoate. Interestingly, 
less pentamidine interacted with hOCT1 when pentamidine formed ion-pairs with xinafoate. This 
may be because the size of pentamidine-xinafoate ion-pairs is outside the normal molecular 
weight of hOCT1 substrates. It may also be because forming ion-pairs with xinafoate affects the 










Chapter 4  Interaction of pentamidine ion-pairs with P-gp 
4.1 Chapter overview 
In this chapter, we will examine the interaction of pentamidine ion-pairs with biological membranes 
using Madin-Darby Canine Kidney (MDCK) cells and xenopus oocytes expressing human P-gp. 
We will first establish and verify these cell models and then study the interaction of pentamidine 
ion-pairs with P-gp. 
 
4.2 Introduction  
The blood-brain barrier is known to express a high density of efflux transporters, as mentioned in 
Chapter 1, including the P-gp (ABCB1; MDR1), MRP1 (ABCC1), BCRP (ABCG2). These efflux 
transporters interact with large molecules (i.e. molecular weights over 600 Daltons).  Both P-gp 
and BCRP are expressed at the luminal side of the brain endothelial cells (Löscher and Potschka, 
2005b; Hoosain et al., 2015). MRP exists in multiple isoforms and different isoforms are located 
on different membranes. It has been widely recognised that the P-gp transporter is a key 
restrictive factor for the cerebral uptake of drugs in CNS (Jonker et al., 1999; Montanari and Ecker, 
2015). Therefore, understanding the role of P-gp in the transport of drugs at the blood-brain barrier 
(BBB) has been and remains of great importance in drug design and development (Hoosain et 
al., 2015).  
 
Pentamidine was found to be effluxed by P-gp at the BBB (L. Sanderson et al., 2009; Watson et 
al., 2012; Sekhar et al., 2017). Its inability to treat the late stage of Human African 
Trypanosomiasis is related to its efflux by P-gp and possibly MRP at the BBB (L. Sanderson et 
al., 2009). Although the physicochemical studies discussed in Chapter 2 and Chapter 3 revealed 
that the ion-pairing method significantly improved the lipophilicity of pentamidine and resulted in 
enhanced passive diffusion across biological membranes, the interaction of pentamidine ion-pairs 
with P-gp at the BBB is unknown.  
 
As summarized by Hoosain (et al., 2015), currently there are three major models explaining the 
mechanisms of drugs efflux by the P-gp transporter: the pore model, vacuum cleaner model, and 
the flippase model. (i) The pore model. It hypothesizes that drugs interact with P-gp on the interior 
membrane and then is effluxed out of cells through protein channels; (ii) The vacuum cleaner 
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model (figure 4-1). This model suggests that substrates are first recognised and bound with P-gp 
at the inner leaflet (one sheet of the lipid bilayer) of plasma membranes, then pumped out of the 
cells through protein channels. (iii) The flippase model (figure 4-1). It is the most accepted model. 
It hypothesizes that drugs are first flipped from the inner leaflet (inner sheet of the lipid bilayer) to 
the outer leaflet (outer sheet of the lipid bilayer) against concentration gradients before reaching 
the extracellular space through passive diffusion.  
 
 
Figure 4-1 The hypothesized structure of P-gp, and mechanisms of the vacuum cleaner and flippase 
model for P-gp efflux. The image modified from (Sharom, 2014). 
 
There are a few methods developed to either inhibit or bypass the P-gp transporter so that drugs 
absorption across the BBB can be improved, such as the use of a P-gp inhibitor, nanocarrier, or 
liposomes (Hoosain et al., 2015). Among these, the combination with a P-gp inhibitor is the most 
widely studied method and some inhibitors have been successfully used in the clinic. For 
example, the third generation of P-gp inhibitors including tariquidar, zosuquidar, laniquidar, and 
ONT-093 have been used in chemotherapy regimens (Thomas and Coley, 2003). However, there 
is little evidence that the inhibition can be achieved at non-toxic concentrations (Löscher and 
Potschka, 2005a). Thus, a safer and more effective drug delivery method is of great interest to 
overcome the issue of drug effluxed by P-gp. 
 
The ion-pairing method is a non-invasive and effective way to improve the absorption of drugs 
through multiple routes, including oral, parenteral, transdermal, and ocular (Suresh and Paul, 





of drugs, rather than interactions with membrane transporters (Neubert, 1989; Suresh and Paul, 
2011a). For example, Miller (et al., 2009) found that phenformin-HNAP ion-pairing method 
increased the permeability of phenformin by 4.9 folds in Caco-2 cells. He also found that the 
enhancement of phenformin membrane permeability in Caco-2 cells was in relation to the 
concentrations of the counterion HNAP and was not saturable.  More specifically, the log flux of 
phenformin was in a linear relationship with the log HNAP concentration. The Caco-2 cell is known 
to express the P-gp transporter (Brück et al., 2017) and phenformin is a substrate for P-gp (Choi 
and Song, 2016). So if the P-gp interfered with the ion-pair in addition to the passive diffusion, 
then the efflux of phenformin would most likely not have a linear relationship with the increased 
concentration of the counterion HNAP. Therefore, it seems that there was no relationship between 
P-gp and phenformin-HNAP ion-pairs.  
 
More recently, there was evidence that membrane transporters could have been involved in the 
transport of ion-pair drugs. Benaouda (et al., 2018) applied theophylline-spermine ion-pair on 
A549 epithelial cells. The permeability of theophylline was increased by forming theophylline-
spermine ion-pair at 37 ˚C. However, when the temperature was lower at 4 ˚C, the permeability 
of theophylline was suppressed. This hinted that active transport was involved in the process. In 
our pentamidine ion-pairs study (chapter 3), the accumulation of [3H]pentamidine ion-pairs in 
hCMEC/D3 cells was inhibited. This could be due to inhibition of influx transport and/or increased 
pentamidine efflux. 
 
By analysing 28 published P-gp substrates (Figure 4-2) and 38 published P-gp inhibitors (Figure 
4-3), we found that the majority of P-gp substrates and inhibitors are neutral or positively charged 
at pH 7.4 with a wide range of molecular weights from 200 to over 600 g/mol. It is not known 
whether modifying the charge of pentamidine through ion-pairing would have a direct impact on 










Figure 4-3 Charge and molecular weight of 38 published P-gp inhibitors (source: NCBI database, 1989-
2016). 
 
The hypothesis of this chapter is that ion-pairing of pentamidine with a counterion would affect 
the efflux of pentamidine by the P-gp transporter and therefore change delivery of pentamidine to 
the brain.   
 
The aim of this chapter is to understand the dynamics between pentamidine ion-pairs and P-gp. 
The pentamidine-xinafoate ion-pair was chosen as the model ion-pair to study the interaction of 
ion-pairs with the P-gp transporter, as this counterion was extensively researched in chapter 2 
and chapter 3 and we have generated a robust set of physicochemical and biological data for 
xinafoate. In addition, xinafoate is more lipophilic than the other two counterions 
taurodeoxycholate and octanoate, so it is more likely to form ion-pairs with pentamidine that could 
improve the passive diffusion of pentamidine across membranes and result in a more efficacious 
drug formulation.  
 
The objectives are as follows:  







































• To determine the specific interactions of pentamidine with P-gp using in silico molecular 
docking and compare the results with known P-gp substrates (e.g. dexamethasone) 
• To confirm suitability of the MDCK and MDCK-hMDR1 cell lines for exploring 
pentamidine ion pairs interaction with human MDR1 by determining the toxicity of 
pentamidine-taurodeoxycholate, pentamidine-octanoate, pentamidine-quercetin, and 
pentamidine-xinafoate in these cells using the MTT assay 
• To examine the impact of counterions on the interaction of pentamidine with P-gp using 
Madin-Darby Canine Kidney (MDCK-WT) and MDCK-hMDR1  
• To establish a P-gp single transporter expressing model utilising xenopus oocytes 
• To confirm the identity and functional expression of P-gp in xenopus oocytes through 
DNA sequencing, gel electrophoresis of DNA and RNA, influx (accumulation) and efflux 
transport of P-gp substrates [3H]dexamethasone and [3H]corticosterone 
• To determine the interaction of [3H]pentamidine-xinafoate ion-pair with P-gp by 
measuring the efflux of [3H]pentamidine extruded from xenopus oocytes expressing P-
gp 
 
4.3 Materials and Methods 
4.3.1 Materials  
Ampicillin sodium salt was purchased from Calbiochem, gentamicin sulphate from Apollo 
Scientific, HiSpeed Plamid Midi Kit was purchased from Qiagen (Manchester, UK), mMESSAGE 
mMACHINE T7 Transcription Kit, 3M Sodium Acetate (pH 5.5), 100mm square petri dishes were 
purchased from Thermo Fisher Scientific (Paisley, UK), 100mM Sodium Pyruvate, tris base were 
purchased from Fisher Scientific (Leicestershire, UK), Collagenase Type IV was purchased from 
Gibco, UltraPure Agarose from Invitrogen Life Technologies, 0.5M EDTA solution was purchased 
from Severn Biotech (Worcestershire, UK), magnesium sulphate heptahydrate (>=99.5%), 
potassium chloride were bought from AnalaR, calcium chloride dihydrate (>=99.0%), sodium 
chloride (>=99.5%), sodium dodecyl sulfate (>=92.5%), quinine were purchased from Sigma-
Aldrich, sodium octanoate (>=99.0%), calcium nitrate tetrahydrate, quercetin (>=95.0%), HEPES 
(>=99.5%), sodium taurodeoxycholate hydrate (>=95.0%), LB Agar, boric acid (>=99.5%)  were 
from Sigma Life Science, 1-Hydroxy-2-naphthoic acid (>=97.0%) from Aldrich Chemistry. 
Ethidium Bromide Solution (10mg/ ml) was bought from Alfa Aesar, 3.5’’ tubes from Drummond 
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Scientific, Ultima Gold was purchased from PerkinElmer (Bucks, UK), 1kb DNA ladder, 6x loading 
dye, SalI and NcoI enzymes were purchased from Promega, hydrochloric acid and sodium 
hydroxide standard solution were purchased from Fluka Analytical.  
 
Radiolabelled compounds 
[3H]pentamidine (31.9 Ci/mmol, 31 µM) was custom radiolabelled from Moravek Biochemicals, 
[14C] D-glucose (250-360 mCi/mmol) was purchased from PerkinElmer (Bucks, UK), 
[3H]Dexamethasone (89 Ci/mmol, 11.2 µM) was purchased from GE Healthcare, UK and has a 
specific activity of 3.29 TBq/mmol, [3H]corticosterone (75.0 Ci/mmol, 13 µM) has a specific activity 
of 2.78 TBq/mmol and was purchased from GE Healthcare, UK. 
 
4.3.2 Cell Culture  
Two different types of cells: wild type MDCK (MDCK-WT) and human MDR1 highly expressing 
MDCK (MDCK-hMDR1) cells were utilised in the study, in order to examine the interaction of P-
gp (MDR1) with pentamidine ion-pair complexes. (Source of WT MDCK cells and the MDCK-
MDR1 cells were a gift from Dr David Begley received from GSK (Ware, UK)). This cell line was 
prepared by transfecting the MDCK (Madin-Darby Canine Kidney) cells with human P-gp (MDR1) 
transporter. The passages of cells for wild type MDCK and MDCK-hMDR1 were among P21-26 
and P35-42, respectively. Both cells lines were seeded onto 96-well plates less than 10 
generations after thawing from the liquid nitrogen, as required to maintain the function of cells 
(Kuteykin-Teplyakov et al., 2010; Wang et al., 2013).  
 
For cell culture, both cell lines were grown in T-75 flasks with high glucose Dulbecco's Modified 
Eagle Medium (DMEM) which consists of 4,500 mg/L-glucose, L-glutamine, sodium, pyruvate, 
and sodium bicarbonate with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% 
1x non-essential amino acids (Sigma Aldrich, UK). The cells were kept in a 37 °C incubator with 
5% CO2. The media were changed every 2 to 3 days. Both cell lines were passaged when they 
reached 80-90% confluency. The cells were seeded in a density of 20,000 cells/cm2. After 
splitting, the cells reached 80-90% confluency in 2-3 days. For cell accumulation assays, the cells 




4.3.3 Cytotoxicity Assay  
The viability of MDCK-WT and MDCK-MDR1 cells was measured by MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) to assess the cytotoxicity of taurodeoxycholate, octanoate, 
quercetin and xinafoate. Confluent MDCK-WT (P21-23) and MDCK-MDR1 cells (P35-37) were 
incubated with different concentrations (0, 50, 100 and 200 µM) of counterions in the accumulation 
buffer for 2 h at 37 ˚C. At the end of this incubation time, the buffer was aspirated, and the wells 
were refilled with pre-warmed MTT (1 mg/ml) in DMEM without phenol red and the plates placed 
in an incubator with 5% CO2 at 37 ˚C for 4 h. Following this, the MTT solutions were replaced with 
100 µl propan-2-ol. After 5 min, the viability of cells could be determined by measuring the 
absorbance of samples at 540 nm using a Labsystems Multiscan reader with the Ascent software. 
The absorbance was corrected by protein concentrations with BCA assay. Cells viability was 
compared to the control (i.e. cells in accumulation buffer) and results were expressed as 
percentage viability. 
 
4.3.4 Accumulation of [3H]pentamidine in wild type MDCK and MDCK-MDR1 cells 
The objective of the accumulation assay was to evaluate if the MDCK-WT and MDCK-MDR1 cells 
could be utilised to isolate the impact of P-gp transporter on the transport of pentamidine ion-
pairs. The accumulation assay of [3H]pentamidine (9 nM) in the presence or absence of unlabelled 
(8 μM) was performed on confluent MDCK-WT or MDCK-MDR1 cells in 96-well plates. The 
[14C]sucrose (0.9 μM) acted as a marker for non-specific binding, membrane integrity and 
measurement of extracellular space. The plates were shaken at 120 rpm over 2 h at 37 °C. The 
accumulation buffer was removed at the 5, 20, 30, 60 and 120-min time points, immediately 
followed with three times of washes with ice-cold PBS+ to terminate the transport. Then the cells 
were lysed in 200 μl 1% Triton x-100 and shaken at 120 rpm for 1 h. The 100 μl of the lysates 
were transferred to a scintillation vial with 4 ml of scintillation solution to count for radioactivity. 
The radioactivity was measured as disintegrations per min (dpm) by Packard Tri-Carb 2900TR 
liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK). The radioactivity of the lysates was 
corrected with protein concentrations measured by Bicinchoninic acid (BCA) and background 




4.3.5 Bicinchoninic acid (BCA) assay  
See section 3.3.5 for details. 
 
4.3.6 Expression of results  
The accumulated radioactivity was expressed as a volume of distribution (Vd) which was 
calculated by the ratio of dpm/mg protein to dpm/μl buffer. Results were expressed as the mean 
value of Vd from not less than three different passages of cells/ independent experiments. The 
calculation method can be found in chapter 3 Section 3.3.6. 
 
4.3.7 Molecular Docking of pentamidine onto P-gp 
Computer modelling was utilized to study the specific interactions of pentamidine, 
dexamethasone (positive control i.e. known P-gp substrate), sucrose (negative control i.e. non-
P-gp substrate) and mannitol (negative control i.e. non-P-gp substrate) with the P-gp transporter 
and was completed by Dr Khondaker Miraz Rahman from the medicinal chemistry group at King’s 
College London. Molecular docking was performed using CDOCKER (Discovery studio version 
4.0), a CHARMm based docking tool, where annealing molecular dynamics were simulated to 
each orientation. P-gp contains 2 active ATPase sites, and both binding sites were used for 
docking. Based on the CDOCKER energy, the ligand poses were sorted and then the most 




Figure 4-4 Molecular structure of human P-glycoprotein in the ATP bound, outward-facing conformation 
(Kim and Chen, 2018). 
 
4.3.8 Method to Express P-gp transporter in the lavies xenopus oocytes  
In order to express the P-gp transporter in xenopus oocytes, the cDNA of P-gp vector was 
amplified and verified through DNA sequencing and restriction enzyme digestion. Then the P-gp 
RNA was synthesised and verified by gel electrophoresis. Finally, the P-gp RNA was injected into 
oocytes and the functional expression of P-gp was confirmed by radiolabelled P-gp substrates. 
 
4.3.8.1 Plasmid and inserts  
Human ABCB1 (P-gp) cDNA plasmid (Accession: NM_000927) was purchased from Stratech 
(catalogue number: HG12030-G, Suffolk, UK) manufactured by Sino Biological Inc (Drake et al., 
2018). The P-gp cDNA was cloned into the pGEM-T vector with ampicillin resistance gene for 
selection. The size of the P-gp cDNA is 3843 base pairs.  
 
4.3.8.2 Preparation of agar plates 




4.3.8.3 Amplification of P-gp cDNA  
See section 3.3.10.3 for details. 
 
4.3.8.4 Sequencing of P-gp cDNA insert 
The following customised primers (oligonucleotides), as shown in Table 4-1, were purchased from 
Sigma-Aldrich Company Ltd (Dorset, UK) to sequence the full-length P-gp cDNA insert. The 
primers and the P-gp vector cDNA template were diluted to 10 µM and then posted to GENEWIZ 
(Essex, UK) for Sanger Sequencing.  
 








4.3.8.5 Restriction Enzyme Digestion of P-gp cDNA 
The P-gp cDNA plasmid was digested by enzymes to confirm the identity of the insert. P-gp cDNA 
was digested by SalI and NcoI enzymes at 37 ˚C for overnight. Then sizes of the fragments were 
checked with agarose gel electrophoresis. The agarose was dissolved in 75 ml of 1xTBE buffer 
at a final concentration of 1% (m/v). Ethidium Bromide (4 µl) was used to stain the DNA. 1 kb 
DNA ladder was loaded in parallel with the samples as a reference. 500 ng DNA samples in 
loading buffer were loaded in each well and run at 100 V for 1 h. Then results were visualized 
under UV and images were captured by GeneSnap. 
 
4.3.8.6 Plasmid linearization  
The P-gp plasmid was linearized with the restriction enzyme SalI at 37 ˚C overnight. The 
linearization process was terminated with 1/20th volume of 0.5 M EDTA, 1/10th volume of 3 M Na 
acetate and 2 volumes of ethanol. Then the sample was mixed well and chilled at -20 ˚C overnight 




4.3.8.7 Synthesis of P-gp RNA 
See section 3.3.10.7 for details. 
 
4.3.8.8 Poly-A-tailing P-gp RNA 
The Poly-A tailing Kit (Applied Biosystems) could add a poly-A tail (≥150 bases) to the RNA 
prepared with the Ambion® mMESSAGE mMACHINE® Kit. This capped and tailed RNA may 
increase mRNA stability and therefore could enhance translation following micro-injection 
experiments (Bernstein and Ross, 1989; Gallie, 1991). The procedures of preparing the poly-a 
tailed RNA start with a complete and DNase-treated mMESSAGE mMACHINE reaction (20 µl). 
At room temperature, the tailing reagents: nuclease-free water (36 µl), 5X E-PAP Buffer (20 µl), 
25 mM MnCl2 (10 µl), 10 mM ATP (10 µl) were added to the reaction. After the assembling, a 0.5 
μl of the mix solution was taken out as a control, prior to the addition of 4 μl of E-PAP. Then the 
reaction and the control were incubated at 37 ˚C for 1 h. 
 
4.3.8.9 Verification of RNA                          
The un-tailed P-gp RNA can be verified using Agilent RNA 6000 Nano Kit with 2100 Bioanalyzer, 
as described in Chapter 3 Section 3.3.9.10. The poly-a tailed P-gp RNA was verified on a 
denaturing agarose-formaldehyde gel, since the components in the Poly-A tailing Kit could disrupt 
the signal of the 2100 Bioanalyzer. To prepare for a denaturing agarose-formaldehyde gel, 1 g of 
agarose in 72 ml water was heated until dissolved, then cooled to 60°C. Then 10ml 10X MOPS 
(3-(N-morpholino) propanesulfonic acid) which is composed of 0.4 M MOPS at pH 7.0, 0.1 M 
sodium acetate, 0.01 M EDTA running buffer and 18 ml 37% formaldehyde were mixed with the 
agarose solution, before it was immediately poured to a tank with a comb to form wells. After the 
gel was solidified, the comb was carefully removed from the tank. The gel was covered by 1X 
MOPS running buffer. For samples, 0.5 µl of the RNA marker (Millennium Markers, P/N AM7150) 
and RNA samples were mixed with 4 µl gel loading dye with EDTA containing 50 µg/ml ethidium 
bromide, before heated at 75 °C for 10 min. The samples were loaded into the wells of the gel, 
and then run at 5 volts/cm for 1 h. Then bands of samples were examined under UV light.  
 
4.3.8.10 Preparation of xenopus oocytes expressing P-gp   
The details of preparing for xenopus oocytes can be found in chapter 3 section 3.3.9.11. Briefly, 
stage V and VI oocytes were selected for micro-injection. Each oocyte was injected with 50nl 
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RNA-free water or P-gp cRNA, then placed in MBM with 1 mM sodium pyruvate. The injected 
oocytes were stored at 19-20 ˚C for 3 days before the uptake assay. The MBM was changed 
every day, and broken oocytes were discarded.  
 
4.3.8.11 Verification of P-gp functional expression in oocytes by [3H]dexamethasone and 
[3H]corticosterone  
The functionality of P-gp in oocytes was verified by measuring the influx and efflux transport of 
two P-gp substrates [3H]dexamethasone (Régina et al., 1999) and [3H]corticosterone (Wolf and 
Horwitz, 1992a). The use of P-gp substrates to demonstrate transporter functionality shows 
considerable variation dependent upon binding affinity, membrane partitioning considerations. It 
is important to note that some molecules are inhibitors of P-gp transport and not substrates. We 
utilised two types of experimental design for [3H]dexamethasone and [3H]corticosterone: Influx 
(uptake/accumulation) and efflux intraoocyte injection) assay. For influx (accumulation) assay, 
water-injected oocytes or oocytes expressing P-gp were incubated in MBM with radiolabelled 
drug for up to 1 h, after that the oocytes were washed and the intra-oocyte DPM of radiolabelled 
drug was measured. For efflux assay, the radiolabelled drug was injected into each oocyte at the 
beginning of the experiment, then the amount of radiolabelled drug that went out of the oocyte 
was measured. Note both the influx and efflux assay here are the overall effect by passive 
diffusion and interaction with P-gp.  
 
For influx assay, 8-10 of water-injected oocytes or oocytes expressing P-gp were placed in vials 
with MBM. The MBM was aspirated just before 9 nM [3H]dexamethasone or 13 nM 
[3H]corticosterone in 500 µl of MBM was filled in the vials. Each group of oocytes was incubated 
with the transport buffer for 1 h and then the transport was stopped with three times of washes 
with ice-cold MBM. Each of the oocytes was lysed in 500 µl 10% SDS. Then 4 ml of scintillation 
fluid was added to the each of the oocyte lysates and the DPM was counted on a Packard Tri-
Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, UK). Results were 
expressed as the mean uptake ± standard errors of [3H]dexamethasone or [3H]corticosterone in 
each oocyte (fmol/oocyte). For the calculation method, see 4.2.10. 
 
For efflux assay, oocytes were injected with 30 µg P-gp RNA in 50 nl water or 50 nl RNA-free 
water and then incubated in MBM with pyruvate for 3 days. The average intra-volume of each 
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xenopus oocyte was assumed at 500 nl for the ease of calculation. On the day of efflux assay, 
water-injected oocytes and oocytes expressing P-gp were injected with [3H]dexamethasone or 
[3H]corticosterone in MBM with 1 mM ATP to give final intra-oocyte concentrations of 4 nM for 
[3H]dexamethasone and 25 nM for [3H]corticosterone. After injection, each oocyte was placed in 
a well of a 96-well plate with 100 µl MBM. At the 15, 60, and 120-min time points, the efflux buffer 
was carefully drawn by a fine tip without breaking the oocytes. The efflux buffer from each oocyte 
was placed in scintillation vials. Then 4ml of scintillation solution was added and the DPM was 
counted by Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, 
UK). Results were expressed as the mean efflux ± standard errors of [3H]dexamethasone or 
[3H]corticosterone from each oocyte (pmol or fmol/oocyte). For calculation method, see 4.3.10. 
 
4.3.9 Efflux of [3H]pentamidine and [3H]pentamidine-xinafoate ion-pairs in oocytes 
expressing P-gp  
Oocytes were injected with 30 µg P-gp or 50 nl RNA-free water, and then incubated in MBM with 
pyruvate for 3 days. The average intra-volume of each xenopus oocyte was assumed at 500 nl 
for the ease of calculation. For the efflux of [3H]pentamidine, on the day of efflux assay, water-
injected oocytes and oocytes expressing P-gp were injected with [3H]pentamidine to give final 
intra-oocyte concentrations of 31 nM for [3H]pentamidine. For the efflux of [3H]pentamidine-
xinafoate ion-pairs, the final intra-oocyte concentration of [3H]pentamidine was 8 µM (31 nM 
radiolabeled and 8 µM unlabeled pentamidine), while the final intra-oocyte concentration of 
xinafoate was 8 µM and 160 µM (pentamidine: xinafoate = 1:1 and 1:20). After injection, each 
oocyte was placed in a well of a 96-well plate with 100 µl MBM. At the 60-min time point, the efflux 
buffer was carefully drawn by a fine tip without breaking the oocytes. The efflux buffer from each 
oocyte was placed in scintillation vials. Then 4ml of scintillation solution was added and the DPM 
was counted by Packard Tri-Carb 2900TR liquid scintillation counter (Perkin-Elmer, Beaconsfield, 
UK). Results were expressed as the mean efflux ± standard errors of [3H]pentamidine from 3-4 







4.3.10 Calculation methods for influx and efflux assay 
Step 1: The specific activity of 10 µl uptake or efflux media was calculated. 
For example, 10 µl of 10 mM drug has 100 nMoles/10 µl, 
10 mM= 10, 000 µM/l=10,000 µM/1000 ml= 10 µM/ml = 10,000 nM/1000 µl = 100 nMoles/10 µl  
 
Step 2: Count 10 µl of uptake media - X dpm/ 100 nMoles 
e.g. 1000 DPM/100 nMoles = 100 pmols/DPM 
 
 
Step 3: Y DPMs is converted to pmols in each oocyte. 
The counted DPM in each oocyte was converted to pmols using the conversion ratio in step 2. 
 
 
4.3.11 Statistical analysis  
Results were expressed as mean ± standard errors (S.E.M). The data for uptake assay were 
analysed by one-way ANOVA or two-way ANOVA with GraphPad 7. Significant differences were 




4.4 Results  
4.4.1 Molecular docking of pentamidine onto P-gp  
For the ATPase binding site with the lowest energy, all interactions between pentamidine and P-
gp are hydrogen bonds (figure 4-5): the ether group on pentamidine interacts with ARG262 on P-
gp; the benzene ring on pentamidine attracts to the GLN535 and ALA529 on P-gp; the hydrogen 
on the amidine of pentamidine attaches to the GLU1119 on P-gp. 
 
 
Figure 4-5 Molecular docking of pentamidine onto P-gp transporter. The image was provided by Dr 




For dexamethasone (a P-gp substrate), its oxo group forms a hydrogen bond with GLN724 on P-
gp. Its hydroxy groups also interact MET985, GLU874, GLN346 on P-gp through a hydrogen 
bond. The methyl group on dexamethasone interacts with MET875 on P-gp through hydrophobic 
attraction (figure 4-6).   
 
 
Figure 4-6 Molecular docking of dexamethasone onto P-gp transporter. The image was provided by Dr 
Khondaker Miraz Rahman’s group from Medicinal Chemistry at King’s College London. 
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For mannitol, its hydroxyl functional groups interact with ARG262, TYR1044, and ALA529 on P-gp with 




Figure 4-7 Molecular docking of mannitol into P-gp transporter binding site 1. The image was provided by 





Similar to mannitol, the hydroxyl functional groups of sucrose interact with ARG404, ARG905, 




Figure 4-8 Molecular docking of sucrose into P-gp transporter binding site 1. The image was provided by 





As shown in table 4-2, the best pose of pentamidine and dexamethasone interacts with the 
binding site of P-gp with a free energy of -31.01 kcal/mol and -31.83 kcal/mol, respectively. The 
negative controls mannitol and sucrose have a free energy of -12.64 kcal/mol and +2.95 kcal/mol.   
 
Table 4-2 CDOCKER energy of pentamidine, dexamethasone, mannitol and sucrose with P-gp  
Ligand Pose CDOCKER energy Average energy for 5 poses 
Pentamidine 




Pose 2 -30.8081 
Pose 3 -30.6151 
Pose 4 -30.396 
Pose 5 -30.2606 
Dexamethasone (P-gp substrate) 
Pose 1 -32.9386 
-31.8297 kcal/mol 
 
Pose 2 -32.748 
Pose 3 -32.5801 
Pose 4 -32.5596 
Pose 5 -32.2865 
Pose 6 -31.7978 
Pose 7 -31.4883 
Pose 8 -31.4354 
Pose 9 -30.9809 
Pose 10 -29.482 
Mannitol (non-substrate) 




Pose 2 -13.6015 
Pose 3 -13.0657 
Pose 4 -10.2716 
Pose 5 -9.15363 
Sucrose (non-substrate) 
Pose 1 +0.40632 
+2.95041 kcal/mol 
Pose 2 +1.80311 
Pose 3 +2.29536 
Pose 4 +4.48916 




4.4.2 Cytotoxicity of taurodeoxycholate, octanoate, quercetin, and xinafoate on MDCK-
WT and MDCK-hMDR1 cells 
The cytotoxicity of the four counterions (taurodeoxycholate, octanoate, quercetin, and xinafoate) 
on MDCK-WT and MDCK-hMDR1 cells were examined by MTT assay. For both MDCK-WT and 
MDCK-hMDR1 cells, as displayed in figure 4-9 and 4-10, the viability of the cells did not change 
significantly with 50-200 µM of the four counterions at the 2-h incubation time point. The viability 
of cells in MBM (the buffer used to dissolve counterions) did not change compared to the 
untreated cells in cells media. As expected, the positive control (1%triton) significantly decreased 





Figure 4-9 Cytotoxicity of taurodeoxycholate, octanoate, quercetin, and xinafoate (50-200 µM) in MDCK-
WT cells at 2 h incubation time point. Results were corrected by protein from BCA assay and expressed as 
percentage viability of cells ± SEM (n=3 passages from P21-23/ independent experiments with 6 replicates 
per plate) compared to the viability of cells in accumulation buffer. Data were analysed by one-way 






























































































































































































































































Figure 4-10 Cytotoxicity of taurodeoxycholate, octanoate, quercetin, and xinafoate (50-200 µM) in MDCK-
hMDR1 cells at 2 h incubation time point. Results were corrected by protein from BCA assay and 
expressed as percentage viability of cells ± SEM (n=3 passages from P35-37/ independent experiments 
with 6 replicates per plate) compared to the viability of cells in accumulation buffer. Data were analysed by 




























































































































































































































































4.4.3 Accumulation of [3H]pentamidine in MDCK-WT and MDCK-hMDR1 cells 
4.4.3.1 Accumulation in MDCK-WT cells 
The [14C]sucrose (0.9 μM) acted as a marker for non-specific binding, membrane integrity and 
measurement of extracellular space. As shown in figure 4-11, no significant difference was seen 
in the accumulation of [14C]sucrose with 8 µM pentamidine. This indicated that the cells membrane 
integrity was intact within the 120-min time point.  
 
The accumulation of [3H]pentamidine corrected by sucrose dropped by 90.2% at the 5-min 
(P<0.01), 78.7% at the 20-min (P<0.05), 80.5% at the 30-min (P<0.05), 76.2% at the 60-min 
(P<0.05), and 36.4% at the 120-min time points in the presence of 8 μM unlabelled pentamidine. 








Figure 4-11 Accumulation of 0.9 µM [14C]sucrose and 9 nM [3H]pentamidine corrected by sucrose in 
MDCK-WT cells. The data were corrected by protein concentrations. Results were expressed as mean ± 
SEM from 3 passages of cells/ independent experiments (n=P24, 25, 26) with 6 replicates per time point. 
Data were analysed by two-way ANOVA with Sidak’s multiple comparison test by GraphPad Prism 7. 
 
4.4.3.2 Accumulation in MDCK-hMDR1 cells 
The accumulation of [14C]sucrose was significantly higher by 157.3% (P<0.05) with 8 μM 
pentamidine at the 120-min time point (figure 4-12). This indicated that the cell membrane integrity 
was damaged. Therefore, the data for [3H]pentamidine accumulation in MDCK-MDR1 cells at the 
120-min time point was considered invalid and excluded for analyses.  
 
For [3H]pentamidine, its accumulation with 8 µM unlabelled pentamidine was much lower but did 
not achieve statistical significance. The accumulation of [3H]pentamidine corrected by sucrose 










































































decreased by 88.3% at the 5-min, 80.7% at the 20-min, 72.1% at the 30-min, 64.4% at the 60-







Figure 4-12 Accumulation of 0.9 µM [14C]sucrose and 9 nM [3H]pentamidine corrected by sucrose in 
MDCK-hMDR1 cells. The data were corrected by protein concentrations. Results were expressed as mean 
± SEM from 3 passages of cells/ independent experiments (n=39, 41,42 for MDCK-hMDR1) with 6 
replicates per time point. Data were analysed by two-way ANOVA with Sidak’s multiple comparison test by 
GraphPad Prism 7. 
 
4.4.3.3 Comparison of [3H]pentamidine accumulation in MDCK-WT and MDCK-hMDR1 
cells 
As shown in figure 4-13, the efflux of [3H]pentamidine by the highly expressed hMDR1 transporter 
could not be detected, as there was no significant difference in the accumulation of 
[3H]pentamidine in between the MDCK-WT and MDCK-hMDR1 cells. This is likely to be caused 








































































by the presence of multiple influx and efflux transporters in the MDCK-WT and MDCK-hMDR1 
cells. Therefore, the MDCK-WT and MDCK-hMDR1 cells are not suitable to study the specific 
interaction of pentamidine ion-pairs with the P-gp transporter.  
 
Figure 4-13 Accumulation of 9nM [3H]pentamidine corrected by sucrose in MDCK-WT and MDCK-hMDR1 
cells. The data were corrected by protein concentrations. Results were expressed as mean ± SEM from 3 
passages of cells/ independent experiments (n=P24, 25, 26 for MDCK - WT and n=39, 41, 42 for MDCK-
MDR1) with 6 replicates per time point. Data were analysed by two-way ANOVA with Sidak’s multiple 
comparison test by GraphPad Prism 7. 
 
4.4.4 Method verification  
The P-gp expressing lavies xenopus oocyte model was verified in three ways: (a) confirming the 
sequence and size of P-gp cDNA; (b) verifying the size and integrity P-gp RNA; (c) testing the 
functional expression of P-gp transporter in oocytes with [3H]dexamethasone and 
[3H]corticosterone. 
 
4.4.4.1 P-gp vector sequence and vector map 
The amino acid sequences of the P-gp vector were aligned to the published P-gp sequences 
(NM_000927) from the National Centre for biotechnology Information (NCBI) database. During 
the alignment, a mutation was revealed at the point of 3435 (T>C), as highlighted in red colour in 
figure 4-14. This mutation does not change the resulting amino acid, as noted in the product 
information (catalogue number: HG12030-G) of Sino Biological Inc. The translated amino acids 
sequence was also compared to the U.S. NCBI database and confirmed that they were identical 
to the amino acids sequence of multidrug resistance protein 1 (MDR1) variance 2 (Sequence ID: 
NP_000918.2). There is only one isoform of human P-gp: ABCB1. In mice, there are two isoforms: 





































Abcb1a and Abcb1b and their proteins are 87.3% and 80.5% to the human ABCB1 (Kalabis et 
al., 2005; Krohn et al., 2018). Their sequences can be found in the NCBI database. After 












Figure 4-14 Comparison of the P-gp vector sequences to P-gp sequence (NM_000927) from the NCBI 
database. A (adenine), T (thymine), C (cytosine), G (guanine) are the four bases of DNA. The upper rows 
of the alignment are the sequences from NCBI database (NM_000927), and lower rows are the P-gp 
vector cDNA sequences. The mismatch (mutation) is highlighted in red colour.  
 
 
As mentioned earlier, sequencing P-gp cDNA can verify the identity of P-gp vector. It can also be 
used to select restriction enzymes for DNA linearization. As shown in figure 4-15, the P-gp 
(ABCBA1) gene was inserted in the location from 52-3894 in the vector. The restriction enzyme 




Figure 4-15 P-gp (ABCB1) vector map. The 6843 bp shows the location of ABCBA1 gene in T7 sense 
orientation, the ampicillin selection gene, and the NcoI and SalI restriction sites. The vector map was 





















4.4.4.2 Restriction enzyme digestion of P-gp cDNA 
As shown in Figure 4-16, the identity of the P-gp cDNA was confirmed by gel electrophoresis after 
digested with SalI and NcoI restriction enzymes. The number of fragments and size of bands 
shown on the gel are compared to the P-gp cDNA vector map (figure 4-13) and verified. The band 
for linearization of P-gp cDNA by SalI appeared at the expected size (6843 bp). The bands for 
cDNA double digestion by SalI and NcoI appeared at the expected locations (2962, 1467, 1307, 




Figure 4-16 Restriction enzyme digestion of P-gp. Band 1: 1 kb DNA ladder, band 2: uncut P-gp cDNA, band 
3: P-gp linearised by SalI, band 4: P-gp digested by SalI and NcoI, band 5: 1 kb DNA ladder. The digestion 
was repeated each time before RNA sysnthesis.  
 
Prior to RNA synthesis, the concentration and purity of the linearized P-gp cDNA were measured. 
The figure 4-17 below was an exemplary result measured with Nanodrop. The concentration of 
the P-gp cDNA was 418 ng/µl, which was high enough for the following RNA synthesis which 
usually requires at least 200 ng/µl of pure cDNA. The 260/280 ratio shows the purity of DNA and 
value of ~1.8 is considered pure for DNA. The 260/230 ratio is a secondary measure of nucleic 
acid purity with an expected range of 2.0-2.2. The result of the P-gp cDNA nanodrop revealed 






















































lower than expected. This was usually caused by the residual ethanol that was used to wash 
cDNA. A slightly lower value of 260/230 ratio normally does not affect the success of following 




Figure 4-17 P-gp cDNA measured by Nanodrop.  
 
4.4.4.3 Verification of P-gp RNA 
The size and integrity of the synthesized P-gp RNA was confirmed by Agilent RNA 6000 Nano Kit 
with 2100 Bioanalyzer. As shown in figure 4-18, the size of P-gp RNA band on the RNA gel was 
at around 3.8 kb, which was the expected size of the P-gp inserted clone (3843 bp). The pTRI-
Xef, a control RNA provided in the Invitrogen MEGAscript® T7 Kit, appeared at the expected 









Figure 4-18 RNA Nanochip electrophoresis of P-gp RNA. The x-axis represents the size of RNA 
(nucleotide) and y-axis represents fluorescence intensity. (a) Image of the RNA chip. Band 1: RNA ladder, 
band 2: pTRI-Xef control RNA, band 3: P-gp RNA; (b) Electropherogram of pTRI-Xef control RNA, (c) 
Electropherogram of P-gp RNA.  
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4.4.4.4 Verification of poly-A tailed P-gp RNA on denaturing agarose-formaldehyde gel 
The poly-A tailing kit could add a tail to RNA samples, and the tailed RNA would have a trailing 
band on the denaturing agarose-formaldehyde gel. As shown in figure 4-19, the untailed P-gp 
RNA had an expected size (6843 bp) on the gel (band 2, figure 4-19). The tailed P-gp RNA (band 
3, figure 4-19) was trailing on the gel and started with a bigger size compared to the untailed P-
gp RNA. The pTRI-Xef control RNA (band 4, figure 4-19), provided in the Invitrogen MEGAscript® 
T7 Kit, appeared at the expected transcript size of 1.89 kb on the gel. The tailed pTRI-Xef RNA  
also had a trailing shape and started with a bigger size compared to the untailed pTRI-Xef RNA. 
The results on the denaturing agarose-formaldehyde gel proved that the poly-A tailing of P-gp 













Figure 4-19 Verification of poly-a tailed P-gp RNA on a denaturing agarose-formaldehyde gel. Band 1: 9 kb  
RNA ladder, 2: P-gp RNA, 3: poly-A tailed RNA, 4: TRI-Xef RNA, 5: poly-a tailed pTRI-Xef RNA, 6: 9 kb 
RNA ladder. 
 
4.4.4.5 Transport of [3H]dexamethasone in xenopus oocytes expressing P-gp  
The purpose of the influx (accumulation) and efflux of [3H]dexamethasone in oocytes expressing 
P-gp was to verify the functional expression of P-gp transporter. For the influx of 
[3H]dexamethasone, the water-injected oocytes and oocytes expressing P-gp were incubated in 
MBM with [3H]dexamethasone. There was no significant difference observed at the 1 h incubation 
time point between the water-injected oocytes and oocytes expressing P-gp (figure 4-20).  












































Figure 4-20 Accumulation of [3H]dexamethasone (9 nM) in water-injected and oocytes expressing P-gp 
after 1 h. Oocytes were incubated with [3H]dexamethasone (9 nM) buffer. Data were expressed as mean ± 
standard errors (n= 8-10, from one batch of oocytes/ experiment) and analysed using unpaired t-test with 
Prism GraphPad 7.  
 
Unlike the influx assay, for efflux assay the [3H]dexamethasone was injected into each oocyte 
and the efflux of [3H]dexamethasone was measured. As can be seen from figure 4-21, the oocytes 
injected with P-gp RNA and extra ATP significantly increased the efflux of [3H]dexamethasone 
compared to water-injected oocytes at the 120-min time point. The oocytes injected with poly-A 
tailed P-gp RNA and extra ATP also increased the efflux of [3H]dexamethasone, although it did 
not make much difference compared to the non-tailed P-gp RNA with ATP. Therefore, it was clear 













































Figure 4-21 Efflux of [3H]dexamethasone in oocytes expressing P-gp. Intra-oocytes buffer consisted of 4 
nM [3H]dexamethasone. Data were expressed as mean ± SEM (n= 4-6 from 1 batch of oocytes) and 
analysed by two-way ANOVA.  
 
4.4.4.6 Transport of [3H]corticosterone in xenopus oocytes expressing P-gp  
Corticosterone is a substrate for P-gp (Wolf and Horwitz, 1992b). The purpose of the influx assay 
of [3H]corticosterone in oocytes injected with RNA-free water (control), P-gp RNA, or Poly-A tailed 
P-gp RNA was to verify if P-gp was expressed in the correct direction. The results showed that 
no significant difference of [3H]corticosterone influx in oocytes was observed that were injected 
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Figure 4-22 Influx of 13nM [3H]corticosterone in oocytes injected with water, P-gp RNA and, and Poly-A 
tailed P-gp RNA. The accumulation buffer for the influx assay consisted of 13 nM [3H]corticosterone and 








































































The efflux of [3H]corticosterone in oocytes expressing P-gp with additional  ATP was significantly 
higher by 60.7% compared to the efflux in water-injected oocytes (figure 4-23).  
 
Figure 4-23 Efflux of [3H]corticosterone in oocytes expressing P-gp. Intra-oocytes buffer consisted of 25nM 
[3H]corticosterone. Incubation time was 1h. Data were expressed as mean ± SEM (n= 10 from 1 batch of 






















































4.4.5 Efflux of [3H]pentamidine in xenopus oocytes expressing P-gp  
As can be seen in figure 4-24, the efflux of [3H]pentamidine from oocytes expressing P-gp was 
not significantly different compared to the water-injected oocytes. Also, the presence of 8μM 
unlabelled pentamidine did not seem to suppress the efflux of [3H]pentamidine as the change was 
not statistically significant. 
 
Figure 4-24 Efflux of 31nM [3H]pentamidine in water-injected and P-gp expressed xenopus oocytes. Data 
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4.4.6 Efflux of [3H]pentamidine-xinafoate ion-pairs by P-gp in oocytes 
As shown in figure 4-25, the presence of 38.5% pentamidine-xinafoate ion-pairs significantly 
increased the efflux of [3H]pentamidine for both oocytes injected with water and oocytes 
expressing P-gp. Comparing the water-injected group and the oocytes expressing P-gp with extra 
ATP, the pattern for the efflux of [3H]pentamidine with 3% and 38.5% pentamidine-xinafoate ion-
pairs looks very similar and does not seem to differentiate when P-gp was in the system.  
 
Figure 4-25 Efflux of [3H]pentamidine in water-injected and P-gp expressed xenopus oocytes. Data were 
analysed by two-way ANOVA (n=4 batches / independent experiments with 6-8 oocytes/replicates per 
treatment). The percentage of [3H]pentamidine in ion-pair form was predicted from the HYSS simulations 
(Chapter Section 2.4.7.3). The Log D was measured by shake flask method and HPLC analysis (Chapter 2 
Section 2.4.3). For ease of comparison, these values have been included in this figure. 
 
4.5 Discussion 
The molecular docking simulated the potential binding sites of pentamidine with P-gp transporter 
and confirmed that pentamidine was a P-gp substrate. This corresponds to the results in previous 
in vivo experiments where the distribution of [3H]pentamidine was found to be 2-3 folds higher in 
the brain of P-glycoprotein-deficient (FVB-mdr1a/1b(-/-) type) mice compared to wild-type mice 
(Lisa Sanderson et al., 2009).  
 
The MDCK-hMDR1 cells can be used to study drug delivery as a BBB model. It has been found 
that there is a positive correlation between drugs permeability measured with transwell to be 
transported across the MDCK-hMDR1 cells and their ability to reach CNS (Wang et al., 2005; 
Hellinger et al., 2012), so the MDCK-hMDR1 cells were used to explore the permeability of 
pentamidine ion-pairs across the BBB. MDCK-WT cells do express endogenous P-gp. However, 
the highest expressing isoforms of P-gp in MDCK-WT and MDCK-hMDR1 are different. Tang, 









































8µM [3H]Pentamidine (0% ion-pairs)
+ 8µM Xinafoate (3.0% ion-pairs)
+ 160µM Xinafoate (38.5% ion-pairs)
*** ***
MW of pentamidine: 340.4 g/mol
MW of Xinafoate: 188.18 g/mol
Log D, 7.4 (PEN-XIN, 1:20) = - 0.37
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kDa isoform of human P-gp transporter, while the MDCK-WT cells had more of 170 kDa 
endogenous isoform of canine P-gp than the 150 kDa isoform. MDCK-WT expresses quite a high 
level of endogenous P-gp. Whilst MDCK-hMDR1 also expresses a high level of P-gp, it expresses 
less endogenous (canine) P-gp compared to MDCK-WT. As the human P-gp is expressed in 
MDCK cells, the amount of P-gp in MDCK might have reached the protein threshold and down-
regulated the endogenous P-gp in MDCK-MDR1. Also, the interspecies variance on the binding 
sites and binding affinities with substrates may have a mixed impact on the transport of 
substrates. As a result, the different expression of P-gp in the two cell lines may complicate the 
transport analysis of P-gp substrates in MDCK-WT and MDCK-hMDR1 and sometimes even 
provide misleading results (Kuteykin-Teplyakov et al., 2010).  
 
While the information regarding the exact passages of cells used was not provided by Tang, Horie 
and Borchardt (2002), it was stated that the MDCK-hMDR1 cells used in their study were within 
two months of thawing from liquid nitrogen, with lower passages of MDCK-hMDR1 cells 
expressing more 150 kDa isoform of P-gp. It is unknown that if the different expression of P-gp 
isoforms would affect the transport of P-gp substrates in the two cell lines.  
 
In our study, initially, we intended to isolate the impact of P-gp on the transport of pentamidine 
ion-pairs by leveraging the different levels of P-gp expression in MDCK-WT and MDCK-hMDR1 
cells. Therefore, the two cells lines were validated and the toxicity of different concentrations of 
counterions was tested. The MTT assay of counterions confirmed that taurodeoxycholate, 
octanoate, xinafoate, and quercetin of up to 200µM did not affect the viability of MDCK-WT and 
MDCK-MDR1 cells within 2h incubation time. Thus, the four counterions at concentrations up to 
200µM were safe for the two cell lines.  
 
In the accumulation assay in MDCK-WT and MDCK-hMDR1 cells, no difference of 
[3H]pentamidine accumulation corrected by [14C]sucrose was seen in the two cell lines. This 
suggests that there is no difference in membrane integrity/and or extracellular space between the 
two cell lines/monolayers.  The accumulation of [14C]sucrose did not show significant difference 
with 9nM [3H]pentamidine in both MDCK-WT and MDCK-hMDR1 cells during the 2h incubation, 
which indicated that changes in membrane integrity did not affect the [3H]pentamidine 
accumulation. Thus, we suspect that the efflux of [3H]pentamidine by P-gp could have been 
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masked by its interactions with other transporters in MDCK-WT and MDCK-hMDR1 cells. This 
speculation was supported by the results of 9nM [3H]pentamidine accumulation in the presence 
of 8 µM unlabelled pentamidine, where the accumulation of [3H]pentamidine corrected by 
[14C]sucrose decreased with 8 µM unlabelled pentamidine in both MDCK-WT and MDCK-hMDR1 
cells. This indicated that there influx transporters involved in the accumulation of [3H]pentamidine. 
Quan (et al., 2012) conducted a systematic study on the gene expression of MDCK cells on both 
plastic and transwell formats. A small number of genes encoding ABCs, SLCs, and CYPs were 
detected in MDCK cells, and their level of expression was much higher in the cells grown on 
transwell membranes than cell culture flasks. Among these, ABCB1 (MDR1) and SLC22A2 
(OCT2) were detected. It is possible that the accumulation format that we used in this study for 
MDCK-WT and MDCK-hMDR1 did not allow MDCK-hMDR1 cells to generate a high level of P-
gp transporter to be able to efflux more [3H]pentamidine than MDCK-WT cells. Although SLC22A1 
(OCT1) was not detected by Quan (et al., 2012), we intended to double-check that if there was 
SLC22A1 (OCT1) expressing in the MDCK-WT and MDCK-hMDR1 cells. As explained in Chapter 
3, OCT1 is an influx transporter that is known to interact with pentamidine (X. Ming et al., 2009; 
Sekhar et al., 2017). However, we could not confirm if OCT1 is expressed in MDCK-WT and 
MDCK-hMDR1 as we could not locate a suitable antibody which would be cross-reactive with 
canine proteins. Therefore, the influence of P-gp on the accumulation of [3H]pentamidine ion-pairs 
could, therefore, not be determined with MDCK-WT and MDCK-hMDR1 cells.  
 
In order to address our objective, we, therefore, established a P-gp single transporter expressing 
model in xenopus laevies oocytes. P-gp has been successfully expressed in xenopus laevies 
oocytes to study the efflux of [3H]vinblastine and [3H]digoxin (Castillo et al., 1990; Jutabha et al., 
2010). Similar to the process of establishing oocytes expressing hOCT1 in chapter 3, the P-gp 
expressing oocytes was also verified by various methods. The DNA sequencing and gel 
electrophoresis of DNA digestions verified the identity of P-gp cDNA. The RNA chip confirmed 
the size and integrity of P-gp RNA. The gel electrophoresis on the denaturing agarose-
formaldehyde gel proved that the poly-A tailed P-gp RNA was successfully prepared.  
 
In order to confirm the functional expression of P-gp in oocytes as well as to optimize the 
experimental methods for [3H]pentamidine, we utilised the P-gp substrates, [3H]dexamethasone 
and [3H]corticosterone (Wolf and Horwitz, 1992a; Régina et al., 1999; Mason, Pariante and 
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Thomas, 2008; Narang et al., 2008), in oocytes expressing the P-gp transporter.  The P-gp 
transporter is an ATP-dependent efflux transporter and is expected to transport its substrates out 
of the oocytes (Jutabha et al., 2010).  
 
Our experiments confirmed that the P-gp was inserted in the correct direction at the oocytes 
membrane because there were no difference in the influx of [3H]dexamethasone and 
[3H]corticosterone in oocytes expressing P-gp compared to the water-injected oocytes. The efflux 
assay of [3H]dexamethasone and [3H]corticosterone confirmed the functional of P-gp transporter 
in oocytes. It also revealed that ATP was a key driver for the efflux of P-gp substrates in oocytes. 
In addition, whether the P-gp RNA was poly-A tailed or not did significantly change the efflux of 
[3H]dexamethasone and [3H]corticosterone from oocytes. However, a lack of post-translational P-
gp modifications, (e.g. glycosylation) may have affected the ability of the human P-gp transporter 
to fully function when it was expressed in xenopus oocytes.  This has previously been observed 
for the transporters, band 3 and PAT-1.    
 
For [3H]pentamidine, its efflux in oocytes expressing P-gp did not differ significantly from oocytes 
injected with water. This was likely due to the fact that pentamidine and dexamethasone bound 
to different binding sites at the P-gp transporter. The P-gp transporter is a transmembrane 
glycoprotein which contains two transmembrane domains and two ATP binding regions, with a 
broad range of substrates (Hoosain et al., 2015; Kim and Chen, 2018). As predicted by molecular 
docking, dexamethasone interacts with GLN724, MET985, GLU874, GLN346, MET875, while 
pentamidine attracts to ARG262, GLN535, ALA529, GLU1119 on P-gp. Although the functional 
expression of P-gp was verified by the efflux of [3H]dexamethasone, it was possible that the 
binding sites on P-gp for [3H]pentamidine did not work functionally in oocytes.  
 
In order to examine the interaction of P-gp with [3H]pentamidine-xinafoate ion-pairs, the efflux of 
[3H]pentamidine-xinafoate ion-pairs in oocytes expressing P-gp was measured. The presence of 
38.5% [3H]pentamidine-xinafoate ion-pairs significantly increased the efflux of [3H]pentamidine in 
both water-injected and oocytes expressing P-gp by a similar extent. Therefore, it seems like that 
the [3H]pentamidine-xinafoate ion-pairs facilitated the efflux of [3H]pentamidine through modifying 
the physicochemical properties of pentamidine (i.e. lipophilicity) rather than interacting with the P-




More validation experiments could have been taken place to prove the functional expression of 
P-gp in oocytes. For example, P-gp inhibitors and mutated P-gp transporter could have been used 
in this study. Also, the glycosylation of P-gp in oocytes can be tested with glycosylation mutants 
of P-gp.  
 
4.6 Conclusion 
Based on these data, we propose that pentamidine-xinafoate can improve the ability of 
pentamidine to cross plasma membranes by passive diffusion, but does not affect the efflux of 
pentamidine by P-gp. This may be because the size of the pentamidine-xinafoate ion-pair (i.e. 




Chapter 5 General Discussion and Future Studies  
5.1 General discussion 
The rate of clinical approval for central nervous system (CNS) drugs is the lowest among all 
diseases. This is mainly due to the difficulty in developing drug candidates which cross the blood-
brain barrier (BBB). It takes an average of 12-16 years to bring a CNS drug from preclinical 
development through to clinical trials and finally to market, much longer than the average duration 
of 10-12 years for non-CNS drugs. Around 98% of failure of CNS drug development is attributed 
to their inability to cross the BBB (C. Trippier, 2016).  
 
In this PhD project, we proposed using pentamidine ion-pairs to overcome the limited permeability 
of pentamidine across the BBB and so reformulate pentamidine to be a CNS active drug. In this 
study, we tested the hypothesis that a -1 charged counterion can bind to the +2 pentamidine and 
form a +1 charged ion-pair and in doing so make pentamidine more lipophilic and improve its 
passive transport across the BBB. We also hypothesized that pentamidine ion-pairs would 
improve its influx by hOCT1 and decrease its efflux by P-gp, which are both expressed at the 
BBB.  
 
This study of pentamidine ion-pairs is divided into physicochemical characterisation and 
interactions with biological membranes and the human BBB transporters, hOCT1 and P-gp. The 
physicochemical characterisation of pentamidine was explained in chapter 2, and the interactions 
of pentamidine ion-pairs with hOCT1 and P-gp were addressed in chapter 3 and chapter 4, 
respectively.  
 
Our methodological approach for each arm of the study is outlined in the form of a screening 



































































































































The physicochemical properties of pentamidine ion-pairs were examined in chapter 2. The 
lipophilicity (log D) of pentamidine (8 µM or 33 µM), as determined by octanol-saline shake flask 
at pH 7.4, in the presence of 20 times molar ratio of taurodeoxycholate, octanoate, and xinafoate 
increased by 1.15, 1.06 and 0.82, respectively compared to pentamidine alone suggesting the 
presence of ion-pairs. The lipophilicity of pentamidine was only slightly improved in the presence 
of quercetin. The binding constants (pKa) of pentamidine with taurodeoxycholate, octanoate, and 
xinafoate ranged from 3.1 - 4.1 and were determined by HPLC. The binding of pentamidine with 
counterions is relatively weak, compared to the reported highly stable metal complexes: pKCu2+-
EDTA= 18.8, pKMg2+-EDTA= 8.8 (Wang and Tomasella, 2016). The NMR and fluorescence data 
further confirmed the existence of pentamidine-xinafoate ion-pairs and indicated that the binding 
site of pentamidine with the counterion xinafoate was through the amidine groups of pentamidine 
(figure 5-2). It is reasonable to conclude that pentamidine is unable to form significant numbers 
of ion-pairs with quercetin (<0.1%), due to the minimal lipophilicity improvement of pentamidine 
with quercetin in the shake-flask experiment, as well as the unfit regression of pentamidine - 
quercetin binding constants analysis. They may, however, have other forms of unknown 
interactions rather than ion-pairing. Therefore, the percentage of pentamidine bound to quercetin 
was not predicted by HySS. 
 
Figure 5-2 The chemical structure of pentamidine  
 
The percentage of pentamidine existing as an ion pair with the counterions taurodeoxycholate, 
octanoate, or xinafoate was estimated by HySS. It is clear that if we maintain the molar ratio of 
pentamidine to counterion but increase the actual concentrations of pentamidine and counterions 
in solution, the percentage of pentamidine ion-pairs increases dramatically, according to Le 
Châtelier's Principle. For example, for the pentamidine-xinafoate ion-pair, 99.9% of the 
pentamidine existed as an ion-pair when pentamidine is 8 mM and xinafoate is 160 mM. However, 
when the concentration of pentamidine is decreased to 8 µM and 9 nM and the molar ratio is 
maintained at 1:20, the percentage of pentamidine bound in ion-pairs drops to 38.5% and 0.07%, 
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respectively. Thus higher concentrations of pentamidine and counterions allow the formation of a 
higher percentage of ion pairs as the individual molecules are more likely to come into contact. 
 
From a clinical perspective, the human plasma concentration of pentamidine peaks at 1h after 
intramuscular administration (3.5-4.5 mg pentamidine /kg body weight) and varies from 0.42µM 
(142.8 µg/L) to 13.42µM (4562.8 µg/L) with a median plasma concentration of pentamidine at day 
7 of 4 nM (2.4 µg/L) (Bronner et al., 1991). This could be a concern in the development of 
pentamidine ion-pair formulations for clinical use as it means the percentage of pentamidine 
remaining bound in ion-pairs would be very low after administration as the concentration of 
pentamidine would be reduced as it is distributed and diluted in the different body compartments. 
It would be useful to gain insight into the dissociation rate of pentamidine ion-pairs; unfortunately, 
due to the detection limits of fluorescence lifetime imaging microscopy, the dissociation of 
pentamidine ion-pairs could not be measured.  
 
The interactions of pentamidine ion-pairs with biological membranes and the hOCT1 transporter 
were examined in chapter 3. The accumulation of [3H]pentamidine (9 M and 8 µM) in the human 
blood-brain barrier (hCMEC/D3) cells did not increase in the presence of the counterions 
taurodeoxycholate, octanoate, quercetin and xinafoate. This is contrary to what would be 
expected based on the physicochemical data described in chapter 2. As the lipophilicity (log D) 
of pentamidine at pH 7.4 was improved with the counterions taurodeoxycholate, octanoate, and 
xinafoate you would predict that increasing the lipophilicity of pentamidine by reformulation as an 
ion pair should improve its accumulation in hCMEC/D3 cells. The inability of the counterions to 
improve pentamidine BBB permeability may be caused by several factors: (a) pentamidine ion-
pair formation increases the size of pentamidine. The large size hindering the amount of 
[3H]pentamidine ion-pairs able to pass through the BBB; (b) The ion environment of the 
accumulation buffer in which [3H]pentamidine ion-pairs were dissolved for cell accumulation assay 
was more complicated than the simple saline solution used in the octanol-saline shake flask 
method and reduced the percentage of ion pairs that could be formed. In other words as the ion-
pairs are formed non-covalently, and the binding is relatively weak any competition from ions in 
the complex cell accumulation buffer could dampen the effect of pentamidine ion-pairing. Based 
on the binding constants of ion-pairs and the molecular weights of the counterions, pentamidine 
is more likely to form a stable ion-pair which can be transported across biological membranes 
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more easily with xinafoate than taurodeoxycholate and octanoate. (c) the transport of 
[3H]pentamidine ion-pairs may be intervened by membrane transporters such as hOCT1 and P-
gp; 
 
In order to test these possibilities, the influx of [3H]pentamidine ion-pairs in control oocytes 
(oocytes injected with RNA-free water) and oocytes expressing hOCT1 was tested. The net 
impact of hOCT1 on the transport of [3H]pentamidine ion-pairs was calculated by subtracting the 
influx of [3H]pentamidine in water oocytes (representing the passive diffusion of [3H]pentamidine) 
from the influx of [3H]pentamidine in oocytes expressing hOCT1 (representing both passive 
diffusion and transport by hOCT1 of [3H]pentamidine). For pentamidine-taurodeoxycholate ion-
pair, the [3H]pentamidine influx in water-injected oocytes did not increase with taurodeoxycholate. 
Thus passive diffusion of the more lipophilic ion pair may be inhibited by the large molecular 
weight of taurodeoxycholate (MW=521.7 g/mol). The influx of [3H]pentamidine by hOCT1 was not 
influenced by forming ion-pairs with taurodeoxycholate. For pentamidine-octanoate ion-pair, the 
passive diffusion of [3H]pentamidine with octanoate (MW: 166.16 g/mol) was increased. For 
pentamidine-xinafoate ion-pair, the passive diffusion of [3H]pentamidine by forming ion-pairs with 
xinafoate (MW:188.18 g/mol) was increased. However, there was a tendency for the influx of 
[3H]pentamidine to be decreased by hOCT1 with octanoate and xinafoate in oocytes.  
 
The interactions of pentamidine ion-pairs with P-gp was studied in chapter 4. In our study, initially, 
we intended to isolate the impact of P-gp on the transport of pentamidine ion-pairs by leveraging 
the different levels of P-gp expression in MDCK-WT and MDCK-hMDR1 cells. However, no 
difference in the accumulation of [3H]pentamidine was seen between the two cell lines. This may 
be because the efflux of [3H]pentamidine by human P-gp was masked by its interactions with 
other transporters expressed in the MDCK-WT and MDCK-hMDR1 cells. Therefore, to assess 
the interactions of pentamidine ion-pairs with P-gp, we expressed human P-gp transporter in 
xenopus oocytes. Pentamidine-xinafoate ion-pair was selected as our model ion-pair. In oocytes 
expressing P-gp, no significant change in the efflux of [3H]pentamidine was observed by forming 
38.5% [3H]pentamidine-xinafoate ion-pairs (predicted by HySS). This indicated that the efflux of 
[3H]pentamidine by forming ion-pairs with xinafoate was not influenced by human P-gp expressing 




It is worth mentioning that more validation experiments could have been performed to improve 
the rigour and assurance of the functional expression of hOCT1 and P-gp transporters in oocytes. 
For example, transporter inhibitors can be used to verify the functional expression of hOCT1 and 
P-gp in oocytes. Also, the data generated in this study may have been affected by protein 
glycosylation in oocytes when transporters were expressed. This can be verified using mass 
spectrometry in which the glycosylation site and its microheterogeneity of proteins can be 
checked. A more detailed description can be found in  (An, Froehlich and Lebrilla, 2009).  
 
Based on the results obtained in this PhD project: (a) The passive diffusion of pentamidine is 
improved by forming ion-pairs with taurodeoxycholate (+96.5%), octanoate (+89.1%) and 
xinafoate (+68.9%). (b) When pentamidine forms ion-pairs with xinafoate and octanoate, its influx 
across the BBB by hOCT1 is decreased. This might be caused by the change of binding site of 
pentamidine with hOCT1 when forming pentamidine-xinafoate or pentamidine-octanoate ion-
pairs. The NMR study (Chapter 2) and the molecular docking simulation (Chapter 3) suggested 
that the amidine group on pentamidine was the binding site for both hOCT1 and xinafoate. So 
xinafoate might have blocked the binding site of pentamidine to hOCT1. This may also be true for 
pentamidine-octanoate ion pairs and pentamidine-taurocholate ion pairs.  Although pentamidine-
taurocholate ion pairs did not change the overall influx by OCT1. (c) Pentamidine is still effluxed 
by P-gp and its efflux by P-gp is not changed by forming ion-pairs with xinafoate. This might be 
caused by two factors: (i) Forming ion-pairs with xinafoate could prevent the interaction of 
pentamidine with the specific binding pocket of hOCT1 but not P-gp. (ii) the MW of the 
pentamidine-xinafoate (MW: 528 Da) ion pair is outside the normal MW range for OCT1 (<400 





Table 5-1 Key findings of this PhD project 
Chapter  Hypothesis Objectives Parameters Key findings  
2 The passive diffusion of 
pentamidine across the 
blood-brain barrier is 
improved by ion pairing. 
To measure the lipophilicity (Log D) of 
pentamidine alone and when bound to a 
counterion (i.e. the ion-pair) by shake-flask and 
fluorescence methods. 
 
Lipophilicity (log D) Ion pairing increased the lipophilicity of 
pentamidine. 
The magnitude of change: 
taurodeoxycholate > octanoate > xinafoate > 
quercetin 
To determine the association constants (binding 
constants, pKa) of pentamidine ion-pairs using 









Pentamidine does not form ion pairs with 
quercetin. 
To investigate the binding site of the counterion 
with pentamidine with 13C-NMR and 1H-NMR by 
assessing the chemical shift of H and C assigned 
to pentamidine in the presence of counterions. 
Binding sites  
(only xinafoate 
was assessed) 
The amidine groups on pentamidine could 




To estimate the percentage of pentamidine (%) 
bound with counterions (taurodeoxycholate, 
octanoate and xinafoate) in solutions using 
Hyperquad Simulation and Speciation (HySS) 
software. 
  
Percentage bound The percentage of pentamidine existing as 
an ion pair is extremely low (<1%) when 
pentamidine is at 9nM, even in the presence 
of excess counterions; The percentage of 
pentamidine bound with counterions ranges 
from 1% to 66%, depending on the type and 
concentrations of counterions. 
To further confirm the presence of pentamidine 
ion-pairs and understand the dissociation (pKd) of 
pentamidine ion-pairs with fluorescence-lifetime 
imaging microscopy (FLIM).  
 
Dissociation rate  
(only xinafoate 
was assessed) 
Not determined due to method limitations, 






The ion-pairing of 
pentamidine increases 
the transport of 
pentamidine by hOCT1.  
 
To measure the toxicity of pentamidine-
taurodeoxycholate, pentamidine-octanoate, 
pentamidine-quercetin, and pentamidine-
xinafoate in hCMEC/D3 cells using MTT assay. 
% cell viability 0.1-200 µM of the four counterions do not 
affect membrane integrity of hCMEC/D3 
cells. 
To determine the retention of [3H]pentamidine with 
taurodeoxycholate, octanoate, quercetin, and 
xinafoate in hCMEC/D3 cells by measuring the 
volume of distribution (Vd) of [3H]pentamidine with 
drug accumulation assay and the concentrations 
of protein with bicinchoninic acid (BCA) assay. 
 
Volume of 
distribution (Vd)  
 
The accumulation of [3H]pentamidine (9M 
and 8µM) in human blood-brain barrier 
(hCMEC/D3) cells did not increase in the 
presence of the counterions 
taurodeoxycholate, octanoate, quercetin and 
xinafoate. 
To simulate the interaction of pentamidine with 
hOCT1 membrane transporter using in silico 
molecular docking.  
 
CDOCKER free  
energy (kcal/mol) 
The result confirmed that pentamidine was a 
substrate for hOCT1. 
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To confirm the identity and functional expression 
of hOCT1 in xenopus oocytes through DNA 
sequencing, gel electrophoresis of DNA and RNA, 
and influx of the hOCT1 substrate - 
[3H]acetylcholine into xenopus oocytes 
expressing hOCT1 
DNA sequencing, 
size of DNA and 





The identity and functional expression of 
hOCT1 were confirmed.  
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To determine the interaction of [3H]pentamidine 
ion-pairs with hOCT1 by measuring the influx of 







3H]pentamidine-octanoate ion-pairs inhibited 
the uptake of [3H]pentamidine by hOCT1. 
The formation of [3H]pentamidine-
taurodeoxycholate had no impact on the 
influx of [3H]pentamidine by hOCT1. 
4 Pentamidine ion-pairs 
inhibit the efflux of 
pentamidine by P-gp 
transporter expressed at 
the blood-brain barrier.  
 
To determine the specific interactions of 
pentamidine with P-gp using in silico molecular 
docking and compare the results with known P-gp 




Pentamidine is a substrate for P-gp. 
 
To confirm the suitability of the MDCK and MDCK-
hMDR1 cell lines for exploring pentamidine ion 
% cell viability  50-200 µM of the four selected counterions 
should not cause measurable cytotoxicity 
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pairs interaction with human MDR1 by 
determining the toxicity of pentamidine-
taurodeoxycholate, pentamidine-octanoate, 
pentamidine-quercetin, and pentamidine-
xinafoate in these cells using the MTT assay.                                                  
issues that may influence the interpretation of 
the data obtained from confluent monolayers 
of MDCK and MDCK-hMDR1 cells in this 
study. 
To examine the impact of counterions on the 
interaction of pentamidine with P-gp using Madin-
Darby Canine Kidney (MDCK-WT) and MDCK-
hMDR1. 
The volume of 




The Vd of [3H]pentamidine corrected by 
[14C]sucrose dropped significantly within 60 
mins of incubation when 8µM of unlabelled 
pentamidine was present in MDCK-WT cells. 
These indicated influx transporters were 
involved.  
 
The efflux of [3H]pentamidine by the highly 
expressed hMDR1 transporter could not be 
detected, as there was no significant 
difference in the accumulation of 
[3H]pentamidine in between the MDCK-WT 
and MDCK-hMDR1 cells.  
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To confirm the identity and functional expression 
of P-gp in xenopus oocytes through DNA 
sequencing, gel electrophoresis of DNA and RNA, 
influx (accumulation) and efflux transport of P-gp 
substrates [3H]dexamethasone and 
[3H]corticosterone. 
Sequencing 
alignment, Size of 
enzyme digestion 
of P-gp DNA, Size 








The identity and functional of P-gp in oocytes 
were confirmed.  
To determine the interaction of [3H]pentamidine-
xinafoate ion-pair with P-gp by measuring the 
efflux of [3H]pentamidine extruded from xenopus 





Pentamidine is still effluxed by P-gp and its 
efflux by P-gp is not changed by forming ion-






Figure 5-3 Transport of pentamidine ion-pairs cross the blood-brain barrier.  
 
From the results acquired in this project, we can state that there are several advantages of 
pentamidine ion-pair method for drug delivery across the BBB. Firstly, ion-pairing is a non-
invasive method and safer as it does not force the BBB to open like the focused ultrasound 
method. Pentamidine is also less toxic than current drugs for CNS stage HAT. Importantly 
pentamidine was recently screened against 40 CNS targets, and no major neurotoxicity issues 
were found (Sanderson et al., 2019). Ion-pairing is an inexpensive method, with the potential to 
scale into massive production for therapeutic drugs. As 98% of drug molecules are not able to 
cross the BBB (Pardridge, 2005), ion-pairing could be a potential solution for these molecules. 
Thirdly, ion-pairing is easy to prepare and is effective in improving the lipophilicity of molecules 
(Suresh and Paul, 2011b).  
 
The disadvantages of pentamidine ion-pairing for drug delivery across the BBB are summarized 
as follows: Firstly, pentamidine would not be able to form ion-pairs at the plasma concentrations 
achieved clinically. It is known that the percentage of pentamidine bound in ion-pairs is largely 
dependent on the concentration of pentamidine. The percentage of pentamidine bound in ion-
pairs would be negligible (<0.1%) when the concentration of pentamidine is 9nM, which is within 
the range of pentamidine in cerebrospinal fluid (1.7-3.9 nM) (Bronner et al., 1991). Secondly, 
pentamidine ion-pairs might be unstable in the human body as they face enormous competition 
from ions in the biological environment. Thirdly, although the efflux transporter P-gp does not 
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accelerate the excretion of pentamidine ion-pairs out of the BBB, the influx of pentamidine by 
hOCT1 transporter at the BBB may be hindered by forming ion-pairs.  
 
5.2 Future studies  
In this study we confirmed that pentamidine could form ion-pairs with specific counterions and its 
lipophilicity was improved. Ion-pairs could also enhance the ability of pentamidine to cross plasma 
membranes by passive diffusion.  We also evaluated the ability of the pentamidine ion-pairs to 
interact with cell membranes and transporters using simple and complex BBB models in vitro.    
 
In the future further studies could be designed: 
(i) To overcome the instability of pentamidine ion-pairs and allow ion-pairs to reach 
the BBB in vivo, ion-pairs could be wrapped with liposomes or cyclodextrins to 
improve drug delivery. Liposomes are well-established nanocarriers which can 
encapsulate hydrophilic and lipophilic compounds for targeted drug delivery and 
improved stability (Sercombe et al., 2015). Cyclodextrins are cyclic 
oligosaccharides and have been used for increasing solubility, bioavailability, and 
stability of drugs (Tiwari, Tiwari and Rai, 2010). We could explore the possibility 
of forming pentamidine ion-pairs with liposomes and cyclodextrins to increase 
the stability of pentamidine ion-pairs in future studies. In addition, focused 
ultrasound could be used to target the delivery of encapsulated pentamidine ion-
pairs into the CNS. Focused ultrasound has been applied successfully in 
delivering chemotherapeutic agents, nanoparticles, and peptides across the BBB 
(Chen, Wei and Liu, 2019). Other strategies can also be used to improve the 
delivery of pentamidine ion-pairs across the BBB. For example, nanocarriers or 
artificial  peptides with fatty acid residues might be introduced in future studies to 
overcome the stability issue of pentamidine ion-pairs (Bors and Erdő, 2019). 
(ii) To explore if ion pairs could be designed to reduce the penetration of a drug into 
any target tissue /organ.  This may reduce toxicity issues and any resulting 
adverse effects.  For example, hypoglycaemia and diabetes mellitus associated 
with increasing doses of pentamidine may be prevented (BURRI, 2010).   
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(iii) To further explore the interaction of pentamidine ion-pairs with hOCT1 and P-gp 
using in silico assessment. To do this, we can compare the free energy binding 
of pentamidine ion-pair with transporters to that of pentamidine alone. 
(iv) To determine if pentamidine ion pairs could be formed with other counterions or 
to assess if the selected counterions can form ion-pairs with other drugs (e.g. 
antipsychotic drugs and cancer therapies) whose entry into the CNS is also 
limited by the BBB and interact with the same and different transporters. The 
selected counterions taurodeoxycholate, octanoate, and xinafoate showed 
promising effect as they improve the lipophilicity of pentamidine. These 
counterions have also previously been used in the production of pharmaceutical 
products and do not cause major side effects at the concentrations used in this 
study.  
(v) To test if ion-pairing could improve the permeability of pentamidine or other drug 
across the BBB using in vivo methods.  For example, in vivo whole body 
distribution, brain microdialysis and in situ brain perfusion studies on mice could 
be performed.  
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Warfarin is a vitamin K antagonist that has been traditionally used for 
prophylaxis and treatment of thrombosis. An adverse event associated with 
warfarin treatment is intracranial haemorrhage. To explore the interaction of 
warfarin with the brain vasculature we investigated the ability of warfarin to 
interact with transporters expressed at the blood-brain barrier (BBB) by 
means of a commercially available immortalized adult mouse brain cell line, 
b.End3 cells.
The accumulation of [3H]warfarin into bEnd.3 cells was investigated at five 
different time points: 5 min, 20 min, 30 min, 60 min and 120 min. Different 
transporter inhibitors/ substrates were added to the accumulation buffer and 
the results compared to [3H]warfarin alone (control). Raw data were corrected 
for protein content and extracellular space ([14C]sucrose). Results were 
expressed as the mean (Vd, µl/mg of protein)±SEM, n =4-6 plates, with 6 
replicates per plate, passage number 16-29. Comparisons were made between 
control and test plates of cells at each time point by one-way ANOVA. 
Differences at p <0.05 were considered significant.
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The accumulation of [3H]warfarin (34 nM) was significantly decreased by the 
presence of unlabelled warfarin (Figure 2). However, there was no effect on 
[3H]warfarin accumulation in the presence of P-glycoprotein (P-gp; ABCB1) 
inhibitors and substrates (Figure 2). There was a significant increase with 
breast cancer resistance-associated protein (BCRP; ABCG2) inhibitors (Figure 
3) although no significant change has been observed in the presence of 
multidrug resistance-associated proteins (MRPs; ABCC group) inhibitor (data 
not shown). The significant increase in the presence of ATP depletion method 
indicated the consistency of ABC transporters involvements in the transport of 
warfarin (Figure 4). Incubation with organic anion transporting peptides 
(OATP; SLC21A) substrate significantly increased the accumulation of 
warfarin (Figure 5). Incubation time (minutes)














































H] Warfarin (control) 
+ ATP depletion 
**
Taken together these results suggest that warfarin is a substrate for BCRP and 
OATP and that an influx transporter is involved (identity unknown). Amongst the 
group of ABC transporters, P-gp and/or BCRP are thought to be the dominant 
players and are expressed on the luminal (blood-facing) membrane of the BBB, 
whereas the OATPs of the SLC transporters are localized on both the luminal and 
abluminal (brain-facing) sides of the BBB. Furthermore, the effects on BCRP and 
OATP were not significant until later time points which suggested a time 
dependent effect. It may be that the effect was occurring at an intracellular 
membrane of an organelle.
1. Shaik AN et al. (2016). Journal of Pharmaceutical Sciences 105: 1976-1986.
2. Wessler JD et al. (2013). Journal of the American College of Cardiology 61: 2495-2502.
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Introduction
Methods
Fig 1. Experimental procedures
Results
Fig 2. Accumulation of [3H]warfarin in the absence and presence of P-gp
inhibitors/substrates and self-inhibition (*p< 0.05,**p<0.01,***p<0.001). All 
[3H]warfarin data are corrected for protein content and expressed as 
means±SEM, n=6 plates with 6 replicates per plate.
Fig 3. Accumulation of [3H]warfarin in the absence and presence of BCRP 
inhibitors/substrates and self-inhibition (*p< 0.05,**p<0.01,***p<0.001). All 
[3H]warfarin data are corrected for protein content and expressed as 
means±SEM, n=6 plates with 6 replicates per plate.
Fig 4. Accumulation of [3H]warfarin in the absence and presence of ATP 
depletion (*p< 0.05,**p<0.01,***p<0.001). All [3H]warfarin data are 
corrected for protein content and expressed as means±SEM, n=4 plates 
with 6 replicates per plate.
Fig 5. Accumulation of [3H]warfarin in the absence and presence of OATP 
substrate (*p< 0.05,**p<0.01,***p<0.001). All [3H]warfarin data are 
corrected for protein content and expressed as means±SEM, n=4 plates 
with 6 replicates per plate.




















































 Uptake of [3H]pentamidine with quercetin by 
hOCT1 in oocytes 
No significant difference in the uptake of [3H]pentamidine was found between water-injected or 
oocytes expressing hOCT1 with quercetin. The transport of [3H]pentamidine via hOCT1 was 
reduced when 160µM of quercetin was present although this did not attain statistical significance. 
The increase in the uptake of [14C]sucrose in water-injected oocytes in the presence of 160µM of 
quercetin suggested that this counterion caused membrane damage which resulted in loss of 
membrane integrity .  
 
 
Figure A1. The uptake of [3H]pentamidine and [14C]sucrose by hOCT1 transporter. The concentration of 
pentamidine was 8μM (31nM [3H]pentamidine and 8μM unlabelled pentamidine) and the concentration of 
quercetin was 8μM or 160μM. Data were expressed as mean ± SEM, n=24-26 oocytes from 3 different 
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 Sequence Alignment between hOCT1 and GLUT3 
 
Figure A2 Alignment using the universal protein resource (Uniprot) between S22A1_HUMAN and 
GTR3_HUMAN (https://www.uniprot.org  assessed 9.7.2020). S22A1_HUMAN represents human OCT1 
(SLC22A1) (Uniprot accession: O15245). GTR3_HUMAN (Our chosen pdb code 4ZW9) represents human 
GLUT3 (SLC2A3)  (Uniprot accession: P11169). There are 99 identical (identified by *) positions and 184 
similar positions (very similar identified by :, somewhat similar identified by .). 
 
 
The universal protein resource (Uniprot) cluster omega program allowed us to align the protein 
sequences (https://www.uniprot.org  assessed 9.7.2020).  This analysis revealed that there was 
a 57% sequence homology between OCT1 (Uniprot accession: O15245) and 4ZW9 (Uniprot 
accession: P11169) (Figure A2).
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 Reagents used throughout the thesis 
Product name Company bought Catalogue code 
1kb DNA Ladder Promega Uk Ltd G5711 
ssRNA Ladder 
 
New England Biolabs (Uk) Ltd N0362S 
TRYPSIN-EDTA SOLUTION 
10X, 0.5% TRYPSIN 
Merck Life Science Uk 
Limited 
59418C-100ML 
DPBS, no calcium, no 
magnesium-1,000 mL 
Thermo Fisher Scientific (Life 
Technologies) 
14190136 
Ultima Gold XR, 2x5L Perkin Elmer 6013119 
NotI Promega Uk Ltd R6435 
HindIII Promega Uk Ltd R6041 
EcoRI Promega Uk Ltd R6011 
NcoI New England Biolabs (Uk) Ltd R0193T 
SalI 
 
New England Biolabs (Uk) Ltd R0138S 
TBE BUFFER (10X) Applichem Lifescience A0972.1000 
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